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ABSTRACT 
 
Analysis of the Mechanisms Mediating the Regulation of Acetyl-CoA 
Carboxylase Transcription by the Liver X Receptor and 
Chenodeoxycholic Acid 
 
Saswata Talukdar 
 
 
Agonists of the liver X receptor (LXR) prevent and decrease arterial plaque formation in 
experimental models of atherosclerosis.  The anti-atherosclerotic effects of LXR agonists 
are mediated by an increase in expression of genes involved in cholesterol export.  
Currently, the therapeutic utility of LXR agonists is limited by the fact that these agents 
increase triglyceride levels in the blood and liver.  These undesired effects are caused by 
an increase in transcription of genes controlling triglyceride synthesis, such as acetyl 
CoA carboxylaseα (ACCα).  We have demonstrated that a synthetic LXR agonist, T0-
901317 increases ACCα via both a direct mechanism involving the activation of 
LXR/retinoid X receptor (RXR) heterodimers on the ACCα gene and by an indirect 
mechanism involving the increased expression of sterol regulatory element binding 
protein-1 (SREBP-1).  SREBP-1 binds a site adjacent to the ACCα LXRE and enhances 
the ability of LXR/RXR to activate ACCα transcription.  We screened a number of 
compounds for their ability to inhibit the stimulatory effects of T0-901317 on expression 
of lipogenic genes in primary cultures of hepatocytes.  We found that the bile acid, 
chenodeoxycholic acid (CDCA), inhibited the T0-901317-induced increase in mRNA 
abundance encoding ACCα, fatty acid synthase, and stearoyl CoA desaturase-1.  CDCA 
also blocked the stimulatory effects of T0-901317 on triglyceride secretion into the 
culture medium.  Results from transient transfection analyses identified two cis-acting 
elements that mediated the inhibitory effects of CDCA on T0-901317-induced ACCα 
transcription.  One element bound LXR/RXR heterodimers and the other element bound 
SREBP-1.  Treatment with CDCA decreased the expression of mature, active SREBP-1 
and decreased the binding of LXR/RXR heterodimers to the ACCα promoter.  Further 
studies demonstrated that the CDCA-mediated inhibition of ACCα transcription was 
associated with an activation of extracellular signal-related kinase-1/2 (ERK1/2) and p38 
mitogen activated protein kinase (p38MAPK) and that inhibitors of ERK1/2 and 
p38MAPK abolished or substantially attenuated the inhibitory effect of CDCA on ACCα 
expression.  These results indicate that CDCA inhibits T0-901317-induced ACCα 
expression by decreasing the transcriptional activity of LXR and SREBP-1 and that 
ERK1/2 and p38MAPK are components of the signaling pathway mediating the 
inhibitory effects of CDCA on ACCα expression and triglyceride secretion. 
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"Whatever we understand and enjoy in human products instantly becomes 
ours, wherever they might have their origin." 
                                                            - Rabindranath Tagore (1861-1941) 
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Chapter 1 
I) Introduction 
 
Liver X receptors are ligand dependent transcription factors that belong to the 
nuclear hormone receptor superfamily.  LXRs modulate multiple cellular pathways 
making it a very attractive drug target to prevent and cure a wide range of diseases.  For 
example, agonists of LXR prevent and decrease arterial plaque formation in experimental 
models of cardiovascular disease and atherosclerosis.  The anti-atherosclerotic effects of 
LXR agonists are mediated by an increase in expression of genes involved in cholesterol 
export and high density lipoprotein (HDL) formation.  In rodent models of diabetes, an 
LXR agonist, T0-901317, lowered plasma glucose levels and significantly improved 
insulin sensitivity.  Activation of LXR in mouse liver inhibits gluconeogenesis by 
inhibiting the expression of peroxisome proliferator-activated receptor gamma 
coactivator-1α (PGC-1α), phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-
phosphatase.  In contrast, LXR agonists promote hepatic glucose utilization by increased 
expression of glucokinase.  Recently there is compelling evidence showing an important 
link between cholesterol and Alzheimer's disease.  High plasma levels of HDL have been 
shown to have an inverse effect on Alzheimer's disease.  This effect is primarily due to 
the increase in ABCA1 by LXRs.  LXR agonists applied to a variety of in vitro models, 
including immortalized fibroblasts from Tangier patients, and primary embryonic mouse 
neurons and Alzheimer disease mouse model (APP23 transgenic mice) caused a T0-
901317-dose-dependent decrease in amyloid beta secretion.   
Currently, the therapeutic utility of LXR agonists is limited by the fact that these 
agents also increase triglyceride levels in the blood and liver.  These undesired effects are 
caused by an increase in transcription of genes controlling triglyceride synthesis.  I have 
developed data demonstrating that the LXR agonist, T0-901317, increases the expression 
of ACCα in chicken embryo hepatocytes (CEH).  This result is consistent with previous 
work from our laboratory that ACCα is a LXR target gene.  Results from transient 
transfection analyses indicated that the T0-901317 induction of ACCα mRNA is 
mediated by two cis-acting elements on the ACCα promoter.   
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We screened a number of compounds for their ability to inhibit the stimulatory 
effects of the synthetic LXR agonist, T0-901317, on expression of lipogenic genes in 
primary cultures of hepatocytes.  We found that the primary bile acid, chenodeoxycholic 
acid (CDCA), inhibited the T0-901317-induced increase in abundance of mRNAs 
encoding acetyl CoA carboxylaseα (ACCα), fatty acid synthase, and stearoyl CoA 
desaturase-1.  Interestingly, CDCA enhanced the T0-901317-induced increase in 
abundance of mRNA encoding ABCA1, a key protein involved in HDL formation.  Thus, 
CDCA may enhance the ability of T0-901317 to stimulate HDL formation while reducing 
the effects of T0-901317 on triglyceride accumulation in the blood and liver.   
Results from transient transfection analyses identified two cis-acting elements that 
mediated the inhibitory effects of CDCA on T0-901317-induced ACCα transcription.  
One element bound LXR/retinoid X receptor (RXR) heterodimers and the other element 
bound sterol regulatory element binding protein-1 (SREBP-1).  Treatment with CDCA 
decreased the expression of mature, active SREBP-1, via a post translational mechanism.  
Further studies demonstrated that the CDCA-mediated inhibition of ACCα transcription 
was associated with an activation of extracellular signal-related kinase-1/2 (ERK1/2) and 
p38 mitogen activated protein kinase (p38 MAPK).  Specific inhibitors of ERK1/2 and 
p38MAPK abolished or substantially attenuated the inhibitory effect of CDCA on ACCα 
expression.  These results indicate that CDCA inhibits ACCα transcription by decreasing 
the activity of LXR and SREBP-1, and that ERK1/2 and p38MAPK are involved in 
mediating this effect.   
 
II) BACKGROUND 
A) Acetyl CoA Carboxylase 
1) Structure and function 
Acetyl CoA carboxylase (ACC) catalyzes the ATP-dependent carboxylation of 
acetyl CoA to malonyl CoA.  This reaction is the first committed step in the fatty acid 
synthesis pathway (67, 94).  There are two isoforms of ACC that are encoded by different 
genes.  ACCα (260 kDa) is the principal isoform that is expressed in tissues that exhibit 
high rates of fatty acid synthesis such as liver, adipose tissue and mammary gland.  
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ACCβ (280 kDa) is the major isoform found in heart and skeletal muscle where it is 
thought to primarily function in the regulation of β-oxidation of fatty acids (173).  
2) Regulation of ACC 
The levels of ACCα in the liver are dependent on nutritional and hormonal 
regulation (13, 67).  The effects of nutritional regulation on the ACCα concentration are 
mediated primarily by changes in the rate of transcription of the ACCα gene (65).  In 
livers of starved chickens the rate of ACCα transcription is low.  Consumption of a high 
carbohydrate, low fat diet stimulates an 11-fold increase in ACCα transcription (65).  
Several signaling pathways are involved in mediating the stimulatory effects of dietary 
carbohydrate on ACC transcription in liver.  Increased insulin secretion and glucose 
metabolism are two important signals mediating this response.  Another factor signaling 
changes in carbohydrate status is the active form of thyroid hormone, 3, 5, 3'-
triiodothyronine (T3).  Ingestion of a high carbohydrate meal stimulates a rapid increase 
in the secretion of thyroxine from the thyroid gland and the conversion of thyroxine to T3 
in extrathyroidal tissues (66).  The resulting increase in T3 concentration in liver activates 
the transcription of the genes for ACC.  Ingestion of carbohydrate also increases the 
levels of nuclear T3 receptors (TRs) in liver (23).  This phenomenon may also contribute 
to the stimulation of lipogenic gene transcription by dietary carbohydrate.   
Diet-induced changes in ACCα transcription are mimicked in primary cultures of 
chick embryo hepatocytes by manipulating the concentration of hormones and nutrients 
in the culture medium.  The addition of T3 to the culture medium stimulates a 7-fold 
increase in ACCα transcription (66).  Insulin has no effect on the transcription of ACCα, 
but amplifies the increase in ACCα transcription caused by T3.  Glucagon acting through 
cAMP suppresses the induction of ACCα transcription caused by T3 and insulin (225). 
The ACC gene is transcribed from two promoters, PI and PII, which result in 
alternatively spliced mRNAs containing different 5’ noncoding regions (94).  In rodents, 
PI is active in white adipose tissue and regulated by dietary manipulation (121, 122).  In 
contrast PII is active in all tissues at a low level.  PII promoter for ACCα is specifically 
regulated by sterols through the action of the transcription factor Sp1 and the sterol 
regulatory element binding proteins (SREBPs) (127).  In contrast to the rodents, our 
laboratory has shown that both PI and PII are regulated by nutrients and hormones in 
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chick hepatocytes and that the activity of PII accounts for a greater proportion of the 
changes in total ACCα mRNA abundance than activity of PI (236). 
Our laboratory has identified a unique regulatory element between -108 and -82bp 
in the ACCα gene that confers T3 regulation on ACCα promoter 2 in chicken embryo 
hepatocytes (CEH).  This element stimulates transcription both in the absence and 
presence of T3, with a greater stimulation observed in the presence of T3.  The T3-
independent enhancer activity of this regulatory element was mediated by protein 
complexes containing LXR•RXR heterodimers and the increase in enhancer activity in 
the presence of T3 was mediated by protein complexes containing thyroid hormone 
receptor (TR)•RXR heterodimers and LXR•RXR heterodimers (236).  This regulatory 
element is referred to as a composite thyroid hormone response element/liver X receptor 
response element (T3RE/LXRE).  Immediately downstream of the ACCα T3RE/LXRE is 
a sterol regulatory element (SRE)  
(-80 to -71 bp), that increased the ability of the ACCα-T3RE/LXRE to stimulate ACCα 
transcription in the presence of T3.  The stimulatory effect of the SRE-1 on ACCα 
transcription was mediated by a direct interaction between SREBP-1 and TR.  This 
interaction facilitated the formation of a tetrameric complex comprised of SREBP-
1•SREBP-1/TR•RXR on the ACCα gene.  The formation of this tetrameric complex 
stabilized the binding of SREBP-1 to ACCα SRE-1.  The binding of T3 to thyroid 
hormone receptor (TR) enhanced tetrameric complex formation.  T3 was also shown to 
stimulate the production of the mature, transcriptionally active form of SREBP-1 in 
hepatocytes.  Thus multiple interactions between the TR and SREBP-1 signaling 
pathways contribute to the stimulatory effects of T3 on ACCα transcription (226). 
 
B) Sterol Regulatory Element Binding Protein 
 
1) Structure and function 
Sterol regulatory element binding proteins (SREBPs) belong to a large class of 
transcription factors that contain a basic helix-loop-helix-leucine zipper domain (bHLH-
ZIP).  SREBPs are synthesized as 125 kDa membrane-bound precursors of ~1150 amino 
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acids that require cleavage by a two-step proteolytic process in order to release an N-
terminal fragment that binds DNA and is transcriptionally active (22).  Each SREBP 
precursor is organized into three domains.  The first domain is the N-terminal segment, 
comprised of about 480 amino acids that contains the bHLH-ZIP and which binds DNA.  
The second domain is composed of two hydrophobic transmembrane-spanning segments 
interrupted by a short loop of about 30 amino acids that projects into the lumen of the 
endoplasmic reticulum (ER).  The third domain of 590 amino acids is the C-terminal 
segment of the protein and plays a role in the regulation of cleavage (22, 149). 
To date, three isoforms of SREBP have been identified.  SREBP-1a and SREBP-
1c are produced from the same gene.  They contain differences in their N-terminal region 
due to the use of alternative promoters and first exons (73).  SREBP-2 is derived from a 
gene distinct from SREBP-1 (74).  Most cells in culture express both SREBP-1a and 
SREBP-2.  SREBP-1c is the predominant form of SREBP-1 expressed in liver and 
adipose tissue (182).  In chickens, only one form of SREBP-1 has been identified and this 
form more closely resembles the mammalian SREBP-1a (7).   
 
2) Activation of SREBP via proteolytic processing 
The precursor form of SREBP is anchored to the endoplasmic reticulum (ER).  In 
order for SREBP to enter the nucleus and function as a transcription factor, it must 
undergo a cleavage resulting in the release of the N-terminal fragment from the 
endoplasmic reticulum.  Three proteins are required for SREBP processing.  One is an 
escort protein designated SREBP cleavage-activating protein (SCAP).  The other two are 
proteases, designated Site-1 protease (S1P) and Site-2 protease (S2P).  SREBP is 
synthesized and inserted into the membrane of the endoplasmic reticulum, where its C-
terminal regulatory domain binds to the C-terminal domain of SCAP.  SCAP is both an 
escort for SREBPs and a sensor of sterols.  When cells become depleted in cholesterol, 
SCAP escorts SREBP from the ER to the Golgi, where S1P and S2P are present (41, 177, 
178).  In the Golgi, S1P, a membrane-bound serine protease, cleaves the SREBP in the 
luminal loop between its two membrane-spanning segments, dividing the SREBP 
molecule roughly in half.  The N-terminal bHLH-Zip domain is then released from the 
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membrane after a second cleavage by S2P, a membrane-bound zinc metalloproteinase.  
The N-terminal fragment, referred to as mature SREBP, is transported into the nucleus, 
where it activates transcription by binding nonpalindromic sterol response elements 
(SREs) (93, 128) in the promoter/enhancer regions of genes involved in cholesterol and 
triacylglycerol synthesis (41, 176).  
When the cholesterol content of cells rises, SCAP senses the excess cholesterol 
through its membranous sterol-sensing domain, causing a conformational change such 
that the SCAP/SREBP complex is no longer incorporated into endoplasmic reticulum 
transport vesicles.  This results in SREBPs losing their access to S1P and S2P in the 
Golgi.  The active, N-terminal fragment is not released from the ER membrane, and 
transcription of target genes is inhibited (70). 
Recently, an endoplasmic reticulum protein was identified that binds to the sterol-
sensing domain of SCAP only in the presence of sterols.  This protein, referred to as 
insulin induced gene-1 (INSIG-1), is required for retention of the SCAP/SREBP complex 
in the ER in the presence of sterols.  Sterols induce binding of SCAP to INSIG-1, and this 
interaction is correlated with the inhibition of SCAP exit from the ER.  When sterol 
levels in the cell are high, the sterols bind to SCAP and facilitate the binding of SCAP to 
INSIG-1.  The SCAP-INSIG-1 complex then binds to SREBP and facilitates retention of 
SREBP in the ER.   Interestingly, expression of INSIG-1 is dependent on the presence of 
mature SREBP, and thus constitutes an autoregulatory loop in the regulation of mature 
SREBP production (45, 80, 223).  When sterol levels are high, mature SREBP levels are 
decreased and hence INSIG-1 levels decrease.  On the other hand, when sterol levels are 
low, mature SREBP levels are increased which in turn increase the INSIG-1 gene 
expression which in turn inhibit mature SREBP production.  
Recently, a second ER protein, referred to as INSIG-2, has been identified that 
functions in a manner similar to that of INSIG-1 except for two differences.  First, 
expression of INSIG-2 is not dependent on the presence of mature SREBP.  Second, 
INSIG-2 requires the presence of sterols in order to retain the SCAP-SREBP complex in 
the ER (219, 220).  Three point mutations in the sterol sensing domain of SCAP, 
(L315F), (D443N) and (Y298C), prevent sterol-induced binding of SCAP to INSIG-1 
and -2 and abolish feedback inhibition of SREBP processing by sterols (221).  The 
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combined actions of INSIG-1 and INSIG-2 may allow for fine-tuning of SREBP 
processing under conditions of widely varying sterol demand and supply. 
3) Regulation of transcription by SREBP 
The SREBP target genes include enzymes of cholesterol biosynthesis such as 
HMG-CoA reductase, HMG-CoA synthase, farnesyl diphosphate synthase, squalene 
synthase, and SREBP-2.  Each of these genes contains a SRE or SRE-like sequence in its 
promoter.  SREBPs also bind to regulatory sequences in the promoters of the genes 
involved in the biosynthesis of triacylglycerols such as acetyl-CoA carboxylase, fatty 
acid synthase, and stearoyl-CoA desaturase (41, 93, 128, 176).   
Results of studies employing transgenic mice indicate SREBP-2 is more effective 
in regulating genes involved in cholesterol synthesis, whereas SREBP-1 is more effective 
in controlling genes involved in triacylglycerol synthesis. The mechanism for the 
specificity of the two forms of SREBP is currently unknown.  SREBP-1a is more 
effective than SREBP-1c in modulating transcription due to the shorter acidic 
transactivation domain of the latter protein (146, 184).  In liver and adipose tissue 
SREBP-1c binds to the promoters of several lipogenic enzyme genes and increases their 
expression.  In transgenic mice that lack the SREBP-1 gene, the effects of high 
carbohydrate feeding on lipogenic enzyme expression are abolished (117, 184).  Also, in 
transgenic mice overexpressing SREBP-1c in the liver, rate of lipogenesis and lipogenic 
enzyme expression are dramatically increased (71, 183). 
4) Regulation of SREBP activity  
 
a) Activation of SREBP transcription  
Transcription of SREBP-1 but not SREBP-2, is dramatically increased by high 
carbohydrate feeding.  In rat and chick hepatocyte cultures, diet induced changes in 
SREBP-1 transcription are mimicked by altering the concentration of insulin, T3 and 
glucagon in the culture medium.  Insulin and T3 increase SREBP-1 expression, whereas 
glucagon has the opposite effect (48, 235). 
LXR agonists have also been shown to stimulate SREBP-1 transcription.  This 
effect is mediated by a LXRE in the SREBP promoter.  LXR agonist-induced activation 
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of SREBP-1c transcription is associated with an increase in mature SREBP-1c levels and 
lipogenic enzyme expression (150, 228).  A similar observation has been made in chick 
hepatocytes.  Thus, LXR agonists can stimulate lipogenic genes, at least in part, by 
altering the expression of SREBP-1.   
 
b) Inhibition of SREBP-1 expression 
Long chain polyunsaturated fatty acids have been shown to suppress the insulin-
induced SREBP-1 expression in rat hepatocytes.  This effect is mediated by a decrease in 
transcription of SREBP-1 gene, as well as an enhanced turnover of the SREBP-1 mRNA 
(145, 218).  Previous work in our laboratory has shown hexanoate inhibits ACCα 
transcription, in part, by repressing the ability of insulin and T3 to increase SREBP-1 
mRNA abundance in chicken embryo hepatocytes.  This effect disrupts the positive 
interaction between SREBP-1 and T3 bound TR on the ACCα gene previously identified 
by our laboratory (235).  Data from our preliminary studies show that hexanoate 
decreases the mRNA expression of SREBP-1.  These data suggest that fatty acid 
inhibition of SREBP-1 expression in rat and chicken hepatocytes may occur through a 
similar mechanism.  cAMP inhibits SREBP-1 expression in chicken embryo hepatocytes 
via a mechanism not involving changes in SREBP-1 mRNA abundance (235).   
 
5) Post translational regulation of SREBP activity 
 Sumoylation of SREBP-1 has been shown to control SREBP-1 activity.  SUMO-1 
is a protein responsible for posttranslational modification of many proteins and has a 
remarkably similar secondary structure to ubiquitin.  Most proteins are sumoylated by a 
multi-step process.  SUMO-1 target proteins include several transcription factors and 
regulate protein function through changes in protein-protein interactions and by 
stabilizing the target proteins.  Recent work has shown that SREBP-1 and -2 have two 
and one major sumoylation sites respectively.  Sumoylation decreases the transcriptional 
activity of both SREBP-1 and –2 resulting in the decrease of expression of their target 
genes (68).   
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SREBP-1 activity is also regulated by phosphorylation.  Previous work has shown 
that SREBPs are substrates for Erk1 and Erk2 in vitro.  Phosphorylation of serine 117 of 
SREBP-1a by ERK induces a conformational change resulting in an increase in 
transcriptional activity of SREBP-1a (170).  SREBP-1a, -1c, and -2 are ubiquitinated and 
degraded by the 26S proteasome pathway.  Phosphorylation of Thr426 and Ser430 in the 
424TLTTPPPSD motif in SREBP-1a corresponds to Thr393 and Ser399 in SREBP-1c.  
Phosphorylation of the TLTTPPPSD motif by Gsk3β promotes binding of the ubiquitin 
ligase, SCFFbw7, which targets SREBP for 26S proteasomal degradation.  Inhibition of 
Gsk3β activity by LiCl or insulin promotes the accumulation of SREBP.  Insulin inhibits 
Gsk3β activity by increasing the Akt-mediated phosphorylation of Gsk3β at Ser9 (191), 
(95).  n-3 polyunsaturated fatty acids (PUFAs) decrease the mature, active form of 
SREBP-1 in primary rat hepatocytes through 26S proteasome and Erk-dependent 
pathways.  Specific inhibitors of these pathways attenuate the inhibitory effect of PUFA 
on mature SREBP-1 levels (15).  The mechanisms by which Erk phosphorylation, and 
26S proteasomal mediate degradation of mature SREBP-1 are yet to be identified. 
 
C) Liver X Receptors  
1) Structure and Function 
Liver X receptors (LXRs) were first identified as orphan members of the nuclear 
receptor superfamily (212).  Two members of the LXR family have been identified: 
LXRα (also known as RD-1) and LXRβ (also known as UR, NER, OR-1 and RIP15) 
(196, 212).  Both LXRα and LXRβ are involved in the control of cholesterol and fatty 
acid metabolism (25),(126),(169),(166),(34),(106).  The expression patterns of the two 
LXR proteins differ significantly.  LXRα in adult animals is predominantly expressed in 
tissues that are known to play important roles in lipid metabolism.  The highest levels are 
found in the liver (hence the name liver X receptor), kidney, small intestine, spleen, 
adipose tissue, pituitary and adrenals.  In contrast, expression of LXRβ is much more 
widespread; and it is found in almost every tissue examined, including liver and brain 
(167),(33).  As is the case with other non-steroid nuclear receptors, the majority of LXR 
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proteins are localized in the nucleus and require heterodimerization with the retinoid X 
receptor (RXR) in order to bind DNA and regulate transcription (82, 212).  
Three structural domains comprise LXRs.  An N-terminal domain contains a 
strong transcriptional activation function (AF1) that is important for cell and target gene 
specificity.  A highly conserved DNA binding domain (DBD) is contained in the more 
central region of the receptor and is characterized by two C4-type zinc fingers.  The C-
terminal region of the receptor contains the ligand binding domain (LBD), and a ligand-
regulated transcriptional activation function (AF2).  This LXR domain also mediates the 
recruitment of transcriptional co-regulatory proteins.  The structural domains of LXR are 
observed in other members of the nuclear hormone receptor superfamily (52, 130, 192). 
 
2) Identification of ligands of LXR 
A major breakthrough in elucidating the physiological role of the LXR was the 
finding that oxysterols serve as their ligands.  The best studied and the most potent 
activators to date are a specific group of mono-oxidized derivatives of cholesterol that 
include, 24(S)-hydroxycholesterol, 22(R)-hydroxycholesterol and 24(S) epoxycholesterol 
(82, 212).  All of the activators analyzed thus far are able to activate both LXRα and 
LXRβ.  The compounds elicit a response at concentrations observed in LXR target 
tissues.  24(S), 25-epoxycholestrol, one of the most potent LXR ligands to be 
characterized, is known to be present at concentrations of 1-5 μM in human and murine 
liver where LXRα expression is the highest.  22(R)-hydroxycholesterol is found at 
micromolar concentrations in the placenta, where LXRβ expression is high.  Levels of 
24(S)-hydroxycholesterol are high in the brain, adrenals and liver.  The binding affinities 
of these oxysterols (Kd = 70-900 nM) correlates with their ability to activate LXR-
mediated transcription in vivo (81-83, 112). 
Fluorescence polarization-based screening assays have led to the identification of 
non-steroidal LXR ligands that may be used as drugs in preventing and treating 
atherosclerosis.  In this assay, the recruitment of a rhodamine-labeled coactivator peptide 
fragment to LXR is used to assess the binding of ligand to LXR.  This coactivator peptide 
fragment contains a LXXLL motif, (where L is leucine and X is any amino acid) that has 
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been shown to interact with LXR in an agonist-dependent manner.  Screening a chemical 
library using this assay has led to the identification of T0-314407 (N-methyl-N-[4-(2, 2, 
2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl] benzene sulfonamide).  A 
derivative of T0-314407 that exhibited enhanced selectivity was developed by structure-
activity relationship studies.  This compound was referred to as T0-901317 (N-(2,2,2-
trifluoro-ethyl)-N-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-
benzenesulfonamide).  T0-901317 also exhibited a greater potency than endogenous 
oxysterol ligands in stimulating transcription (49, 82, 112, 179).   
3) Biological Actions of LXR 
LXR•RXR heterodimers regulate target genes by binding to specific DNA 
sequences referred to as LXR response elements (LXREs).  LXREs are usually 
comprised of a direct repeat of two hexanucleotide half sites separated by a 4 bp spacer 
(212).  In addition to being activated by oxysterols, LXR•RXR heterodimers have been 
shown to be activated by ligands of RXR such as 9-cis retinoic acid (9-cis RA) (6, 107).  
LXR agonists stimulate multiple processes controlling cholesterol export from the 
body.  For example, LXR agonists cause an increase in expression of genes encoding 
apolipoprotein E (apo E) and cholesterol transporters ABCA1 and ABCG1 (125).  Apo E, 
ABCA1 and ABCG1 are involved in cholesterol efflux to HDL, a critical component of 
the reverse cholesterol transport pathway (54, 111, 123, 169).  In liver, LXR agonists also 
activate the transcription of cholesterol 7 alpha hydroxylase (CYP7A1), which encodes 
the pace setting enzyme catalyzing the conversion of cholesterol to bile acids (150).  Bile 
acid formation is the primary pathway of cholesterol excretion from the body.  LXR 
activation also increases expression of hepatic transporters involved in biliary cholesterol 
excretion such as ABCG5 and ABCG8.  The oxysterol mediated increase in expression of 
ABCA1, ABCG5 and ABCG8 in the small intestine reduces the efficiency of cholesterol 
absorption by accelerating cholesterol efflux into the intestinal lumen (12).  Another 
protein induced by LXR agonists is cholesterol ester transfer protein (CETP).  CETP 
catalyzes the transfer of cholesterol ester from HDL to chylomicrons and very low 
density lipoproteins (VLDL), thus facilitating cholesterol transport to the liver.  The 
mechanism for the effects of LXR agonists on transcription of genes involved in 
cholesterol export is mediated by the activation of LXR•RXR heterodimers bound to the 
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promoter/regulatory region (133).  The effects of LXR agonists on processes controlling 
cholesterol export result in a reduction in blood cholesterol levels and increase in HDL 
formation.  Interestingly, administration of GW3965, another synthetic LXR agonist, has 
been shown to not only prevent but also reverse atherosclerotic lesions in the aorta of 
mice lacking the LDL receptor and apo E gene (87). 
In addition to controlling cholesterol metabolism, LXR regulates the de novo 
synthesis of fatty acids.  LXR agonists increase the expression of SREBP-1c (38, 228), a 
transcription factor that stimulates transcription of various lipogenic genes including 
ACCα, FAS and stearoyl CoA desaturase (SCD) (42, 90, 144).  Thus LXR agonists may 
stimulate transcription of lipogenic genes via an indirect mechanism involving the 
activation of SREBP-1 expression.  LXR agonists may also stimulate lipogenesis via a 
direct mechanism as LXREs have also been identified in the genes for ACCα, FAS and 
SCD.  Increased lipogenesis caused by LXR agonists results in the development of fatty 
liver.  This phenomenon has limited the use of these agents for the treatment and 
prevention of atherosclerosis.   
A second potent and selective LXR agonist identified by fluorescence polarization 
screening is GW3965.  Oral administration of the synthetic LXR agonist, T0901317, to 
mice lacking the LDL receptor or apolipoprotein E stimulates an increase in blood HDL 
levels and reverses the formation of atherosclerotic lesions in the aorta (194), (87).  Oral 
administration of GW3965 to mice increased plasma HDL concentration (87).  Recently, 
another synthetic ligand for LXR, termed LN6500, has been identified, that will be 
discussed later in this section (2).  As T0-901317 is commercially available, we are using 
this compound in our studies analyzing the regulation of ACCα by the LXR pathway. 
The role of LXR agonists in glucose homeostasis has been studied in rodent 
models of diabetes.  T0-901317 lowered plasma glucose level in both db/db and Zucker 
diabetic fatty (ZDF) rat models in a dose dependent manner.  In the fa/fa insulin-resistant 
rat model, T0-901317 significantly improved insulin sensitivity.  The low plasma glucose 
levels were due to a dramatic inhibition of PEPCK mRNA transcription.  Further studies 
in primary hepatocytes have shown that hepatic activation of LXRs is sufficient to 
mediate the inhibition of gluconeogenic pathway (26).   
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Moreover, GW3965 improves glucose tolerance in a murine model of diet-
induced obesity and insulin resistance.  Activation of LXR in mouse liver inhibits 
gluconeogenic pathway by inhibiting the expression of peroxisome proliferator-activated 
receptor gamma coactivator-1α (PGC-1α), phosphoenolpyruvate carboxykinase 
(PEPCK), and glucose-6-phosphatase.  In contrast, LXR agonists promote hepatic 
glucose utilization by increased expression of glucokinase.  Activation of LXR in adipose 
tissue, increases transcription of the insulin-sensitive glucose transporter, GLUT4, which 
is a direct transcriptional target for the LXR•RXR heterodimers.  In LXR null cells and 
intact animals, the ability of LXR agonists to induce GLUT4 expression is abolished 
(105).  These results suggest a major role for LXRs in the coordination of lipid and 
glucose metabolism. 
Recently there is compelling evidence showing an important link between 
cholesterol and Alzheimer's disease.  Vascular risk factors such as high total plasma 
cholesterol, particularly low density lipoprotein (LDL) cholesterol, influence the 
progression or the incidence of Alzheimer's disease (21, 96, 97, 114, 213).  In contrast, 
plasma high density lipoprotein (HDL) cholesterol are inversely associated with 
cardiovascular disease (92) and Alzheimer's disease (14, 135).  Oxysterols decrease 
amyloid beta (A beta) secretion in vitro.  This effect is primarily due to the increase in 
ABCA1 by LXRs.  T0-901317 applied to a variety of in vitro models, including 
immortalized fibroblasts from Tangier patients, and primary embryonic mouse neurons 
and Alzheimer disease mouse model (APP23 transgenic mice) caused a concentration-
dependent decrease in A beta secretion (101).   
 
4) Regulation of LXR activity  
Several distinct pathways have been identified that modulate LXR transcription 
activity.  One such pathway involves small heterodimer partner (SHP), an unusual 
member of the nuclear hormone receptor superfamily.  SHP lacks the typical DNA 
binding domain observed in most nuclear hormone receptors.  SHP has been shown to 
interact with LXR and other nuclear hormone receptors.  In transient transfection assays, 
overexpression of SHP inhibits LXR activation of ABCA1 transcription.  Bile acids have 
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been shown to stimulate SHP expression in human intestinal cell lines.  This phenomenon 
has been proposed as a mechanism for the inhibitory effects of bile acids on the 
expression of the LXR target, ABCG1 (20).   
Another mechanism by which LXR activity is inhibited is by competition for the 
binding of oxysterols to the receptor.  Many compounds antagonize the binding of LXR 
agonists.  For example, polyunsaturated fatty acids (PUFAs) antagonize the binding of 
oxysterols to LXRα in hepatoma cells with arachidonic acid being the most potent, 
followed by linoleic and oleic acids, whereas saturated fatty acids have no effect.  PUFAs 
also interfere with LXR•RXR binding to LXREs.  PUFAs are natural agonists for 
peroxisome proliferator activated nuclear receptors (PPARs).  Ligand-activated PPAR 
induces transcription of LXRα gene through a PPAR response element (145, 229).  Thus 
PUFAs may potentially induce LXRα levels in cells while inhibiting LXRα binding of 
activating ligands such as oxysterols.  Evidence that PUFAs are physiological regulators 
of LXR signaling is currently lacking.   
Recently, the hypolipidemic agent, fenofibrate, has been shown to repress LXR-
activation of lipogenic gene expression in hepatocytes.  Fenofibrate binds directly to the 
LXR ligand binding domain, and displaces a naturally occurring LXR ligand.  
Interestingly, the antagonistic effects of fenofibrate on LXR signaling are gene specific.  
Fenofibrate inhibits LXR activation of lipogenic genes (ACCα, FAS, SREBP), but has no 
effect on LXR activation of ABCA1.  Fenofibrate could induce distinct structural 
changes in LXR that influence its ability to interact with other proteins, such as 
transcription factors residing at selective target gene promoters or with coactivators or 
corepressors that are critical for target gene regulation (47, 147, 197). 
Data from our laboratory have shown that bile acids (chenodeoxycholic acid) 
inhibit the T0-901317-induced expression of lipogenic genes.  Interestingly, 
chenodeoxycholic acid enhances T0-901317-induced expression of ABCA1.  Thus, the 
action of CDCA on LXR-induced gene expression is similar to that of fenofibrate in that 
it is gene-specific.  Currently, there is no evidence that CDCA or metabolites of CDCA 
directly interact with LXR.   
Another protein, PGC-1α has been shown to act as a coactivator for the LXRα.  
More will be discussed about PGC-1α and LXR interactions later in this Chapter.  
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Previous work has shown that the selective, potent and orally active LXR agonist, 
GW4064, enhances the recruitment of SRC-1 to human LXRα in vitro (51, 76).  Studies 
have shown that LXRs interact with corepressors such as N-CoR (nuclear receptor 
corepressor) and SMRT (silent mediator of retinoic acid receptor and thyroid receptor), in 
the absence of LXR agonists and that ectopic expression of N-CoR represses 
transcription directed by LXR.  Chromatin immunoprecipitation (ChIP) experiments have 
demonstrated that N-CoR is recruited to endogenous LXR target genes and that addition 
of LXR agonists releases N-CoR (72, 203).  Thus, to develop LXR ligands as drugs for 
the treatment of atherosclerosis, partial, selective activators of LXRs are needed that 
induce cholesterol efflux in macrophages but do not induce fatty acid synthesis in liver.  
Among the currently known ligands for LXRs, some compounds, such as the 
T0901317, have a purely agonistic activity, whereas others, such as GW3965, have been 
reported to be more selective in their activation of LXR function (162, 179).  Based on 
structural data, it has been predicted that cofactor interactions induced by T0901317 and 
a natural ligand would differ from each other (211).  For drug development, partial and 
selective agonists are desired, which activate the target receptors in a tissue-specific 
manner.  For example, tamoxifen and raloxifen have been shown to activate the estrogen 
receptor in a tissue-specific manner (134).  Responses to raloxifen and tamoxifen are 
sensitive to the amount of coactivators and corepressors in a cell.  Thus availability or 
changes of coactivators or corepressors are responsible for variable degrees of agonism or 
antagonism of these agents.  These studies have led to the hypothesis that relative 
availability of corepressors and coactivators in a cell determines the agonistic or 
antagonistic behavior of partial agonists (186).  According to the model, a variety of 
conformations can be adopted by the receptor between the two extremes of a purely 
antagonistic state and a purely agonistic state (187).  Partial agonists would induce 
conformations that are to be placed in intermediate positions between the two extreme 
states.   
The different conformations that LXRα can adopt goes beyond a linear scale.  For 
example, GW3965 increases binding of LXRα to coactivators comparably to T0901317, 
but there is a dramatic difference on corepressor binding.  On the other hand, GW3965 
and LN6500 have similar effects on corepressor binding, but LN6500 increases 
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coactivator binding more than that of GW3965.  Thus, the hypothesis that availability of 
corepressors and coactivators in a cell determines the agonistic or antagonistic behavior of 
partial agonists, can be modified as follows.  In addition to the two extremes on the linear 
scale of pure agonists and pure antagonists the following conformations are also possible 
(a) induction of corepressor and coactivator binding simultaneously; (b) partial induction 
of coactivator binding without induction of corepressor binding; (c) partial induction of 
both coactivator and repressor binding; and (d) inhibition of the binding of any cofactor, 
that results in derepression.  This phenomenon described in (d) has been demonstrated in 
LXR-knockout mice (203). 
The fundamental problem for using LXR pathway as drug targets is that in 
addition to preventing the formation of atherosclerotic plaque by increasing HDL, LXR 
agonists increase serum and liver triglyceride levels.  Recently, GW3965 has been shown 
to have a weaker effect on increase in triglyceride levels in mice than T0901317 (136).  
This provides a good example of partial agonism as described above.  Moreover, LN6500 
has a weaker agonistic property than GW3965 (2).  These observations suggest 
alterations in coactivator or corepressor recruitment to LXR is a possible mechanism 
controlling LXR transcriptional activity.  T0-901317 and bile acids may regulate ACCα 
transcription in hepatocytes by modulating the recruitment of coactivators and 
corepressors to the ACCα gene.   
 
D) Regulation of gene expression by bile acids 
 Bile acids, derived from cholesterol, are physiologically important amphipathic 
molecules that perform several functions in lipid physiology.  First, their synthesis 
provides a disposal mechanism to counterbalance cholesterol synthesis and allow 
homeostasis to be achieved.  Second, their detergent actions are essential in the intestine 
for the uptake of hydrophobic nutrients such as triacylglycerols and fat-soluble vitamins 
and in the liver for the solubilization of metabolites such as bilirubin.  Third, 
intermediates and end products of the bile acid pathway regulate the expression of genes 
involved in the synthesis of cholesterol, fatty acids, and bile acids themselves.  
Cholesterol is oxidized to oxysterols that, in turn, increase expression of bile acid 
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synthesis via LXR-mediated stimulation of cholesterol 7 alpha hydroxylase (CYP7A1), 
which catalyzes the first and rate-limiting step in the classical bile acid synthetic 
pathway, transcription in liver.  To prevent the accumulation of potentially harmful levels 
of bile acids, a feedback regulatory system that controls expression of CYP7A1 has 
evolved.  This system is initiated by the binding of bile acids to the farnesoid X receptor 
(FXR), a member of the nuclear hormone receptor superfamily (56).  Chenodeoxycholic 
acid (CDCA) is the most potent natural ligand of FXR (19).  
 
1) Structure and function of bile acids 
There are several bile acids that function differently in a physiological context.  
This strongly suggests that diversity of the side chains that lead to minor structural 
differences of bile acids may lead to their specificity of action.  For example, CDCA is 
the most potent physiological ligand of FXR, but its 7β-epimer, ursodeoxycholic acid 
(UDCA), has no effect on CYP7A1 in vivo and does not activate FXR (129, 148, 189). 
Relative hydrophobicities of bile acids are a primary determinant of the biological 
properties (175).  As bile acids function as detergents to solubilize fat, it has been 
reported that hydrophobic bile acids have a greater capacity to perturb the structure and 
partly digest cell membranes (175, 202).  Powell et. al. have determined the 
hydrophobicity of different bile acids arranged in decreasing order of hydrophobicity as 
follows; DCA>CDCA>HDCA>UDCA>CA (154).  DCA and CDCA induce apoptosis 
very rapidly in colon cancer cell lines via induction of protein kinase-C (PKC) and 
activator protein-1 (AP-1) (159).  However, moderately hydrophobic bile acids such as 
HDCA also induce apoptosis, although at later time points (154).  In contrast, 
ursodeoxycholic acid (UDCA), a less hydrophobic stereoisomer of CDCA, inhibits 
proliferation in colon cancer cell lines (64, 77).  Hydrophobicity of bile acids facilitates 
solubilization and crossing the cell membrane.  Hepatocytes contain transmembrane bile 
acid transport proteins and bile acid nuclear receptors, thus elevated bile acid levels result 
in the activation of signaling pathways by binding directly to intracellular components 
(129, 148).  These examples suggest that one of the major determinants of bile acid 
action and specificity is a measure of its hydrophobicity.   
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2) Bile acids and gene regulation 
Bile acids decrease expression of the CYP7A1 gene through multiple pathways.  
One pathway involves the induction of the repressor, short heterodimeric partner (SHP), 
by ligand-activated FXR (56, 124).  Increased SHP levels inhibit the CYP7A1 promoter 
via interaction with the positive acting transcription factor, LRH.  In support of this 
regulatory pathway, FXR knockout mice exhibit markedly reduced levels of SHP and 
bile acid regulation of CYP7A1.  Recent studies have shown that bile acids also inhibit 
transcription by causing dissociation of coactivators from the promoter of genes (89). 
For a long time bile acids have been shown to have an inverse correlation with 
triglyceride levels.  For example, humans with cholesterol gallstones treated with the bile 
acid chenodeoxycholic acid (CDCA) has been shown to reduce hypertriglyceridemia (5, 
10, 28).  Disruption in the sterol 27-hydroxylase gene in mice leads to a decrease in 
hepatic bile acid pool size that is associated with an increase in CYP7A activity and an 
increase in SREBP-1 and SREBP-2 expression that is associated with an increase in 
cholesterol synthesis and lipogenic gene expression (168).  Mice lacking FXR exhibit 
elevated levels of serum and hepatic triacylglycerol and cholesterol suggesting a role for 
FXR in maintaining lipid homeostasis (185, 207).  Disruption of the CYP7A1 gene in 
mice causes a reduction in bile acid synthesis and bile acid pool size that is associated 
with hypertriglyceridemia and treatment of these mice with a synthetic FXR agonist 
causes a reduction of plasma triacylglycerols (158).  Treatment of wild type mice with a 
synthetic FXR agonist causes a reduction in hepatic SREBP-1 levels (207). 
Recently, a novel G-protein coupled receptor (GPCR) has been identified that is 
referred to as TGR5.  TGR5 functions as a cell surface receptor that binds bile acids as 
agonists.  The primary structure of the TGR5 receptors and their responsiveness to bile 
acids are highly conserved in human, bovine, rabbit, rat, and mouse.  TGR5 mRNA is 
present in the placenta, spleen, and monocytes/macrophages, whereas the nuclear 
receptors are mainly expressed in the liver, kidney, and intestine (91, 129, 148).  
Treatment of CHO cells that express TGR5 increased ERK and cAMP production (91).  
An increase in cAMP levels as a second messenger is a classic response of GPCRs.  
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Moreover, NIH 3T3 murine fibroblasts expressing human muscarinic acetylcholine 
receptors GPCRs increase the activity of ERK5, p38α, p38γ, and p38δ, that results in the 
activation of the c-jun promoter (131).   
Another pathway involves Kupffer cells that act as sensors of concentration of 
bile acids in the liver via enterohepatic circulation (138).  Bile acids increase the 
expression of inflammatory cytokines such as tumor necrosis factor-α (TNFα) and 
interleukin (IL-1β) that are subsequently secreted into the sinusoids as a result of 
interaction with macrophages.  These cytokines are recognized by high affinity receptors 
on hepatic parenchymal cells, that activate protein kinase-C (PKC) (152) and c-jun N-
terminal kinase (JNK) to inhibit  expression of CYP7A1 (36, 138).  Activation of PKC 
has been shown to increase Mg2+ accumulation in hepatocytes via ERK and p38 MAPK 
(199). 
In addition to activating PKC, bile acids modulate gene expression signaling 
cascades such as p53 (160), ERK and p38 (159, 161), phosphatidylinositol 3-kinase 
(PI3K) (174), and the activator protein-1 (AP-1) transcription factor (159).  CDCA 
increases low density lipoprotein receptor (LDLr) gene expression via ERK activation-
mediated stabilization of LDLr mRNA via activating SHP (140).  These authors reported 
that ursodeoxycholic acid (UDCA) had no effect on LDLr and SHP mRNA.  These 
results suggested that the structural difference between CDCA and UDCA, specifically 
the 7β-hydroxy epimer of CDCA, is critical for the activation of ERK and binding to 
FXR (129, 148).  Lithocholic acid (LCA), a weak activator of FXR, is a potent inducer of 
LDLr via a robust activation of ERK.  However, UDCA had no effect on the activation of 
ERK (18).  Octyl β-D-glucopyranoside, a non-ionic and non-cytolytic membrane 
detergent had no effect on ERK activity (132).  These results provide further evidence 
that bile acids activate MAP kinases in a specific manner, not by their detergent effects, 
but by specific side chain residues and three-dimensional structure.   
Administration of bile acids increases energy expenditure in brown adipose tissue, 
preventing obesity and insulin resistance in mice.  This effect is mediated by an induction 
of the cyclic-AMP-dependent thyroid hormone activating enzyme type 2 iodothyronine 
deiodinase (D2).  Treatment of brown adipocytes and human skeletal myocytes with bile 
acids increases D2 activity and oxygen consumption.  These effects are independent of 
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FXR, and are mediated by increased cAMP production from the binding of bile acids 
with TGR5 (206). 
Recently, it has been shown that increased bile acid levels accelerate liver 
regeneration, and decreased bile acid levels inhibit liver regrowth.  This finding is 
supported by the fact that FXR null mice inhibit liver regeneration.  Therefore FXR, and 
possibly other nuclear receptors, may promote homeostasis not only by regulating 
expression of appropriate metabolic target genes but also by driving homeotrophic liver 
growth (75).  The effects of bile acids on liver regeneration can be further accounted for 
by the fact that taurochenodeoxycholic acid (TCDCA), but not glycochenodeoxycholic 
acid (GCDCA), activates phosphatidylinositol 3-kinase (PI3K)-mediated survival 
pathway in isolated, perfused rat livers.  TCDCA moderately induced hepatic injury by 
stimulating apoptosis as opposed to GCDCA, that causes a more severe liver injury.  It 
has been shown that TCDCA increases the PI3K pathway more robustly than GCDCA, 
thus accounting for the relative moderate effects of TCDCA on liver injury.  Inhibitors of 
the PI3 kinase pathway, such as wortmannin, reversed the effects of TCDCA and 
GCDCA on liver injury, in that TCDCA resulted in a more severe liver injury and 
GCDCA had a far lesser injury.  These results showed that TCDCA block its toxic effect 
in intact liver, by activating the PI3K dependent survival pathway (174).  Another recent 
report showed that a relatively hydrophilic bile acid UDCA, protects reperfusion injury of 
the heart by activating the PI3K pathway (164).  These findings suggest a protective, or 
growth promoting role of bile acids.  Physiologically, the growth promoting effects of 
some bile acids may act to oppose the pro-apoptotic effects of more hydrophobic bile 
acids.   
 
3) Bile acids and fibroblast growth factor-19 (FGF-19) 
Another pathway mediating bile acid regulation of CYP7A1 expression involves 
the fibroblast growth factor 19 (FGF-19).  FGF-19 is a member of the fibroblast growth 
factor (FGF) family of secreted signaling molecules.  FGF-19 is a high affinity ligand for 
its receptor, fibroblast growth factor receptor 4 (FGFR4) and is the first member of the 
FGF family to show exclusive binding to FGFR4.  FGFR4 belongs to the receptor 
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tyrosine kinase family of receptors.  Bile acids increase the expression of FGF-19 in 
human hepatocytes by binding FXR on the FGF-19 gene promoter.  Increased FGF-19 
levels, in turn, inhibit transcription of CYP7A1 via a mechanism involving the activation 
of Jun-N terminal kinase (JNK) signaling pathway (60, 69, 217, 233).   
In support of a role of FGF-19 in bile acid regulation of CYP7A1, FGFR4 
knockout mice have an elevated bile acid excretion and expression of CYP7A1 (232).  In 
contrast, transgenic mice expressing a constitutively active form of FGFR4 have 
increased JNK activity, decreased CYP7A1 expression, and a reduced bile acid pool size 
(231).  Transgenic mice overexpressing FGF-19 showed a decrease in fat mass and 
increased energy expenditure.  These animals overexpressing FGF-19 were resistant to 
high fat diet, in that they did not develop obesity or diabetes.  Expression of acetyl CoA 
carboxylase 2, malic enzyme and stearoyl CoA desaturase in the liver were decreased 
along with a decrease in liver triglyceride levels in these animals (198).  In humans 
Paraoxonase-1 (PON1), an enzyme that metabolizes organophosphate insecticides is 
secreted by the liver and transported in the blood complexed to HDL.  Bile acids inhibit 
the expression of PON1 via increase of FGF-19 (181). 
Recently, it has been demonstrated that expression of FGF15, the mouse ortholog 
of human FGF19, is induced by FXR agonists in small intestine.  FGF15 mediated 
inhibition of hepatic bile acid synthesis involves both FGFR4 and SHP (78).  We have 
shown that bile acids increase FGF-19 mRNA expression in chicken embryo hepatocytes.  
Work from our lab by Sushant Bhatnagar has shown that recombinant human FGF-19 
inhibits insulin-induced expression of glucokinase and lipogenic genes such as ACC1 and 
SCD in primary rat hepatocytes.  We hypothesize that inhibition of T0-901317-induced 
lipogenic gene expression in chick hepatocytes is mediated by increased FGF-19 
expression.   
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E) Peroxisome gamma coactivator -1 alpha (PGC-1α) 
1) Structure and function 
PGC-1α belongs to a small family of transcriptional coactivators that includes 
PGC-1β and PGC-1-related coactivator.  PGC-1α was first identified as a protein that 
interacts with the nuclear hormone receptor PPARγ, that is the regulator of adipocyte 
differentiation (157).  From structure-function analysis of PGC-1α it has been 
demonstrated that the N terminus of the protein consists of a transcriptional activation 
domain that includes the nuclear hormone receptor-interacting motif (LXXLL).  This 
motif mediates ligand-dependent interaction of coactivators with nuclear hormone 
receptors.  The C-terminal region of PGC-1α consists of an RNA-binding motif (RMM) 
and a serine-arginine-rich (RS) domain (4, 62, 102, 119).  Transcriptional coactivators are 
recruited to particular DNA sequences in promoters of genes through direct interaction 
with transcription factors.  The LXXLL motif of PGC-1α has been shown to mediate 
ligand-dependent interaction with nuclear receptors such as estrogen receptor (ER) (195), 
PPARα (200), RXRα (39), and glucocorticoid receptor (GR) (98).   
 
2) PGC-1α and gene regulation 
PGC-1α has been shown to be a coactivator for LXRα.  In transient transfection 
studies, PGC-1α potentiates the LXR-mediated autoregulation and transactivation of the 
LXRα promoter via the LXRE on the cholesteryl ester transfer-protein (CETP) gene 
promoter in a ligand-dependent manner.  As described above, the LXXLL motif of PGC-
1α is located in the vicinity of the binding region for a putative repressor that will be 
described later in this section.  The repressor sequesters PGC-1α from PPARα and the 
glucocorticoid receptor.  However, this repressor does not interfere with PGC-1α-
mediated coactivation of LXR-dependent gene transcription (142).  Previous reports have 
shown that p38 MAPK phosphorylates PGC-1α on Thr262, Ser265, and Thr298.  
Phosphorylation of PGC-1α on these residues results in increased stability and half-life of 
the protein (156).  Inhibition of p38 MAP kinase activity had only a moderate inhibitory 
effect on LXR coactivation by PGC-1α.  Thus PGC-1α has been established as a bona 
fide LXR coactivator and suggests the involvement of distinct motifs of PGC-1α and/or 
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additional cofactors in the modulation of LXR and PPARα transcriptional activities 
(142).  Interestingly, HNF4 also interacts with this motif of PGC-1α in the absence of an 
agonist, suggesting that this nuclear hormone receptor is in an active conformation even 
without the addition of exogenous ligand (227).   
Non-LXXLL motifs of PGC-1α also mediate interaction with transcription 
factors.  For example, a region between amino acids 200 and 400 interacts with PPARγ 
(157) and NRF-1 (216) and a region between amino acids 400 to 500 interacts with 
MEF2-C (137).  Most coactivators increase transcriptional activity by either intrinsic 
chromatin remodeling activity, or by recruiting other proteins that have intrinsic 
chromatin remodeling activity (53, 139, 190).  PGC-1α lacks significant amino acid 
sequence homology to other transcriptional coactivator families and it does not possess 
intrinsic histone acetyl transferase (HAT) activity.  However, the N-terminal domain of 
PGC-1α recruits proteins that contain HAT activity, such as SRC-1 and CREB binding 
protein CBP/p300 (155).  In addition, PGC-1α is also present in a complex that contains 
RNA polymerase II.   
Interestingly, the binding of SRC-1 and CBP/p300 to the N-terminus of PGC-1α 
is dependent upon docking of transcription factors such PPARγ and NRF-1 to the amino 
acids 200-400 region of PGC-1α (155).  This suggests that PGC-1α is in a relatively 
inactive state when not bound to a transcription factor.  However, when a transcription 
factor binds to PGC-1α, it is activated, and results in a conformation change that recruits 
SRC-1 and CBP/p300 into the complex.  Thus, transcription factor docking switches on 
the activity of PGC-1α.  Whether this phenomenon of transcriptional activation via a 
transcription factor docking event is a common feature of coactivators remains to be 
determined.  Transcription factors are targets of multiple signal transduction pathways, 
but there is evidence to suggest that coactivators can also be targets of these signaling 
pathways in response to hormones, growth factors and ligands.  For example, 
transcriptional activity of CBP is increased in response to calcium signaling through 
calmodulin kinase IV (29).  In addition, SRC-1 has been shown to be a target of cAMP 
signaling through protein kinase A PKA (172).  Therefore, regulation of transcriptional 
coactivator function provides a target to integrate different responses to specific signals 
across multiple transcription factors.  
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As discussed previously, p38 MAPK phosphorylates PGC-1α at three residues 
Thr262, Ser265, and Thr298 (156).  Phosphorylation of PGC-1α on those residues leads 
to increased stability and half-life of PGC-1α.  It is interesting that these 
phosphorylations occur in a region previously shown to play a regulatory role in PGC-1α 
binding to transcription factors.  It is unclear whether the p38 MAPK-mediated 
phosphorylations affect transcription factor docking or the recruitment of other 
coactivator proteins to the PGC-1α complex.  It is also unclear as to how these phospho-
amino acids change protein stability.  
Activation of p38 MAPK leads to an increase in transcriptional activity of PGC-
1α.  In the absence of nuclear hormone receptor, PGC-1α associates with a strong 
transcriptional repressor, referred to as p160 myb binding protein (p160MYB), that keeps 
PGC-1α in an inactive state.  It is unclear whether p160myb by itself is a transcriptional 
repressor, or whether it recruits the binding of another repressor on the promoter.  
Activation of p38 MAPK phosphorylates PGC-1α that removes p160myb and facilitates 
the association of PGC-1α with the nuclear hormone receptor at the transcription site (43, 
99).  Binding to the nuclear hormone receptor causes a conformational change on PGC-
1α that helps to stabilize the active state (155).  Interestingly, transcriptional activity of 
PPARα associated with PGC-1α can be activated via the p38 MAPK pathway (9).   
Hepatic nuclear factor-4α (HNF-4α) and PGC-1α are key activators of hepatic 
gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase (PEPCK) and 
Glucose-6-Phosphatase (G6Pase).  These genes are activated during fasting and inhibited 
during the fed state.  SREBP-1a and -1c inhibited PEPCK promoter activity that was 
induced by HNF-4α.  Electrophoretic mobility shift assays showed that SREBP-1 did not 
bind to the PEPCK promoter, and that the inhibitory effect was more potent in SREBP-1a 
than SREBP-1c.  This inhibitory effect was abolished by deletion of the amino-terminal 
transactivation domain of SREBP-1.  SREBP-1 competitively inhibits PGC-1α 
recruitment, that is a fundamental requirement for HNF-4α activation.  Transgenic mice 
overexpressing SREBP-1a and -1c showed an inhibition of hepatic PEPCK and G6Pase 
mRNA abundance.  These results identify a novel role of SREBP-1 as an inhibitor of 
gluconeogenic genes by inhibiting PGC-1α recruitment to HNF-4α (222). 
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F) Peroxisome proliferator activated receptor gamma coactivator 
-1 beta (PGC-1β) 
PGC-1β is a transcriptional coactivator that has been recently identified as a close 
member of PGC-1α.  The biological activities of PGC-1β are currently unknown (102, 
118).  The tissue distribution of PGC-1β is similar to that of PGC-1α.  However, they are 
differentially regulated during development and in response to changes in nutritional 
status (88, 118).  Recently it has been shown that high fat feeding increases PGC-1β and 
SREBP-1a and -1c.  PGC-1β has been shown to be a coactivator of SREBP and LXR.  
This increase in SREBP-1 and LXR activity increases de novo lipogenesis and 
lipoprotein secretion.  PGC-1β coactivation of SREBP and LXR by high fat leads to 
hypertriglyceridemia and hypercholesterolemia (120).   
  
G) Mitogen activated protein kinases 
Mitogen activated protein kinases (MAPKs) consist of a family of protein kinases 
that are conserved across species from unicellular organisms to complex organisms 
including humans.  Protein kinases are enzymes that covalently attach phosphate to Ser, 
Thr and Tyr residues on other proteins in the cell.  MAPKs phosphorylate Ser and Thr 
residues on target proteins that are substrates, and modulate multiple cellular processes 
such as gene regulation, mitosis, metabolism and apoptosis.  The phosphorylation of 
substrate proteins by MAPKs functions as a molecular switch to turn on or turn off the 
activity of the target protein that ultimately alter cellular processes.  There are several 
substrates of MAPKs that modulate multiple functions such as other protein kinases, 
transcription factors and phospholipases.  Protein phophatases remove the phosphate 
attached by MAPKs to inactivate the substrate proteins (165, 209).   
 MAPKs are part of a signaling cascade comprised of three kinases that are 
regulated by phosphorylation.  MAPKs are substrates for MAPK kinases (MKKs) that 
phosphorylate and activate MAPKs.  Specific phosphatases of the MAPKs, remove the 
phosphate from the MAPKs and render them inactive.  MKKs in turn, are phosphorylated 
and activated by MAPK kinase kinases (MKKKs).  In multicellular organisms, there are 
three conserved and well characterized MAPK families.  These include the extracellular 
signal-regulated kinases ERK1 and ERK2 (16, 17), the c-Jun N-terminal kinases JNK-1, -
   26
2 and -3 (63, 104), and p38 MAPKs p38α, p38β, p38γ and p38δ (84, 85, 108, 116, 188).  
Recently a fourth MAPK, ERK5 has been identified and is being studied (237).  
Additional proteins kinases have been identified during sequencing the human and mouse 
genomes that may function as MAPKs, one of them being ERK7, but very little is known 
about this protein (1).    
 
1) ERK  
Mammalian ERK1/2 MAPKs are referred to as the classical mitogen kinase 
cascade, consisting of the MAPKKKs A-Raf, B-Raf, and Raf-1, the MAPKKs MEK1 and 
MEK2, and the MAPKs ERK1 and ERK2.  ERK1 (44 kD) and -2 (42 kD) have 85% 
amino acid identity and are expressed in almost all tissues; however, their relative 
distribution in tissues differ widely (31).  Both ERK1/2 are activated by a vast number of 
ligands and cellular processes with some cell type specificity.  Activators of ERK1/2 
include serum, growth factors, phorbol esters and to a lesser extent by ligands of the 
heterotrimeric G protein-coupled receptors, cytokines and osmotic stress (115).  These 
agents and events activate ERK pathway by activating receptor tyrosine kinases (RTKs) 
on the cell surface and G protein-coupled receptors.  Activated RTKs in turn, activate the 
Raf/MEK/ERK cascade through different isoforms of the small GTP-binding protein Ras 
(24, 214).   
ERK1/2 are distributed in almost all cells in the inactive, unphosphorylated state, 
but upon activation, a significant population of ERK1/2 accumulates in the nucleus (30, 
55, 113).  The mechanism of nuclear accumulation of ERK1/2 are unclear; however, 
phosphorylation, dimerization, nuclear retention and release from cytoplasmic anchors 
are suggested in mediating the effect (153).  Since ERK1/2 pathway has been shown to 
be a key regulator of cellular proliferation, chemical inhibitors of the ERK pathway are 
being tested in clinical trials as potential anticancer agents (100).  Two structurally 
unrelated compounds, U0126 (44) and PD98059 (3, 40), are commonly used to 
specifically inhibit the ERK1/2 pathway in cell culture.  The use of these compounds has 
been widely validated in the literature in various cell culture systems.  Both these 
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compounds are noncompetitive inhibitors of MEK1/2/5 and inhibit phosphorylation and 
activation of ERK1/2/5 (8). 
 
2) Transcriptional regulation by ERK 
ERK1/2 increases the phosphorylation and activation of several downstream 
MAPK-activated protein kinases referred to as p90 ribosomal S6 kinases (RSKs) 
proteins.  The RSK family consists of four human isoforms that share 70% amino acid 
similarity.  RSK like proteins have also been identified in other species such as 
Drosophila, Xenopus, chicken and yeast.  These proteins are Ser/Thr kinases that 
modulate the activity of target proteins (46, 86, 204).   
Activation of the ERK pathway facilitates the interaction between RSK1 and the 
transcriptional coactivator CREB-binding protein (CBP) (141).  CBP and its paralog p300 
facilitate complex formation between different components of the basal transcriptional 
machinery.  RSK1 interaction with CBP was found to modulate its function, but the exact 
outcome of this interaction remains to be determined.  Binding of phospho-p90RSK (P-
p90RSK) to CBP mediated transcription inhibition of cAMP-responsive genes via the 
cAMP-inducible factor CREB.  In contrast, formation of the P-p90RSK-CBP complex 
was required for increase in transcription of Ras-responsive genes (141, 205).  
Interestingly, CBP and p300 have been shown to associate with several transcription 
factors also known to be RSK1 and RSK2 substrates, such as c-Fos, c-Jun, ER81, and 
NF-κB, suggesting that RSK1 binding to CBP may provide a second mechanism of 
transcriptional control (171).  It is interesting to note that although both ERK and RSK 
accumulate in the nucleus upon activation, it is unclear whether ERK1/2 directly 
modulates the activity of proteins.  All data so far suggest that RSK proteins mediate the 
effects of ERK on target proteins.   
Deoxycholic acid (DCA), lithocholic acid (LCA) and CDCA, but not 
ursodeoxycholic acid (UDCA), increase the mRNA abundance of the LDL receptor, even 
in the presence of a potent inhibitor of the LDL receptor, 25-hydroxycholesterol.  
Surprisingly, this increase of the LDL receptor mRNA is not mediated by FXR.  CDCA 
increased the phosphorylated, active form of ERK, and inhibition of ERK activity by 
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U0126 abolished the CDCA-mediated increase of LDL receptor.  Thus, CDCA-mediated 
increase of ERK stabilizes LDL receptor mRNA and the ERK inhibitor accelerates its 
turnover (140). 
As discussed previously, ERK has been shown to mediate lipogenic gene 
inhibition by inhibiting the mature, transcriptionally active form of SREBP-1 (15).  This 
is another example by which ERK can inhibit gene transcription.  Our studies have 
shown that activation of ERK mediates inhibitory effects of CDCA on ACCα mRNA 
expression.   
 
3) p38 MAP kinase 
The p38 MAPK module consists of the four known p38 isoforms (α, β, γ, and δ), 
several MAPKKKs, including MEKKs 1 to 4, the MAPKKs MKK3 and MKK6 (103).  
Most stimuli or agents that stimulate JNK pathway also stimulate p38 MAPK.  The 
functional role of p38 MAPK has largely been determined by using the anti-inflammatory 
drug SB203580 (110).  SB203580 inhibits p38α, β and β2 (not γ and δ) by competing 
with the substrate, ATP (57, 230).  While SB203580 inhibits p38 activity, it does not 
significantly affect the activation of p38.  SB203580 does not inhibit PKA, PKC, MEKs, 
MEKKs or ERK and JNK MAPKs (35, 50, 230). 
 p38 is present in both the nucleus and cytoplasm of cells.  The subcellular 
localization of p38 MAPK kinase upon cellular stimuli is unclear.  On one hand, upon 
receiving activation stimuli, p38 MAPK translocates from the cytoplasm to the nucleus 
(163), and on the other, active p38 MAPK is also present in the cytoplasm of stimulated 
cells (11).  p38 MAPK activation in macrophages, neutrophils, and T cells by numerous 
extracellular modulators of inflammation mediates normal immune and inflammatory 
responses (143).  p38 MAPK phosphorylates several cellular targets, including the 
transcription factors ATF1 and -2, MEF2A, Sap-1, Elk-1, NF-κB, Ets-1, and p53 (103). 
 
4) Transcriptional regulation by p38 MAPK 
Mitogen- and stress-activated kinases 1 and 2 (MSK1 and MSK2) are 
downstream substrates of both ERK1/2 and p38α and p38β MAPK.  MSKs are 
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predominantly located in the nucleus in the inactive state as they contain a C-terminal 
nuclear localization signal (NLS).  MSK1 and MSK2 phosphorylate and activate CREB 
on ser133 in vitro with a significantly lower Km than that of RSK1 and MK2 (37, 151).  
This data has been confirmed by data that showed the involvement of MSK1 and -2 in 
CREB phosphorylation with different inhibitors (58, 109).  MSK1 has been shown to 
mediate NF-κB-dependent transcription by phosphorylating the NF-κB isoform p65 on 
Ser276 (201).  MSK1 has also been shown to phosphorylate and activate other 
transcription factors such as ER81 (79) and STAT3 (210, 234). 
Hepatic gluconeogenesis is essential for maintaining blood glucose levels during 
fasting and is the major contributor to postprandial and fasting hyperglycemia in diabetes.  
Glucagon, elevated in the blood during fasting and diabetes increases gluconeogenesis.  
Glucagon activates p38 MAPK in primary hepatocytes.  Mice treated with the p38 
MAPK inhibitor SB203580 reduced fasting plasma glucose levels.  Inhibition of p38 
MAPK inhibited gluconeogenesis by decreasing the mRNA abundance of gluconeogenic 
genes such as phosphoenolpyruvate carboxykinase and glucose-6-phosphatase.  PGC-1α 
and CREB have been shown to mediate hepatic gluconeogenesis.  Inhibition of p38 
MAPK decreased PGC-1α and CREB.  These results have established a role for p38 
MAPK in cAMP-dependent activation of genes involved in gluconeogenesis (27). 
Recently, it has been shown that polyunsaturated fatty acids such as arachidonic 
acid inhibit the insulin-induced abundance of glucose-6-phosphate dehydrogenase 
(G6PD) mRNA in hepatocytes.  Arachidonic acid increases phosphorylation and 
activation of p38 MAPK that phosphorylates Ser307 residue of insulin receptor substrate 
(IRS-1) and inhibits the activity.  This inhibition of IRS-1 inhibits activation of phosphor-
Akt and inhibits insulin signaling (193).  As G6PD is a lipogenic gene, this report 
suggests a link between activation of p38 MAPK and inhibition of lipogenic genes.  Our 
data shows that CDCA inhibits ACCα mRNA abundance at least in part, by increasing 
the phosphorylation and activation of p38 MAPK.   
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5) JNK 
Three members have been identified that are referred to as JNK1, JNK2, and 
JNK3 (also known as SAPKγ, SAPKα, and SAPKβ, respectively) that are ubiquitously 
expressed.  Activators of JNK include cytokines, UV irradiation, growth factor 
deprivation, DNA-damaging agents, and, to a lesser extent, growth factors, serum and 
some G protein-coupled receptors (103).  The MAPKKs that phosphorylates and activates 
JNK are referred to as MEK4 and MEK7, which are themselves phosphorylated and 
activated by several MAPKKKs, that include MEKK1-4, MLK2 and -3 (103).  JNKs 
relocalize from the cytoplasm to the nucleus following activation (103).  The best known 
substrate for JNKs is the transcription factor c-Jun.  Phosphorylation of c-Jun on ser63 
and ser73 by JNK leads to increased c-Jun-dependent transcription (208).  Several other 
transcription factors have been shown to be phosphorylated by the JNKs, such as ATF-2, 
NF-ATc1, HSF-1, and STAT3 (31, 103).  It is interesting to note that although some 
cytoplasmic targets of JNK are known, the fact that activated JNK does not exhibit 
exclusive nuclear localization suggests that many other cytoplasmic substrates remain to 
be identified.  Interestingly, JNK-activated MKs are unknown. 
As discussed above, FGF-19 activates JNK that results in feedback inhibition of 
CYP7A.  Transcription regulation by JNK has been discussed in Section D 2).  Our data 
shows that CDCA increases the phosphorylation and activation of JNK in primary 
hepatocytes.   
 
H) AMP-activated protein kinase 
 When cellular AMP:ATP ratio increases, AMP activates a wide range of cellular 
processes by binding to AMP-activated protein kinase (AMPK) that activates pathways 
that generate ATP while inhibiting pathways that utilize ATP (59).  AMP causes an 
allosteric activation of AMPK.  Binding of AMP makes AMPK a better substrate for 
upstream kinases, that phosphorylates AMPK at Thr172.  Binding of AMP to AMPK also 
inhibits dephosphorylation of Thr172 by phosphatases (59).  AMPK is phosphorylated 
and activated by its upstream protein kinase, referred to as LKB1 (61, 180, 215).  
Phosphorylated and activated AMPK (P-AMPK) inhibits fatty acid synthesis and 
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cholesterol biosynthesis and activates catabolic pathways such as fatty acid oxidation, 
glucose uptake and glycolysis (59).  P-AMPK inhibits lipogenesis by inhibiting SREBP-1 
(238).  P-AMPK also inhibits the coactivator p300 by phosphorylating the protein at 
(Ser89), and inhibiting the binding to nuclear hormone receptors (224).  P-AMPK also 
phosphorylates and inactivates ACC at Ser79.  Phosphorylation of ACC at this residue is 
a direct measure of AMPK activity (32, 59).   
  
   32
REFERENCES 
 
1. Abe, M. K., W. L. Kuo, M. B. Hershenson, and M. R. Rosner. 1999. 
Extracellular signal-regulated kinase 7 (ERK7), a novel ERK with a C-terminal 
domain that regulates its activity, its cellular localization, and cell growth. Mol 
Cell Biol 19:1301-12. 
2. Albers, M., B. Blume, T. Schlueter, M. B. Wright, I. Kober, C. Kremoser, U. 
Deuschle, and M. Koegl. 2006. A novel principle for partial agonism of liver X 
receptor ligands. Competitive recruitment of activators and repressors. J Biol 
Chem 281:4920-30. 
3. Alessi, D. R., A. Cuenda, P. Cohen, D. T. Dudley, and A. R. Saltiel. 1995. PD 
098059 is a specific inhibitor of the activation of mitogen-activated protein kinase 
kinase in vitro and in vivo. J Biol Chem 270:27489-94. 
4. Andersson, U., and R. C. Scarpulla. 2001. Pgc-1-related coactivator, a novel, 
serum-inducible coactivator of nuclear respiratory factor 1-dependent 
transcription in mammalian cells. Mol Cell Biol 21:3738-49. 
5. Angelin, B., K. Einarsson, K. Hellstrom, and B. Leijd. 1978. Effects of 
cholestyramine and chenodeoxycholic acid on the metabolism of endogenous 
triglyceride in hyperlipoproteinemia. J Lipid Res 19:1017-24. 
6. Antonio, V., B. Janvier, A. Brouillet, M. Andreani, and M. Raymondjean. 
2003. Oxysterol and 9-cis-retinoic acid stimulate the group IIA secretory 
phospholipase A2 gene in rat smooth-muscle cells. Biochem J 376:351-60. 
7. Assaf, S., D. Hazard, F. Pitel, M. Morisson, M. Alizadeh, F. Gondret, C. Diot, 
A. Vignal, M. Douaire, and S. Lagarrigue. 2003. Cloning of cDNA encoding 
the nuclear form of chicken sterol response element binding protein-2 (SREBP-2), 
chromosomal localization, and tissue expression of chicken SREBP-1 and -2 
genes. Poult Sci 82:54-61. 
8. Ballif, B. A., and J. Blenis. 2001. Molecular mechanisms mediating mammalian 
mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival 
signals. Cell Growth Differ 12:397-408. 
9. Barger, P. M., A. C. Browning, A. N. Garner, and D. P. Kelly. 2001. p38 
mitogen-activated protein kinase activates peroxisome proliferator-activated 
receptor alpha: a potential role in the cardiac metabolic stress response. J Biol 
Chem 276:44495-501. 
10. Bateson, M. C., D. Maclean, J. R. Evans, and I. A. Bouchier. 1978. 
Chenodeoxycholic acid therapy for hypertriglyceridaemia in men. Br J Clin 
Pharmacol 5:249-54. 
11. Ben-Levy, R., S. Hooper, R. Wilson, H. F. Paterson, and C. J. Marshall. 1998. 
Nuclear export of the stress-activated protein kinase p38 mediated by its substrate 
MAPKAP kinase-2. Curr Biol 8:1049-57. 
12. Berge, K. E., H. Tian, G. A. Graf, L. Yu, N. V. Grishin, J. Schultz, P. 
Kwiterovich, B. Shan, R. Barnes, and H. H. Hobbs. 2000. Accumulation of 
dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC 
transporters. Science 290:1771-5. 
   33
13. Bianchi, A., J. L. Evans, A. J. Iverson, A. C. Nordlund, T. D. Watts, and L. 
A. Witters. 1990. Identification of an isozymic form of acetyl-CoA carboxylase. 
J Biol Chem 265:1502-9. 
14. Bonarek, M., P. Barberger-Gateau, L. Letenneur, V. Deschamps, A. Iron, B. 
Dubroca, and J. F. Dartigues. 2000. Relationships between cholesterol, 
apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the 
PAQUID study. Neuroepidemiology 19:141-8. 
15. Botolin, D., Y. Wang, B. Christian, and D. B. Jump. 2006. Docosahexaneoic 
acid (22:6,n-3) regulates rat hepatocyte SREBP-1 nuclear abundance by Erk- and 
26S proteasome-dependent pathways. J Lipid Res 47:181-92. 
16. Boulton, T. G., S. H. Nye, D. J. Robbins, N. Y. Ip, E. Radziejewska, S. D. 
Morgenbesser, R. A. DePinho, N. Panayotatos, M. H. Cobb, and G. D. 
Yancopoulos. 1991. ERKs: a family of protein-serine/threonine kinases that are 
activated and tyrosine phosphorylated in response to insulin and NGF. Cell 
65:663-75. 
17. Boulton, T. G., G. D. Yancopoulos, J. S. Gregory, C. Slaughter, C. Moomaw, 
J. Hsu, and M. H. Cobb. 1990. An insulin-stimulated protein kinase similar to 
yeast kinases involved in cell cycle control. Science 249:64-7. 
18. Brady, L. M., D. W. Beno, and B. H. Davis. 1996. Bile acid stimulation of early 
growth response gene and mitogen-activated protein kinase is protein kinase C-
dependent. Biochem J 316 ( Pt 3):765-9. 
19. Bramlett, K. S., S. Yao, and T. P. Burris. 2000. Correlation of farnesoid X 
receptor coactivator recruitment and cholesterol 7alpha-hydroxylase gene 
repression by bile acids. Mol Genet Metab 71:609-15. 
20. Brendel, C., K. Schoonjans, O. A. Botrugno, E. Treuter, and J. Auwerx. 
2002. The small heterodimer partner interacts with the liver X receptor alpha and 
represses its transcriptional activity. Mol Endocrinol 16:2065-76. 
21. Breteler, M. M. 2000. Vascular risk factors for Alzheimer's disease: an 
epidemiologic perspective. Neurobiol Aging 21:153-60. 
22. Brown, M. S., and J. L. Goldstein. 1997. The SREBP pathway: regulation of 
cholesterol metabolism by proteolysis of a membrane-bound transcription factor. 
Cell 89:331-40. 
23. Burman, K. D., Y. Lukes, F. D. Wright, and L. Wartofsky. 1977. Reduction in 
hepatic triiodothyronine binding capacity induced by fasting. Endocrinology 
101:1331-4. 
24. Campbell, S. L., R. Khosravi-Far, K. L. Rossman, G. J. Clark, and C. J. Der. 
1998. Increasing complexity of Ras signaling. Oncogene 17:1395-413. 
25. Cao, G., T. P. Beyer, X. P. Yang, R. J. Schmidt, Y. Zhang, W. R. Bensch, R. 
F. Kauffman, H. Gao, T. P. Ryan, Y. Liang, P. I. Eacho, and X. C. Jiang. 
2002. Phospholipid transfer protein is regulated by liver X receptors in vivo. J 
Biol Chem 277:39561-5. 
26. Cao, G., Y. Liang, C. L. Broderick, B. A. Oldham, T. P. Beyer, R. J. Schmidt, 
Y. Zhang, K. R. Stayrook, C. Suen, K. A. Otto, A. R. Miller, J. Dai, P. 
Foxworthy, H. Gao, T. P. Ryan, X. C. Jiang, T. P. Burris, P. I. Eacho, and G. 
J. Etgen. 2003. Antidiabetic action of a liver x receptor agonist mediated by 
inhibition of hepatic gluconeogenesis. J Biol Chem 278:1131-6. 
   34
27. Cao, W., Q. F. Collins, T. C. Becker, J. Robidoux, E. G. Lupo, Jr., Y. Xiong, 
K. W. Daniel, L. Floering, and S. Collins. 2005. p38 Mitogen-activated protein 
kinase plays a stimulatory role in hepatic gluconeogenesis. J Biol Chem 
280:42731-7. 
28. Carulli, N., M. Ponz de Leon, M. Podda, M. Zuin, A. Strata, G. Frigerio, and 
A. Digrisolo. 1981. Chenodeoxycholic acid and ursodeoxycholic acid effects in 
endogenous hypertriglyceridemias. A controlled double-blind trial. J Clin 
Pharmacol 21:436-42. 
29. Chawla, S., G. E. Hardingham, D. R. Quinn, and H. Bading. 1998. CBP: a 
signal-regulated transcriptional coactivator controlled by nuclear calcium and 
CaM kinase IV. Science 281:1505-9. 
30. Chen, R. H., C. Sarnecki, and J. Blenis. 1992. Nuclear localization and 
regulation of erk- and rsk-encoded protein kinases. Mol Cell Biol 12:915-27. 
31. Chen, Z., T. B. Gibson, F. Robinson, L. Silvestro, G. Pearson, B. Xu, A. 
Wright, C. Vanderbilt, and M. H. Cobb. 2001. MAP kinases. Chem Rev 
101:2449-76. 
32. Chen, Z. P., G. K. McConell, B. J. Michell, R. J. Snow, B. J. Canny, and B. E. 
Kemp. 2000. AMPK signaling in contracting human skeletal muscle: acetyl-CoA 
carboxylase and NO synthase phosphorylation. Am J Physiol Endocrinol Metab 
279:E1202-6. 
33. Collins, J. L., A. M. Fivush, M. A. Watson, C. M. Galardi, M. C. Lewis, L. B. 
Moore, D. J. Parks, J. G. Wilson, T. K. Tippin, J. G. Binz, K. D. Plunket, D. 
G. Morgan, E. J. Beaudet, K. D. Whitney, S. A. Kliewer, and T. M. Willson. 
2002. Identification of a nonsteroidal liver X receptor agonist through parallel 
array synthesis of tertiary amines. J Med Chem 45:1963-6. 
34. Costet, P., Y. Luo, N. Wang, and A. R. Tall. 2000. Sterol-dependent 
transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. 
J Biol Chem 275:28240-5. 
35. Cuenda, A., J. Rouse, Y. N. Doza, R. Meier, P. Cohen, T. F. Gallagher, P. R. 
Young, and J. C. Lee. 1995. SB 203580 is a specific inhibitor of a MAP kinase 
homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 
364:229-33. 
36. Davis, R. A., J. H. Miyake, T. Y. Hui, and N. J. Spann. 2002. Regulation of 
cholesterol-7alpha-hydroxylase: BAREly missing a SHP. J Lipid Res 43:533-43. 
37. Deak, M., A. D. Clifton, L. M. Lucocq, and D. R. Alessi. 1998. Mitogen- and 
stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and 
SAPK2/p38, and may mediate activation of CREB. Embo J 17:4426-41. 
38. DeBose-Boyd, R. A., J. Ou, J. L. Goldstein, and M. S. Brown. 2001. 
Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in 
rat hepatoma cells requires endogenous LXR ligands. Proc Natl Acad Sci U S A 
98:1477-82. 
39. Delerive, P., Y. Wu, T. P. Burris, W. W. Chin, and C. S. Suen. 2002. PGC-1 
functions as a transcriptional coactivator for the retinoid X receptors. J Biol Chem 
277:3913-7. 
   35
40. Dudley, D. T., L. Pang, S. J. Decker, A. J. Bridges, and A. R. Saltiel. 1995. A 
synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl 
Acad Sci U S A 92:7686-9. 
41. Duncan, E. A., M. S. Brown, J. L. Goldstein, and J. Sakai. 1997. Cleavage site 
for sterol-regulated protease localized to a leu-Ser bond in the lumenal loop of 
sterol regulatory element-binding protein-2. J Biol Chem 272:12778-85. 
42. Edwards, P. A., D. Tabor, H. R. Kast, and A. Venkateswaran. 2000. 
Regulation of gene expression by SREBP and SCAP. Biochim Biophys Acta 
1529:103-13. 
43. Fan, M., J. Rhee, J. St-Pierre, C. Handschin, P. Puigserver, J. Lin, S. Jaeger, 
H. Erdjument-Bromage, P. Tempst, and B. M. Spiegelman. 2004. Suppression 
of mitochondrial respiration through recruitment of p160 myb binding protein to 
PGC-1alpha: modulation by p38 MAPK. Genes Dev 18:278-89. 
44. Favata, M. F., K. Y. Horiuchi, E. J. Manos, A. J. Daulerio, D. A. Stradley, W. 
S. Feeser, D. E. Van Dyk, W. J. Pitts, R. A. Earl, F. Hobbs, R. A. Copeland, 
R. L. Magolda, P. A. Scherle, and J. M. Trzaskos. 1998. Identification of a 
novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 
273:18623-32. 
45. Feramisco, J. D., J. L. Goldstein, and M. S. Brown. 2004. Membrane topology 
of human insig-1, a protein regulator of lipid synthesis. J Biol Chem 279:8487-96. 
46. Fisher, T. L., and J. Blenis. 1996. Evidence for two catalytically active kinase 
domains in pp90rsk. Mol Cell Biol 16:1212-9. 
47. Forcheron, F., A. Cachefo, S. Thevenon, C. Pinteur, and M. Beylot. 2002. 
Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in 
hyperlipidemic type 2 diabetic patients. Diabetes 51:3486-91. 
48. Foretz, M., C. Pacot, I. Dugail, P. Lemarchand, C. Guichard, X. Le Liepvre, 
C. Berthelier-Lubrano, B. Spiegelman, J. B. Kim, P. Ferre, and F. Foufelle. 
1999. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene 
expression by glucose. Mol Cell Biol 19:3760-8. 
49. Forman, B. M., B. Ruan, J. Chen, G. J. Schroepfer, Jr., and R. M. Evans. 
1997. The orphan nuclear receptor LXRalpha is positively and negatively 
regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci U S 
A 94:10588-93. 
50. Gallagher, T. F., G. L. Seibel, S. Kassis, J. T. Laydon, M. J. Blumenthal, J. C. 
Lee, D. Lee, J. C. Boehm, S. M. Fier-Thompson, J. W. Abt, M. E. Soreson, J. 
M. Smietana, R. F. Hall, R. S. Garigipati, P. E. Bender, K. F. Erhard, A. J. 
Krog, G. A. Hofmann, P. L. Sheldrake, P. C. McDonnell, S. Kumar, P. R. 
Young, and J. L. Adams. 1997. Regulation of stress-induced cytokine 
production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg Med Chem 
5:49-64. 
51. Gan, X., R. Kaplan, J. G. Menke, K. MacNaul, Y. Chen, C. P. Sparrow, G. 
Zhou, S. D. Wright, and T. Q. Cai. 2001. Dual mechanisms of ABCA1 
regulation by geranylgeranyl pyrophosphate. J Biol Chem 276:48702-8. 
52. Glass, C. K. 1994. Differential recognition of target genes by nuclear receptor 
monomers, dimers, and heterodimers. Endocr Rev 15:391-407. 
   36
53. Glass, C. K., and M. G. Rosenfeld. 2000. The coregulator exchange in 
transcriptional functions of nuclear receptors. Genes Dev 14:121-41. 
54. Goldstein, J. L., and M. S. Brown. 2001. Molecular medicine. The cholesterol 
quartet. Science 292:1310-2. 
55. Gonzalez, F. A., A. Seth, D. L. Raden, D. S. Bowman, F. S. Fay, and R. J. 
Davis. 1993. Serum-induced translocation of mitogen-activated protein kinase to 
the cell surface ruffling membrane and the nucleus. J Cell Biol 122:1089-101. 
56. Goodwin, B., S. A. Jones, R. R. Price, M. A. Watson, D. D. McKee, L. B. 
Moore, C. Galardi, J. G. Wilson, M. C. Lewis, M. E. Roth, P. R. Maloney, T. 
M. Willson, and S. A. Kliewer. 2000. A regulatory cascade of the nuclear 
receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 
6:517-26. 
57. Gum, R. J., M. M. McLaughlin, S. Kumar, Z. Wang, M. J. Bower, J. C. Lee, 
J. L. Adams, G. P. Livi, E. J. Goldsmith, and P. R. Young. 1998. Acquisition 
of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, 
by alteration of one or more amino acids within the ATP binding pocket. J Biol 
Chem 273:15605-10. 
58. Hamm, J., D. R. Alessi, and R. M. Biondi. 2002. Bi-functional, substrate 
mimicking RNA inhibits MSK1-mediated cAMP-response element-binding 
protein phosphorylation and reveals magnesium ion-dependent conformational 
changes of the kinase. J Biol Chem 277:45793-802. 
59. Hardie, D. G. 2004. The AMP-activated protein kinase pathway--new players 
upstream and downstream. J Cell Sci 117:5479-87. 
60. Harmer, N. J., L. Pellegrini, D. Chirgadze, J. Fernandez-Recio, and T. L. 
Blundell. 2004. The crystal structure of fibroblast growth factor (FGF) 19 reveals 
novel features of the FGF family and offers a structural basis for its unusual 
receptor affinity. Biochemistry 43:629-40. 
61. Hawley, S. A., J. Boudeau, J. L. Reid, K. J. Mustard, L. Udd, T. P. Makela, 
D. R. Alessi, and D. G. Hardie. 2003. Complexes between the LKB1 tumor 
suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the 
AMP-activated protein kinase cascade. J Biol 2:28. 
62. Heery, D. M., E. Kalkhoven, S. Hoare, and M. G. Parker. 1997. A signature 
motif in transcriptional co-activators mediates binding to nuclear receptors. 
Nature 387:733-6. 
63. Hibi, M., A. Lin, T. Smeal, A. Minden, and M. Karin. 1993. Identification of 
an oncoprotein- and UV-responsive protein kinase that binds and potentiates the 
c-Jun activation domain. Genes Dev 7:2135-48. 
64. Hillaire, S., F. Ballet, D. Franco, K. D. Setchell, and R. Poupon. 1995. Effects 
of ursodeoxycholic acid and chenodeoxycholic acid on human hepatocytes in 
primary culture. Hepatology 22:82-7. 
65. Hillgartner, F. B., T. Charron, and K. A. Chesnut. 1996. Alterations in 
nutritional status regulate acetyl-CoA carboxylase expression in avian liver by a 
transcriptional mechanism. Biochem J 319 ( Pt 1):263-8. 
66. Hillgartner, F. B., T. Charron, and K. A. Chesnut. 1997. Triiodothyronine 
stimulates and glucagon inhibits transcription of the acetyl-CoA carboxylase gene 
   37
in chick embryo hepatocytes: glucose and insulin amplify the effect of 
triiodothyronine. Arch Biochem Biophys 337:159-68. 
67. Hillgartner, F. B., L. M. Salati, and A. G. Goodridge. 1995. Physiological and 
molecular mechanisms involved in nutritional regulation of fatty acid synthesis. 
Physiol Rev 75:47-76. 
68. Hirano, Y., S. Murata, K. Tanaka, M. Shimizu, and R. Sato. 2003. Sterol 
regulatory element-binding proteins are negatively regulated through SUMO-1 
modification independent of the ubiquitin/26 S proteasome pathway. J Biol Chem 
278:16809-19. 
69. Holt, J. A., G. Luo, A. N. Billin, J. Bisi, Y. Y. McNeill, K. F. Kozarsky, M. 
Donahee, Y. Wang da, T. A. Mansfield, S. A. Kliewer, B. Goodwin, and S. A. 
Jones. 2003. Definition of a novel growth factor-dependent signal cascade for the 
suppression of bile acid biosynthesis. Genes Dev 17:1581-91. 
70. Horton, J. D., J. L. Goldstein, and M. S. Brown. 2002. SREBPs: activators of 
the complete program of cholesterol and fatty acid synthesis in the liver. J Clin 
Invest 109:1125-31. 
71. Horton, J. D., I. Shimomura, M. S. Brown, R. E. Hammer, J. L. Goldstein, 
and H. Shimano. 1998. Activation of cholesterol synthesis in preference to fatty 
acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol 
regulatory element-binding protein-2. J Clin Invest 101:2331-9. 
72. Hu, X., S. Li, J. Wu, C. Xia, and D. S. Lala. 2003. Liver X receptors interact 
with corepressors to regulate gene expression. Mol Endocrinol 17:1019-26. 
73. Hua, X., J. Wu, J. L. Goldstein, M. S. Brown, and H. H. Hobbs. 1995. 
Structure of the human gene encoding sterol regulatory element binding protein-1 
(SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 
and 22q13. Genomics 25:667-73. 
74. Hua, X., C. Yokoyama, J. Wu, M. R. Briggs, M. S. Brown, J. L. Goldstein, 
and X. Wang. 1993. SREBP-2, a second basic-helix-loop-helix-leucine zipper 
protein that stimulates transcription by binding to a sterol regulatory element. 
Proc Natl Acad Sci U S A 90:11603-7. 
75. Huang, W., K. Ma, J. Zhang, M. Qatanani, J. Cuvillier, J. Liu, B. Dong, X. 
Huang, and D. D. Moore. 2006. Nuclear receptor-dependent bile acid signaling 
is required for normal liver regeneration. Science 312:233-6. 
76. Huuskonen, J., P. E. Fielding, and C. J. Fielding. 2004. Role of p160 
coactivator complex in the activation of liver X receptor. Arterioscler Thromb 
Vasc Biol 24:703-8. 
77. Ikegami, T., Y. Matsuzaki, J. Shoda, M. Kano, N. Hirabayashi, and N. 
Tanaka. 1998. The chemopreventive role of ursodeoxycholic acid in 
azoxymethane-treated rats: suppressive effects on enhanced group II 
phospholipase A2 expression in colonic tissue. Cancer Lett 134:129-39. 
78. Inagaki, T., M. Choi, A. Moschetta, L. Peng, C. L. Cummins, J. G. 
McDonald, G. Luo, S. A. Jones, B. Goodwin, J. A. Richardson, R. D. Gerard, 
J. J. Repa, D. J. Mangelsdorf, and S. A. Kliewer. 2005. Fibroblast growth 
factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. 
Cell Metab 2:217-25. 
   38
79. Janknecht, R. 2003. Regulation of the ER81 transcription factor and its 
coactivators by mitogen- and stress-activated protein kinase 1 (MSK1). Oncogene 
22:746-55. 
80. Janowski, B. A. 2002. The hypocholesterolemic agent LY295427 up-regulates 
INSIG-1, identifying the INSIG-1 protein as a mediator of cholesterol 
homeostasis through SREBP. Proc Natl Acad Sci U S A 99:12675-80. 
81. Janowski, B. A., M. J. Grogan, S. A. Jones, G. B. Wisely, S. A. Kliewer, E. J. 
Corey, and D. J. Mangelsdorf. 1999. Structural requirements of ligands for the 
oxysterol liver X receptors LXRalpha and LXRbeta. Proc Natl Acad Sci U S A 
96:266-71. 
82. Janowski, B. A., P. J. Willy, T. R. Devi, J. R. Falck, and D. J. Mangelsdorf. 
1996. An oxysterol signalling pathway mediated by the nuclear receptor LXR 
alpha. Nature 383:728-31. 
83. Javitt, N. B. 2002. 25R,26-Hydroxycholesterol revisited: synthesis, metabolism, 
and biologic roles. J Lipid Res 43:665-70. 
84. Jiang, Y., C. Chen, Z. Li, W. Guo, J. A. Gegner, S. Lin, and J. Han. 1996. 
Characterization of the structure and function of a new mitogen-activated protein 
kinase (p38beta). J Biol Chem 271:17920-6. 
85. Jiang, Y., H. Gram, M. Zhao, L. New, J. Gu, L. Feng, F. Di Padova, R. J. 
Ulevitch, and J. Han. 1997. Characterization of the structure and function of the 
fourth member of p38 group mitogen-activated protein kinases, p38delta. J Biol 
Chem 272:30122-8. 
86. Jones, S. W., E. Erikson, J. Blenis, J. L. Maller, and R. L. Erikson. 1988. A 
Xenopus ribosomal protein S6 kinase has two apparent kinase domains that are 
each similar to distinct protein kinases. Proc Natl Acad Sci U S A 85:3377-81. 
87. Joseph, S. B., E. McKilligin, L. Pei, M. A. Watson, A. R. Collins, B. A. 
Laffitte, M. Chen, G. Noh, J. Goodman, G. N. Hagger, J. Tran, T. K. Tippin, 
X. Wang, A. J. Lusis, W. A. Hsueh, R. E. Law, J. L. Collins, T. M. Willson, 
and P. Tontonoz. 2002. Synthetic LXR ligand inhibits the development of 
atherosclerosis in mice. Proc Natl Acad Sci U S A 99:7604-9. 
88. Kamei, Y., H. Ohizumi, Y. Fujitani, T. Nemoto, T. Tanaka, N. Takahashi, T. 
Kawada, M. Miyoshi, O. Ezaki, and A. Kakizuka. 2003. PPARgamma 
coactivator 1beta/ERR ligand 1 is an ERR protein ligand, whose expression 
induces a high-energy expenditure and antagonizes obesity. Proc Natl Acad Sci U 
S A 100:12378-83. 
89. Kassam, A., B. Miao, P. R. Young, and R. Mukherjee. 2003. Retinoid X 
receptor (RXR) agonist-induced antagonism of farnesoid X receptor (FXR) 
activity due to absence of coactivator recruitment and decreased DNA binding. J 
Biol Chem 278:10028-32. 
90. Kast, H. R., C. M. Nguyen, A. M. Anisfeld, J. Ericsson, and P. A. Edwards. 
2001. CTP:phosphocholine cytidylyltransferase, a new sterol- and SREBP-
responsive gene. J Lipid Res 42:1266-72. 
91. Kawamata, Y., R. Fujii, M. Hosoya, M. Harada, H. Yoshida, M. Miwa, S. 
Fukusumi, Y. Habata, T. Itoh, Y. Shintani, S. Hinuma, Y. Fujisawa, and M. 
Fujino. 2003. A G protein-coupled receptor responsive to bile acids. J Biol Chem 
278:9435-40. 
   39
92. Kawashiri, M. A., C. Maugeais, and D. J. Rader. 2000. High-density 
lipoprotein metabolism: molecular targets for new therapies for atherosclerosis. 
Curr Atheroscler Rep 2:363-72. 
93. Kim, J. B., G. D. Spotts, Y. D. Halvorsen, H. M. Shih, T. Ellenberger, H. C. 
Towle, and B. M. Spiegelman. 1995. Dual DNA binding specificity of 
ADD1/SREBP1 controlled by a single amino acid in the basic helix-loop-helix 
domain. Mol Cell Biol 15:2582-8. 
94. Kim, K. H. 1997. Regulation of mammalian acetyl-coenzyme A carboxylase. 
Annu Rev Nutr 17:77-99. 
95. Kim, K. H., M. J. Song, E. J. Yoo, S. S. Choe, S. D. Park, and J. B. Kim. 
2004. Regulatory role of glycogen synthase kinase 3 for transcriptional activity of 
ADD1/SREBP1c. J Biol Chem 279:51999-2006. 
96. Kivipelto, M., E. L. Helkala, M. P. Laakso, T. Hanninen, M. Hallikainen, K. 
Alhainen, S. Iivonen, A. Mannermaa, J. Tuomilehto, A. Nissinen, and H. 
Soininen. 2002. Apolipoprotein E epsilon4 allele, elevated midlife total 
cholesterol level, and high midlife systolic blood pressure are independent risk 
factors for late-life Alzheimer disease. Ann Intern Med 137:149-55. 
97. Kivipelto, M., E. L. Helkala, M. P. Laakso, T. Hanninen, M. Hallikainen, K. 
Alhainen, H. Soininen, J. Tuomilehto, and A. Nissinen. 2001. Midlife vascular 
risk factors and Alzheimer's disease in later life: longitudinal, population based 
study. Bmj 322:1447-51. 
98. Knutti, D., A. Kaul, and A. Kralli. 2000. A tissue-specific coactivator of steroid 
receptors, identified in a functional genetic screen. Mol Cell Biol 20:2411-22. 
99. Knutti, D., D. Kressler, and A. Kralli. 2001. Regulation of the transcriptional 
coactivator PGC-1 via MAPK-sensitive interaction with a repressor. Proc Natl 
Acad Sci U S A 98:9713-8. 
100. Kohno, M., and J. Pouyssegur. 2003. Pharmacological inhibitors of the ERK 
signaling pathway: application as anticancer drugs. Prog Cell Cycle Res 5:219-24. 
101. Koldamova, R. P., I. M. Lefterov, M. Staufenbiel, D. Wolfe, S. Huang, J. C. 
Glorioso, M. Walter, M. G. Roth, and J. S. Lazo. 2005. The liver X receptor 
ligand T0901317 decreases amyloid beta production in vitro and in a mouse 
model of Alzheimer's disease. J Biol Chem 280:4079-88. 
102. Kressler, D., S. N. Schreiber, D. Knutti, and A. Kralli. 2002. The PGC-1-
related protein PERC is a selective coactivator of estrogen receptor alpha. J Biol 
Chem 277:13918-25. 
103. Kyriakis, J. M., and J. Avruch. 2001. Mammalian mitogen-activated protein 
kinase signal transduction pathways activated by stress and inflammation. Physiol 
Rev 81:807-69. 
104. Kyriakis, J. M., and J. Avruch. 1990. pp54 microtubule-associated protein 2 
kinase. A novel serine/threonine protein kinase regulated by phosphorylation and 
stimulated by poly-L-lysine. J Biol Chem 265:17355-63. 
105. Laffitte, B. A., L. C. Chao, J. Li, R. Walczak, S. Hummasti, S. B. Joseph, A. 
Castrillo, D. C. Wilpitz, D. J. Mangelsdorf, J. L. Collins, E. Saez, and P. 
Tontonoz. 2003. Activation of liver X receptor improves glucose tolerance 
through coordinate regulation of glucose metabolism in liver and adipose tissue. 
Proc Natl Acad Sci U S A 100:5419-24. 
   40
106. Laffitte, B. A., S. B. Joseph, M. Chen, A. Castrillo, J. Repa, D. Wilpitz, D. 
Mangelsdorf, and P. Tontonoz. 2003. The phospholipid transfer protein gene is 
a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol 
Cell Biol 23:2182-91. 
107. Landis, M. S., H. V. Patel, and J. P. Capone. 2002. Oxysterol activators of liver 
X receptor and 9-cis-retinoic acid promote sequential steps in the synthesis and 
secretion of tumor necrosis factor-alpha from human monocytes. J Biol Chem 
277:4713-21. 
108. Lechner, C., M. A. Zahalka, J. F. Giot, N. P. Moller, and A. Ullrich. 1996. 
ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast 
differentiation. Proc Natl Acad Sci U S A 93:4355-9. 
109. Lee, C. W., J. S. Nam, Y. K. Park, H. K. Choi, J. H. Lee, N. H. Kim, J. Cho, 
D. K. Song, H. W. Suh, J. Lee, Y. H. Kim, and S. O. Huh. 2003. 
Lysophosphatidic acid stimulates CREB through mitogen- and stress-activated 
protein kinase-1. Biochem Biophys Res Commun 305:455-61. 
110. Lee, J. C., J. T. Laydon, P. C. McDonnell, T. F. Gallagher, S. Kumar, D. 
Green, D. McNulty, M. J. Blumenthal, J. R. Heys, S. W. Landvatter, and et 
al. 1994. A protein kinase involved in the regulation of inflammatory cytokine 
biosynthesis. Nature 372:739-46. 
111. Lee, M. H., K. Lu, S. Hazard, H. Yu, S. Shulenin, H. Hidaka, H. Kojima, R. 
Allikmets, N. Sakuma, R. Pegoraro, A. K. Srivastava, G. Salen, M. Dean, and 
S. B. Patel. 2001. Identification of a gene, ABCG5, important in the regulation of 
dietary cholesterol absorption. Nat Genet 27:79-83. 
112. Lehmann, J. M., S. A. Kliewer, L. B. Moore, T. A. Smith-Oliver, B. B. Oliver, 
J. L. Su, S. S. Sundseth, D. A. Winegar, D. E. Blanchard, T. A. Spencer, and 
T. M. Willson. 1997. Activation of the nuclear receptor LXR by oxysterols 
defines a new hormone response pathway. J Biol Chem 272:3137-40. 
113. Lenormand, P., C. Sardet, G. Pages, G. L'Allemain, A. Brunet, and J. 
Pouyssegur. 1993. Growth factors induce nuclear translocation of MAP kinases 
(p42mapk and p44mapk) but not of their activator MAP kinase kinase 
(p45mapkk) in fibroblasts. J Cell Biol 122:1079-88. 
114. Lesser, G., K. Kandiah, L. S. Libow, A. Likourezos, B. Breuer, D. Marin, R. 
Mohs, V. Haroutunian, and R. Neufeld. 2001. Elevated serum total and LDL 
cholesterol in very old patients with Alzheimer's disease. Dement Geriatr Cogn 
Disord 12:138-45. 
115. Lewis, T. S., P. S. Shapiro, and N. G. Ahn. 1998. Signal transduction through 
MAP kinase cascades. Adv Cancer Res 74:49-139. 
116. Li, Z., Y. Jiang, R. J. Ulevitch, and J. Han. 1996. The primary structure of p38 
gamma: a new member of p38 group of MAP kinases. Biochem Biophys Res 
Commun 228:334-40. 
117. Liang, G., J. Yang, J. D. Horton, R. E. Hammer, J. L. Goldstein, and M. S. 
Brown. 2002. Diminished hepatic response to fasting/refeeding and liver X 
receptor agonists in mice with selective deficiency of sterol regulatory element-
binding protein-1c. J Biol Chem 277:9520-8. 
118. Lin, J., P. Puigserver, J. Donovan, P. Tarr, and B. M. Spiegelman. 2002. 
Peroxisome proliferator-activated receptor gamma coactivator 1beta (PGC-1beta 
   41
), a novel PGC-1-related transcription coactivator associated with host cell factor. 
J Biol Chem 277:1645-8. 
119. Lin, J., P. T. Tarr, R. Yang, J. Rhee, P. Puigserver, C. B. Newgard, and B. M. 
Spiegelman. 2003. PGC-1beta in the regulation of hepatic glucose and energy 
metabolism. J Biol Chem 278:30843-8. 
120. Lin, J., R. Yang, P. T. Tarr, P. H. Wu, C. Handschin, S. Li, W. Yang, L. Pei, 
M. Uldry, P. Tontonoz, C. B. Newgard, and B. M. Spiegelman. 2005. 
Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta 
coactivation of SREBP. Cell 120:261-73. 
121. Lopez-Casillas, F., M. V. Ponce-Castaneda, and K. H. Kim. 1992. Acetyl-
coenzyme A carboxylase mRNA metabolism in the rat liver. Metabolism 41:201-
7. 
122. Lopez-Casillas, F., M. V. Ponce-Castaneda, and K. H. Kim. 1991. In vivo 
regulation of the activity of the two promoters of the rat acetyl coenzyme-A 
carboxylase gene. Endocrinology 129:1049-58. 
123. Lu, K., M. H. Lee, S. Hazard, A. Brooks-Wilson, H. Hidaka, H. Kojima, L. 
Ose, A. F. Stalenhoef, T. Mietinnen, I. Bjorkhem, E. Bruckert, A. Pandya, H. 
B. Brewer, Jr., G. Salen, M. Dean, A. Srivastava, and S. B. Patel. 2001. Two 
genes that map to the STSL locus cause sitosterolemia: genomic structure and 
spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 
and ABCG8, respectively. Am J Hum Genet 69:278-90. 
124. Lu, T. T., M. Makishima, J. J. Repa, K. Schoonjans, T. A. Kerr, J. Auwerx, 
and D. J. Mangelsdorf. 2000. Molecular basis for feedback regulation of bile 
acid synthesis by nuclear receptors. Mol Cell 6:507-15. 
125. Lund, E. G., J. G. Menke, and C. P. Sparrow. 2003. Liver X receptor agonists 
as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler 
Thromb Vasc Biol 23:1169-77. 
126. Luo, Y., and A. R. Tall. 2000. Sterol upregulation of human CETP expression in 
vitro and in transgenic mice by an LXR element. J Clin Invest 105:513-20. 
127. Magana, M. M., S. S. Lin, K. A. Dooley, and T. F. Osborne. 1997. Sterol 
regulation of acetyl coenzyme A carboxylase promoter requires two 
interdependent binding sites for sterol regulatory element binding proteins. J 
Lipid Res 38:1630-8. 
128. Magana, M. M., and T. F. Osborne. 1996. Two tandem binding sites for sterol 
regulatory element binding proteins are required for sterol regulation of fatty-acid 
synthase promoter. J Biol Chem 271:32689-94. 
129. Makishima, M., A. Y. Okamoto, J. J. Repa, H. Tu, R. M. Learned, A. Luk, 
M. V. Hull, K. D. Lustig, D. J. Mangelsdorf, and B. Shan. 1999. Identification 
of a nuclear receptor for bile acids. Science 284:1362-5. 
130. Mangelsdorf, D. J., C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. 
Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon, and R. M. 
Evans. 1995. The nuclear receptor superfamily: the second decade. Cell 83:835-
9. 
131. Marinissen, M. J., M. Chiariello, M. Pallante, and J. S. Gutkind. 1999. A 
network of mitogen-activated protein kinases links G protein-coupled receptors to 
   42
the c-jun promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular 
signal-regulated kinase 5. Mol Cell Biol 19:4289-301. 
132. Marriott, S. J., G. R. Griffith, and R. A. Consigli. 1987. Octyl-beta-D-
glucopyranoside extracts polyomavirus receptor moieties from the surfaces of 
mouse kidney cells. J Virol 61:375-82. 
133. Masson, D., B. Staels, T. Gautier, C. Desrumaux, A. Athias, N. Le Guern, M. 
Schneider, Z. Zak, L. Dumont, V. Deckert, A. Tall, X. C. Jiang, and L. 
Lagrost. 2004. Cholesteryl ester transfer protein modulates the effect of liver X 
receptor agonists on cholesterol transport and excretion in the mouse. J Lipid Res 
45:543-50. 
134. McDonnell, D. P. 2003. Mining the complexities of the estrogen signaling 
pathways for novel therapeutics. Endocrinology 144:4237-40. 
135. Merched, A., Y. Xia, S. Visvikis, J. M. Serot, and G. Siest. 2000. Decreased 
high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations 
are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 
21:27-30. 
136. Miao, B., S. Zondlo, S. Gibbs, D. Cromley, V. P. Hosagrahara, T. G. 
Kirchgessner, J. Billheimer, and R. Mukherjee. 2004. Raising HDL cholesterol 
without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR 
modulator. J Lipid Res 45:1410-7. 
137. Michael, L. F., Z. Wu, R. B. Cheatham, P. Puigserver, G. Adelmant, J. J. 
Lehman, D. P. Kelly, and B. M. Spiegelman. 2001. Restoration of insulin-
sensitive glucose transporter (GLUT4) gene expression in muscle cells by the 
transcriptional coactivator PGC-1. Proc Natl Acad Sci U S A 98:3820-5. 
138. Miyake, J. H., S. L. Wang, and R. A. Davis. 2000. Bile acid induction of 
cytokine expression by macrophages correlates with repression of hepatic 
cholesterol 7alpha-hydroxylase. J Biol Chem 275:21805-8. 
139. Naar, A. M., B. D. Lemon, and R. Tjian. 2001. Transcriptional coactivator 
complexes. Annu Rev Biochem 70:475-501. 
140. Nakahara, M., H. Fujii, P. R. Maloney, M. Shimizu, and R. Sato. 2002. Bile 
acids enhance low density lipoprotein receptor gene expression via a MAPK 
cascade-mediated stabilization of mRNA. J Biol Chem 277:37229-34. 
141. Nakajima, T., A. Fukamizu, J. Takahashi, F. H. Gage, T. Fisher, J. Blenis, 
and M. R. Montminy. 1996. The signal-dependent coactivator CBP is a nuclear 
target for pp90RSK. Cell 86:465-74. 
142. Oberkofler, H., E. Schraml, F. Krempler, and W. Patsch. 2003. Potentiation 
of liver X receptor transcriptional activity by peroxisome-proliferator-activated 
receptor gamma co-activator 1 alpha. Biochem J 371:89-96. 
143. Ono, K., and J. Han. 2000. The p38 signal transduction pathway: activation and 
function. Cell Signal 12:1-13. 
144. Osborne, T. F. 2000. Sterol regulatory element-binding proteins (SREBPs): key 
regulators of nutritional homeostasis and insulin action. J Biol Chem 275:32379-
82. 
145. Ou, J., H. Tu, B. Shan, A. Luk, R. A. DeBose-Boyd, Y. Bashmakov, J. L. 
Goldstein, and M. S. Brown. 2001. Unsaturated fatty acids inhibit transcription 
of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by 
   43
antagonizing ligand-dependent activation of the LXR. Proc Natl Acad Sci U S A 
98:6027-32. 
146. Pai, J. T., O. Guryev, M. S. Brown, and J. L. Goldstein. 1998. Differential 
stimulation of cholesterol and unsaturated fatty acid biosynthesis in cells 
expressing individual nuclear sterol regulatory element-binding proteins. J Biol 
Chem 273:26138-48. 
147. Panzenboeck, U., I. Kratzer, A. Sovic, A. Wintersperger, E. Bernhart, A. 
Hammer, E. Malle, and W. Sattler. 2006. Regulatory effects of synthetic liver 
X receptor- and peroxisome-proliferator activated receptor agonists on sterol 
transport pathways in polarized cerebrovascular endothelial cells. Int J Biochem 
Cell Biol. 
148. Parks, D. J., S. G. Blanchard, R. K. Bledsoe, G. Chandra, T. G. Consler, S. 
A. Kliewer, J. B. Stimmel, T. M. Willson, A. M. Zavacki, D. D. Moore, and J. 
M. Lehmann. 1999. Bile acids: natural ligands for an orphan nuclear receptor. 
Science 284:1365-8. 
149. Parraga, A., L. Bellsolell, A. R. Ferre-D'Amare, and S. K. Burley. 1998. Co-
crystal structure of sterol regulatory element binding protein 1a at 2.3 A 
resolution. Structure 6:661-72. 
150. Peet, D. J., S. D. Turley, W. Ma, B. A. Janowski, J. M. Lobaccaro, R. E. 
Hammer, and D. J. Mangelsdorf. 1998. Cholesterol and bile acid metabolism 
are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 
93:693-704. 
151. Pierrat, B., J. S. Correia, J. L. Mary, M. Tomas-Zuber, and W. Lesslauer. 
1998. RSK-B, a novel ribosomal S6 kinase family member, is a CREB kinase 
under dominant control of p38alpha mitogen-activated protein kinase 
(p38alphaMAPK). J Biol Chem 273:29661-71. 
152. Pongracz, J., P. Clark, J. P. Neoptolemos, and J. M. Lord. 1995. Expression of 
protein kinase C isoenzymes in colorectal cancer tissue and their differential 
activation by different bile acids. Int J Cancer 61:35-9. 
153. Pouyssegur, J., V. Volmat, and P. Lenormand. 2002. Fidelity and spatio-
temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol 64:755-
63. 
154. Powell, A. A., J. M. LaRue, A. K. Batta, and J. D. Martinez. 2001. Bile acid 
hydrophobicity is correlated with induction of apoptosis and/or growth arrest in 
HCT116 cells. Biochem J 356:481-6. 
155. Puigserver, P., G. Adelmant, Z. Wu, M. Fan, J. Xu, B. O'Malley, and B. M. 
Spiegelman. 1999. Activation of PPARgamma coactivator-1 through 
transcription factor docking. Science 286:1368-71. 
156. Puigserver, P., J. Rhee, J. Lin, Z. Wu, J. C. Yoon, C. Y. Zhang, S. Krauss, V. 
K. Mootha, B. B. Lowell, and B. M. Spiegelman. 2001. Cytokine stimulation of 
energy expenditure through p38 MAP kinase activation of PPARgamma 
coactivator-1. Mol Cell 8:971-82. 
157. Puigserver, P., Z. Wu, C. W. Park, R. Graves, M. Wright, and B. M. 
Spiegelman. 1998. A cold-inducible coactivator of nuclear receptors linked to 
adaptive thermogenesis. Cell 92:829-39. 
   44
158. Pullinger, C. R., C. Eng, G. Salen, S. Shefer, A. K. Batta, S. K. Erickson, A. 
Verhagen, C. R. Rivera, S. J. Mulvihill, M. J. Malloy, and J. P. Kane. 2002. 
Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a 
hypercholesterolemic phenotype. J Clin Invest 110:109-17. 
159. Qiao, D., W. Chen, E. D. Stratagoules, and J. D. Martinez. 2000. Bile acid-
induced activation of activator protein-1 requires both extracellular signal-
regulated kinase and protein kinase C signaling. J Biol Chem 275:15090-8. 
160. Qiao, D., S. V. Gaitonde, W. Qi, and J. D. Martinez. 2001. Deoxycholic acid 
suppresses p53 by stimulating proteasome-mediated p53 protein degradation. 
Carcinogenesis 22:957-64. 
161. Qiao, D., E. D. Stratagouleas, and J. D. Martinez. 2001. Activation and role of 
mitogen-activated protein kinases in deoxycholic acid-induced apoptosis. 
Carcinogenesis 22:35-41. 
162. Quinet, E. M., D. A. Savio, A. R. Halpern, L. Chen, C. P. Miller, and P. 
Nambi. 2004. Gene-selective modulation by a synthetic oxysterol ligand of the 
liver X receptor. J Lipid Res 45:1929-42. 
163. Raingeaud, J., S. Gupta, J. S. Rogers, M. Dickens, J. Han, R. J. Ulevitch, and 
R. J. Davis. 1995. Pro-inflammatory cytokines and environmental stress cause 
p38 mitogen-activated protein kinase activation by dual phosphorylation on 
tyrosine and threonine. J Biol Chem 270:7420-6. 
164. Rajesh, K. G., R. Suzuki, H. Maeda, M. Yamamoto, X. Yutong, and S. 
Sasaguri. 2005. Hydrophilic bile salt ursodeoxycholic acid protects myocardium 
against reperfusion injury in a PI3K/Akt dependent pathway. J Mol Cell Cardiol 
39:766-76. 
165. Ray, L. B., and T. W. Sturgill. 1988. Insulin-stimulated microtubule-associated 
protein kinase is phosphorylated on tyrosine and threonine in vivo. Proc Natl 
Acad Sci U S A 85:3753-7. 
166. Repa, J. J., K. E. Berge, C. Pomajzl, J. A. Richardson, H. Hobbs, and D. J. 
Mangelsdorf. 2002. Regulation of ATP-binding cassette sterol transporters 
ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 
277:18793-800. 
167. Repa, J. J., G. Liang, J. Ou, Y. Bashmakov, J. M. Lobaccaro, I. Shimomura, 
B. Shan, M. S. Brown, J. L. Goldstein, and D. J. Mangelsdorf. 2000. 
Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-
1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 14:2819-30. 
168. Repa, J. J., E. G. Lund, J. D. Horton, E. Leitersdorf, D. W. Russell, J. M. 
Dietschy, and S. D. Turley. 2000. Disruption of the sterol 27-hydroxylase gene 
in mice results in hepatomegaly and hypertriglyceridemia. Reversal by cholic acid 
feeding. J Biol Chem 275:39685-92. 
169. Repa, J. J., S. D. Turley, J. A. Lobaccaro, J. Medina, L. Li, K. Lustig, B. 
Shan, R. A. Heyman, J. M. Dietschy, and D. J. Mangelsdorf. 2000. Regulation 
of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. 
Science 289:1524-9. 
170. Roth, G., J. Kotzka, L. Kremer, S. Lehr, C. Lohaus, H. E. Meyer, W. Krone, 
and D. Muller-Wieland. 2000. MAP kinases Erk1/2 phosphorylate sterol 
   45
regulatory element-binding protein (SREBP)-1a at serine 117 in vitro. J Biol 
Chem 275:33302-7. 
171. Roux, P. P., and J. Blenis. 2004. ERK and p38 MAPK-activated protein kinases: 
a family of protein kinases with diverse biological functions. Microbiol Mol Biol 
Rev 68:320-44. 
172. Rowan, B. G., N. Garrison, N. L. Weigel, and B. W. O'Malley. 2000. 8-
Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate 
ligand-independent activation of the chicken progesterone receptor and are critical 
for functional cooperation between SRC-1 and CREB binding protein. Mol Cell 
Biol 20:8720-30. 
173. Ruderman, N. B., A. K. Saha, D. Vavvas, and L. A. Witters. 1999. Malonyl-
CoA, fuel sensing, and insulin resistance. Am J Physiol 276:E1-E18. 
174. Rust, C., L. M. Karnitz, C. V. Paya, J. Moscat, R. D. Simari, and G. J. Gores. 
2000. The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-
kinase-dependent survival signaling cascade. J Biol Chem 275:20210-6. 
175. Sagawa, H., S. Tazuma, and G. Kajiyama. 1993. Protection against 
hydrophobic bile salt-induced cell membrane damage by liposomes and 
hydrophilic bile salts. Am J Physiol 264:G835-9. 
176. Sakai, J., E. A. Duncan, R. B. Rawson, X. Hua, M. S. Brown, and J. L. 
Goldstein. 1996. Sterol-regulated release of SREBP-2 from cell membranes 
requires two sequential cleavages, one within a transmembrane segment. Cell 
85:1037-46. 
177. Sakai, J., A. Nohturfft, D. Cheng, Y. K. Ho, M. S. Brown, and J. L. 
Goldstein. 1997. Identification of complexes between the COOH-terminal 
domains of sterol regulatory element-binding proteins (SREBPs) and SREBP 
cleavage-activating protein. J Biol Chem 272:20213-21. 
178. Sakai, J., A. Nohturfft, J. L. Goldstein, and M. S. Brown. 1998. Cleavage of 
sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction 
with SREBP cleavage-activating protein. Evidence from in vivo competition 
studies. J Biol Chem 273:5785-93. 
179. Schultz, J. R., H. Tu, A. Luk, J. J. Repa, J. C. Medina, L. Li, S. Schwendner, 
S. Wang, M. Thoolen, D. J. Mangelsdorf, K. D. Lustig, and B. Shan. 2000. 
Role of LXRs in control of lipogenesis. Genes Dev 14:2831-8. 
180. Shaw, R. J., M. Kosmatka, N. Bardeesy, R. L. Hurley, L. A. Witters, R. A. 
DePinho, and L. C. Cantley. 2004. The tumor suppressor LKB1 kinase directly 
activates AMP-activated kinase and regulates apoptosis in response to energy 
stress. Proc Natl Acad Sci U S A 101:3329-35. 
181. Shih, D. M., H. R. Kast-Woelbern, J. Wong, Y. R. Xia, P. A. Edwards, and A. 
J. Lusis. 2006. A role for FXR and human FGF-19 in the repression of 
paraoxonase-1 gene expression by bile acids. J Lipid Res 47:384-92. 
182. Shimano, H. 2001. Sterol regulatory element-binding proteins (SREBPs): 
transcriptional regulators of lipid synthetic genes. Prog Lipid Res 40:439-52. 
183. Shimano, H., J. D. Horton, R. E. Hammer, I. Shimomura, M. S. Brown, and 
J. L. Goldstein. 1996. Overproduction of cholesterol and fatty acids causes 
massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J 
Clin Invest 98:1575-84. 
   46
184. Shimano, H., J. D. Horton, I. Shimomura, R. E. Hammer, M. S. Brown, and 
J. L. Goldstein. 1997. Isoform 1c of sterol regulatory element binding protein is 
less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin 
Invest 99:846-54. 
185. Sinal, C. J., M. Tohkin, M. Miyata, J. M. Ward, G. Lambert, and F. J. 
Gonzalez. 2000. Targeted disruption of the nuclear receptor FXR/BAR impairs 
bile acid and lipid homeostasis. Cell 102:731-44. 
186. Smith, C. L., Z. Nawaz, and B. W. O'Malley. 1997. Coactivator and corepressor 
regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-
hydroxytamoxifen. Mol Endocrinol 11:657-66. 
187. Smith, C. L., and B. W. O'Malley. 2004. Coregulator function: a key to 
understanding tissue specificity of selective receptor modulators. Endocr Rev 
25:45-71. 
188. Stein, B., M. X. Yang, D. B. Young, R. Janknecht, T. Hunter, B. W. Murray, 
and M. S. Barbosa. 1997. p38-2, a novel mitogen-activated protein kinase with 
distinct properties. J Biol Chem 272:19509-17. 
189. Stravitz, R. T., P. B. Hylemon, D. M. Heuman, L. R. Hagey, C. D. 
Schteingart, H. T. Ton-Nu, A. F. Hofmann, and Z. R. Vlahcevic. 1993. 
Transcriptional regulation of cholesterol 7 alpha-hydroxylase mRNA by 
conjugated bile acids in primary cultures of rat hepatocytes. J Biol Chem 
268:13987-93. 
190. Struhl, K. 1998. Histone acetylation and transcriptional regulatory mechanisms. 
Genes Dev 12:599-606. 
191. Sundqvist, A., M. T. Bengoechea-Alonso, X. Ye, V. Lukiyanchuk, J. Jin, J. 
W. Harper, and J. Ericsson. 2005. Control of lipid metabolism by 
phosphorylation-dependent degradation of the SREBP family of transcription 
factors by SCF(Fbw7). Cell Metab 1:379-91. 
192. Svensson, S., T. Ostberg, M. Jacobsson, C. Norstrom, K. Stefansson, D. 
Hallen, I. C. Johansson, K. Zachrisson, D. Ogg, and L. Jendeberg. 2003. 
Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-
binding domains in a fully agonistic conformation. Embo J 22:4625-33. 
193. Talukdar, I., W. Szeszel-Fedorowicz, and L. M. Salati. 2005. Arachidonic acid 
inhibits the insulin induction of glucose-6-phosphate dehydrogenase via p38 MAP 
kinase. J Biol Chem 280:40660-7. 
194. Tangirala, R. K., E. D. Bischoff, S. B. Joseph, B. L. Wagner, R. Walczak, B. 
A. Laffitte, C. L. Daige, D. Thomas, R. A. Heyman, D. J. Mangelsdorf, X. 
Wang, A. J. Lusis, P. Tontonoz, and I. G. Schulman. 2002. Identification of 
macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci 
U S A 99:11896-901. 
195. Tcherepanova, I., P. Puigserver, J. D. Norris, B. M. Spiegelman, and D. P. 
McDonnell. 2000. Modulation of estrogen receptor-alpha transcriptional activity 
by the coactivator PGC-1. J Biol Chem 275:16302-8. 
196. Teboul, M., E. Enmark, Q. Li, A. C. Wikstrom, M. Pelto-Huikko, and J. A. 
Gustafsson. 1995. OR-1, a member of the nuclear receptor superfamily that 
interacts with the 9-cis-retinoic acid receptor. Proc Natl Acad Sci U S A 92:2096-
100. 
   47
197. Thomas, J., K. S. Bramlett, C. Montrose, P. Foxworthy, P. I. Eacho, D. 
McCann, G. Cao, A. Kiefer, J. McCowan, K. L. Yu, T. Grese, W. W. Chin, T. 
P. Burris, and L. F. Michael. 2003. A chemical switch regulates fibrate 
specificity for peroxisome proliferator-activated receptor alpha (PPARalpha ) 
versus liver X receptor. J Biol Chem 278:2403-10. 
198. Tomlinson, E., L. Fu, L. John, B. Hultgren, X. Huang, M. Renz, J. P. 
Stephan, S. P. Tsai, L. Powell-Braxton, D. French, and T. A. Stewart. 2002. 
Transgenic mice expressing human fibroblast growth factor-19 display increased 
metabolic rate and decreased adiposity. Endocrinology 143:1741-7. 
199. Torres, L. M., C. Cefaratti, B. Perry, and A. Romani. 2006. Involvement of 
ERK1/2 and p38 in Mg(2+) accumulation in liver cells. Mol Cell Biochem. 
200. Vega, R. B., J. M. Huss, and D. P. Kelly. 2000. The coactivator PGC-1 
cooperates with peroxisome proliferator-activated receptor alpha in transcriptional 
control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. 
Mol Cell Biol 20:1868-76. 
201. Vermeulen, L., G. De Wilde, P. Van Damme, W. Vanden Berghe, and G. 
Haegeman. 2003. Transcriptional activation of the NF-kappaB p65 subunit by 
mitogen- and stress-activated protein kinase-1 (MSK1). Embo J 22:1313-24. 
202. Vyvoda, O. S., R. Coleman, and G. Holdsworth. 1977. Effects of different bile 
salts upon the composition and morphology of a liver plasma membrane 
preparation. Deoxycholate is more membrane damaging than cholate and its 
conjugates. Biochim Biophys Acta 465:68-76. 
203. Wagner, B. L., A. F. Valledor, G. Shao, C. L. Daige, E. D. Bischoff, M. 
Petrowski, K. Jepsen, S. H. Baek, R. A. Heyman, M. G. Rosenfeld, I. G. 
Schulman, and C. K. Glass. 2003. Promoter-specific roles for liver X 
receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene 
expression. Mol Cell Biol 23:5780-9. 
204. Wang, H. C. 1996. Induction of down-regulation of the kinase activities of Mek, 
p42Erk, p90RSK, and p63SAMK in chicken embryo fibroblast at the late stage of 
src-induced cellular transformation. J Cell Physiol 168:87-96. 
205. Wang, Z., B. Zhang, M. Wang, and B. I. Carr. 2003. Persistent ERK 
phosphorylation negatively regulates cAMP response element-binding protein 
(CREB) activity via recruitment of CREB-binding protein to pp90RSK. J Biol 
Chem 278:11138-44. 
206. Watanabe, M., S. M. Houten, C. Mataki, M. A. Christoffolete, B. W. Kim, H. 
Sato, N. Messaddeq, J. W. Harney, O. Ezaki, T. Kodama, K. Schoonjans, A. 
C. Bianco, and J. Auwerx. 2006. Bile acids induce energy expenditure by 
promoting intracellular thyroid hormone activation. Nature 439:484-9. 
207. Watanabe, M., S. M. Houten, L. Wang, A. Moschetta, D. J. Mangelsdorf, R. 
A. Heyman, D. D. Moore, and J. Auwerx. 2004. Bile acids lower triglyceride 
levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 
113:1408-18. 
208. Weston, C. R., and R. J. Davis. 2002. The JNK signal transduction pathway. 
Curr Opin Genet Dev 12:14-21. 
   48
209. Widmann, C., S. Gibson, M. B. Jarpe, and G. L. Johnson. 1999. Mitogen-
activated protein kinase: conservation of a three-kinase module from yeast to 
human. Physiol Rev 79:143-80. 
210. Wierenga, A. T., I. Vogelzang, B. J. Eggen, and E. Vellenga. 2003. 
Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is 
mediated by a MEK-, ERK-, and MSK1-dependent pathway. Exp Hematol 
31:398-405. 
211. Williams, S., R. K. Bledsoe, J. L. Collins, S. Boggs, M. H. Lambert, A. B. 
Miller, J. Moore, D. D. McKee, L. Moore, J. Nichols, D. Parks, M. Watson, 
B. Wisely, and T. M. Willson. 2003. X-ray crystal structure of the liver X 
receptor beta ligand binding domain: regulation by a histidine-tryptophan switch. 
J Biol Chem 278:27138-43. 
212. Willy, P. J., K. Umesono, E. S. Ong, R. M. Evans, R. A. Heyman, and D. J. 
Mangelsdorf. 1995. LXR, a nuclear receptor that defines a distinct retinoid 
response pathway. Genes Dev 9:1033-45. 
213. Wolozin, B. 2004. Cholesterol and the biology of Alzheimer's disease. Neuron 
41:7-10. 
214. Wood, K. W., C. Sarnecki, T. M. Roberts, and J. Blenis. 1992. ras mediates 
nerve growth factor receptor modulation of three signal-transducing protein 
kinases: MAP kinase, Raf-1, and RSK. Cell 68:1041-50. 
215. Woods, A., S. R. Johnstone, K. Dickerson, F. C. Leiper, L. G. Fryer, D. 
Neumann, U. Schlattner, T. Wallimann, M. Carlson, and D. Carling. 2003. 
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr 
Biol 13:2004-8. 
216. Wu, Z., P. Puigserver, U. Andersson, C. Zhang, G. Adelmant, V. Mootha, A. 
Troy, S. Cinti, B. Lowell, R. C. Scarpulla, and B. M. Spiegelman. 1999. 
Mechanisms controlling mitochondrial biogenesis and respiration through the 
thermogenic coactivator PGC-1. Cell 98:115-24. 
217. Xie, M. H., I. Holcomb, B. Deuel, P. Dowd, A. Huang, A. Vagts, J. Foster, J. 
Liang, J. Brush, Q. Gu, K. Hillan, A. Goddard, and A. L. Gurney. 1999. FGF-
19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 
11:729-35. 
218. Xu, J., M. Teran-Garcia, J. H. Park, M. T. Nakamura, and S. D. Clarke. 
2001. Polyunsaturated fatty acids suppress hepatic sterol regulatory element-
binding protein-1 expression by accelerating transcript decay. J Biol Chem 
276:9800-7. 
219. Yabe, D., M. S. Brown, and J. L. Goldstein. 2002. Insig-2, a second 
endoplasmic reticulum protein that binds SCAP and blocks export of sterol 
regulatory element-binding proteins. Proc Natl Acad Sci U S A 99:12753-8. 
220. Yabe, D., R. Komuro, G. Liang, J. L. Goldstein, and M. S. Brown. 2003. 
Liver-specific mRNA for Insig-2 down-regulated by insulin: implications for fatty 
acid synthesis. Proc Natl Acad Sci U S A 100:3155-60. 
221. Yabe, D., Z. P. Xia, C. M. Adams, and R. B. Rawson. 2002. Three mutations in 
sterol-sensing domain of SCAP block interaction with insig and render SREBP 
cleavage insensitive to sterols. Proc Natl Acad Sci U S A 99:16672-7. 
   49
222. Yamamoto, T., H. Shimano, Y. Nakagawa, T. Ide, N. Yahagi, T. Matsuzaka, 
M. Nakakuki, A. Takahashi, H. Suzuki, H. Sone, H. Toyoshima, R. Sato, and 
N. Yamada. 2004. SREBP-1 interacts with hepatocyte nuclear factor-4 alpha and 
interferes with PGC-1 recruitment to suppress hepatic gluconeogenic genes. J 
Biol Chem 279:12027-35. 
223. Yang, T., P. J. Espenshade, M. E. Wright, D. Yabe, Y. Gong, R. Aebersold, J. 
L. Goldstein, and M. S. Brown. 2002. Crucial step in cholesterol homeostasis: 
sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates 
retention of SREBPs in ER. Cell 110:489-500. 
224. Yang, W., Y. H. Hong, X. Q. Shen, C. Frankowski, H. S. Camp, and T. Leff. 
2001. Regulation of transcription by AMP-activated protein kinase: 
phosphorylation of p300 blocks its interaction with nuclear receptors. J Biol 
Chem 276:38341-4. 
225. Yin, L., Y. Zhang, T. Charron, and F. B. Hillgartner. 2000. Thyroid hormone, 
glucagon, and medium-chain fatty acids regulate transcription initiated from 
promoter 1 and promoter 2 of the acetyl-CoA carboxylase-alpha gene in chick 
embryo hepatocytes. Biochim Biophys Acta 1517:91-9. 
226. Yin, L., Y. Zhang, and F. B. Hillgartner. 2002. Sterol regulatory element-
binding protein-1 interacts with the nuclear thyroid hormone receptor to enhance 
acetyl-CoA carboxylase-alpha transcription in hepatocytes. J Biol Chem 
277:19554-65. 
227. Yoon, J. C., P. Puigserver, G. Chen, J. Donovan, Z. Wu, J. Rhee, G. 
Adelmant, J. Stafford, C. R. Kahn, D. K. Granner, C. B. Newgard, and B. M. 
Spiegelman. 2001. Control of hepatic gluconeogenesis through the transcriptional 
coactivator PGC-1. Nature 413:131-8. 
228. Yoshikawa, T., H. Shimano, M. Amemiya-Kudo, N. Yahagi, A. H. Hasty, T. 
Matsuzaka, H. Okazaki, Y. Tamura, Y. Iizuka, K. Ohashi, J. Osuga, K. 
Harada, T. Gotoda, S. Kimura, S. Ishibashi, and N. Yamada. 2001. 
Identification of liver X receptor-retinoid X receptor as an activator of the sterol 
regulatory element-binding protein 1c gene promoter. Mol Cell Biol 21:2991-
3000. 
229. Yoshikawa, T., H. Shimano, N. Yahagi, T. Ide, M. Amemiya-Kudo, T. 
Matsuzaka, M. Nakakuki, S. Tomita, H. Okazaki, Y. Tamura, Y. Iizuka, K. 
Ohashi, A. Takahashi, H. Sone, J. Osuga Ji, T. Gotoda, S. Ishibashi, and N. 
Yamada. 2002. Polyunsaturated fatty acids suppress sterol regulatory element-
binding protein 1c promoter activity by inhibition of liver X receptor (LXR) 
binding to LXR response elements. J Biol Chem 277:1705-11. 
230. Young, P. R., M. M. McLaughlin, S. Kumar, S. Kassis, M. L. Doyle, D. 
McNulty, T. F. Gallagher, S. Fisher, P. C. McDonnell, S. A. Carr, M. J. 
Huddleston, G. Seibel, T. G. Porter, G. P. Livi, J. L. Adams, and J. C. Lee. 
1997. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind 
in the ATP site. J Biol Chem 272:12116-21. 
231. Yu, C., F. Wang, C. Jin, X. Huang, and W. L. McKeehan. 2005. Independent 
repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) 
by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile 
acids. J Biol Chem 280:17707-14. 
   50
232. Yu, C., F. Wang, M. Kan, C. Jin, R. B. Jones, M. Weinstein, C. X. Deng, and 
W. L. McKeehan. 2000. Elevated cholesterol metabolism and bile acid synthesis 
in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 
275:15482-9. 
233. Yu, S., L. Zheng, S. L. Asa, and S. Ezzat. 2002. Fibroblast growth factor 
receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 
promoter. Am J Physiol Endocrinol Metab 283:E490-5. 
234. Zhang, Y., G. Liu, and Z. Dong. 2001. MSK1 and JNKs mediate 
phosphorylation of STAT3 in UVA-irradiated mouse epidermal JB6 cells. J Biol 
Chem 276:42534-42. 
235. Zhang, Y., L. Yin, and F. B. Hillgartner. 2003. SREBP-1 integrates the actions 
of thyroid hormone, insulin, cAMP, and medium-chain fatty acids on ACCalpha 
transcription in hepatocytes. J Lipid Res 44:356-68. 
236. Zhang, Y., L. Yin, and F. B. Hillgartner. 2001. Thyroid hormone stimulates 
acetyl-coA carboxylase-alpha transcription in hepatocytes by modulating the 
composition of nuclear receptor complexes bound to a thyroid hormone response 
element. J Biol Chem 276:974-83. 
237. Zhou, G., Z. Q. Bao, and J. E. Dixon. 1995. Components of a new human 
protein kinase signal transduction pathway. J Biol Chem 270:12665-9. 
238. Zhou, G., R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. 
Ventre, T. Doebber, N. Fujii, N. Musi, M. F. Hirshman, L. J. Goodyear, and 
D. E. Moller. 2001. Role of AMP-activated protein kinase in mechanism of 
metformin action. J Clin Invest 108:1167-74. 
 
   51
 
Chapter 2 
 
The Mechanism Mediating the Activation of Acetyl-CoA Carboxylase-α 
Gene Transcription by the Liver X Receptor 
 
 
 
This Chapter is presented as a manuscript that has been submitted for 
publication in  
 
The Journal of Lipid Research 
 
The copyright policies of this Journal can be found at  
http://www.jlr.org/misc/Copyright_Permission.shtml
   52
 
The Mechanism Mediating the Activation of Acetyl-CoA Carboxylase-α 
Gene Transcription by the Liver X Receptor 
 
 
Saswata Talukdar and F. Bradley Hillgartner* 
 
 
 
Department of Biochemistry and Molecular Pharmacology, School of Medicine, West 
Virginia University, Morgantown, West Virginia 26506  USA 
 
 
 
 
 
 
 
Running Title: Regulation of Acetyl-CoA Carboxylase by LXR 
 
 
 
 
 
 
 
 
 
 
 
 
 
* To whom correspondence should be addressed: Department of Biochemistry and 
Molecular Pharmacology, P.O. Box 9142, West Virginia University, Morgantown, 
WV  26506-9142 
 
Tel.: 304-293-7751 
 Fax: 304-293-6846 
 Email: fbhillgartner@hsc.wvu.edu  
   53
ABSTRACT 
In avians and mammals, agonists of the liver X receptor (LXR) increase the 
expression of enzymes comprising the fatty acid synthesis pathway.  Here, we investigate 
the mechanism by which the synthetic LXR agonist, T0-901317, increases the 
transcription of the acetyl-CoA carboxylase-α (ACCα) gene in chick embryo hepatocyte 
cultures.  Transfection analyses demonstrate that activation of ACCα transcription by T0-
901317 is mediated by a cis-acting regulatory unit (-101 to -71 bp) that is comprised of a 
LXR response element (LXRE) and a sterol regulatory element (SRE).  The SRE 
enhances the ability of the LXRE to activate ACCα transcription in the presence of T0-
901317.  Treating hepatocytes with T0-901317 increases the concentration of mature 
sterol regulatory element-binding protein-1 (SREBP-1) in the nucleus and the acetylation 
of histone H3 and histone H4 at the ACCα LXR response unit.  These results indicate 
that T0-901317 increases hepatic ACCα transcription by directly activating LXR• 
retinoid X receptor (RXR) heterodimers and by increasing the activity of an accessory 
transcription factor (SREBP-1) that enhances ligand-induced-LXR•RXR activity.  We 
also show that T0-901317 treatment decreases LXR•RXR binding and increases nuclear 
T3 receptor•RXR binding to the ACCα LXRE.  We propose that changes in the binding 
of nuclear receptor complexes to the ACCα LXRE limit the activation of ACCα 
transcription by T0-901317. 
 
 
Supplementary keywords: fatty acid synthesis, liver, sterol regulatory element binding 
protein, LXR, chicken, histone acetylation 
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INTRODUCTION 
The first committed step of the fatty acid synthesis pathway is the ATP-dependent 
carboxylation of acetyl-CoA to form malonyl-CoA.  This reaction, catalyzed by acetyl-
CoA carboxylase-α (ACCα), constitutes a key control point in the synthesis of long-
chain fatty acids from carbohydrate (1, 2).  Malonyl-CoA serves as a donor of C2 units 
for the synthesis of palmitate catalyzed by fatty acid synthase.  Malonyl-CoA is also a 
substrate of specific elongases involved in the chain elongation of fatty acids to very 
long-chain fatty acids (3).  The essential role of ACCα in lipid biosynthesis has been 
confirmed by studies demonstrating that knockout of the ACCα gene disrupts embryonic 
development prior to day 7.5 (4).  
In lipogenic tissues of avians and mammals, transcription of the ACCα gene is 
regulated by nutritional and hormonal factors.  For example, ACCα transcription is low 
in livers of starved chicks, feeding a high-carbohydrate, low-fat diet stimulates an 11-fold 
increase in ACCα transcription (5).  Diet-induced changes in ACCα transcription are 
mimicked in primary cultures of chick embryo hepatocytes by manipulating the 
concentrations of hormones and nutrients in the culture medium (6).  Incubating chick 
embryo hepatocytes with the active form of thyroid hormone, 3,5’,3-triiodothyronine 
(T3), stimulates a 5 to 7-fold increase in ACCα transcription.  The mechanism by which 
T3 increases ACCα transcription involves multiple processes.  First, T3 interacts with the 
nuclear T3 receptor (TR) bound to a T3 response element (T3RE) on the more 
downstream promoter (promoter 2) of the ACCα gene (7).  This T3RE (-101 to -86 bp) is 
comprised of two hexameric half-sites arranged as direct repeats with 4 bp separating the 
   55
half-sites (DR-4 element).  Second, T3 treatment increases the binding of TR•retinoid X 
receptor (RXR) heterodimers to the ACCα T3RE.  The mechanism for this effect has not 
yet been defined.  Third, T3 treatment increases the binding of sterol regulatory element-
binding protein-1 (SREBP-1) to a sterol regulatory element (SRE) (-80 to -71 bp) located 
immediately downstream of the ACCα T3RE (8).  SREBP-1 directly interacts with 
TR•RXR heterodimers and enhances the ability of this complex to activate ACCα 
transcription in the presence of T3 (9). 
In our studies analyzing the regulation of ACCα transcription by T3, we observed 
that the ACCα T3RE not only bound protein complexes containing TR•RXR 
heterodimers but also bound protein complexes containing liver X receptor (LXR)•RXR 
heterodimers (7).  LXRs are nuclear hormone receptors that are bound and activated by 
naturally occurring oxysterols (10, 11).  Two isoforms of LXR, designated LXRα and 
LXRβ, have been identified in avians and mammals.  LXRβ is expressed in a wide 
variety of tissues, whereas LXRα is selectively expressed in liver, adipose tissue, 
intestine, and macrophages (12, 13).  LXRs play a key role in regulating cholesterol 
excretion by mediating the stimulatory effects of oxysterols on the transcription of genes 
involved in reverse cholesterol transport and bile acid synthesis.  For example, naturally 
occurring oxysterols and synthetic, non steroidal LXR agonists activate the transcription 
of a battery of genes involved in cholesterol efflux (ABCA1, ABCG1, ABCG5, and 
ABCG8), cholesterol clearance (cholesterol ester transfer protein and apolipoprotein E), 
and cholesterol catabolism (cholesterol 7α-hydroxylase) (14-16).  For each of these 
genes, regulation of transcription by LXR agonists is conferred by a LXR response 
element (LXRE) that binds LXR•RXR heterodimers.  Because oxysterols are produced in 
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proportion to cellular cholesterol content, LXRs have been proposed to function as 
sensors in a feed-forward pathway that stimulates reverse cholesterol transport and 
cholesterol excretion in response to high cholesterol levels in the diet.  Consistent with 
this proposal, mice lacking the LXRα and/or LXRβ gene exhibit diminished cholesterol 
excretion and elevated cholesterol levels in the blood and liver when fed a high-
cholesterol diet (17, 18). 
The ability of LXR agonists to activate genes involved in cholesterol excretion has 
led to an evaluation of the atheroprotective properties of these compounds in murine 
models of atherosclerosis.  Oral administration of the synthetic LXR ligand/agonist, 
T0901317, to mice lacking the LDL receptor or apolipoprotein E causes an increase in 
blood HDL levels and reverses the formation of atherosclerotic lesions in the aorta (19, 
20).  These exciting findings are tempered by the observation that treatment with 
T0901317 also causes hypertriglyceridemia and the development of a fatty liver in 
rodents and chickens (21-24).  These undesired effects of T0901317 are caused by 
alterations in the expression of enzymes comprising the fatty acid synthesis pathway.  For 
example, T0-901317 treatment increases the hepatic expression of the mRNAs encoding 
ACCα, fatty acid synthase (FAS), ATP-citrate lyase (ATP-CL), and stearoyl-CoA 
desaturase-1 (SCD1) (23-25).  The aim of the present study is to determine the 
mechanism by which T0-901317 regulates the expression of ACCα in avian liver.  We 
show that T0-901317 acts directly on the liver to increase the expression of ACCα and 
that the extent of this effect is modulated by the presence of insulin and T3.  We further 
show that T0-901317 increases ACCα transcription by activating LXR•RXR 
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heterodimers bound to the ACCα gene and that SREBP-1 interacts with LXR•RXR to 
enhance the stimulatory effects of T0-901317 on ACCα transcription. 
 
EXPERIMENTAL PROCEDURES 
Cell culture and analytical assays 
Hepatocytes were isolated from livers of 19-day-old chick embryos as previously 
described (26).  Cells were incubated in serum-free Waymouth's medium MD752/1 
containing penicillin (60 μg/ml) and streptomycin (100 μg/ml) on untreated petri dishes 
at 40°C in a humidified atmosphere of 5% CO2 and 95% air.  Hormone and other 
additions were as described in the legends of figures.  The triacylglycerol concentration 
of the culture medium was measured using an enzymatic kit (Sigma). 
 
Isolation of RNA and quantitation of mRNA levels   
 Medium was removed and RNA was extracted from hepatocytes by the 
guanidium thiocyanate/phenol/chloroform method (27).  Total RNA (15 µg) was 
separated by size in 0.9% agarose, 0.7 M formaldehyde gels, and then transferred to a 
Nytran membrane (Schleicher & Schuell) using a Vacuum blotting apparatus (Pharmacia 
Biotechnology).  The RNA was crosslinked to the membrane by UV and baked at 80°C 
for 30-60 min.  RNA blots were hybridized with 32P-labeled DNA probes labeled by 
random priming (28).  Hybridization and washes were as described (29).  Membranes 
were subjected to storage phosphor autoradiography.  Hybridization signals were 
quantified using ImageQuant software (Molecular Dynamics).  cDNAs for chicken 
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ACCα (5), FAS (30), SCD1 (31), SREBP-1 (32), ATP-CL (33), ABCA1 (23), LXR (34), 
and malic enzyme (35) have been described.  
 
Plasmids  
 Reporter plasmids are named by designating the 5' and 3' ends of the ACCα DNA 
fragment relative to the transcription start site of promoter 2.  A series of 5' deletions and 
3' deletions of ACCα promoter 2 in the context of p[ACC-2054/+274]CAT have been 
previously described (7).  An ACCα promoter construct containing a mutation of the 
SRE between -79 and -72 bp in the context of p[ACC-108/+274]CAT has been 
previously described in (9).  p[ACC-108/-66]TKCAT, p[ACC-84/-66]TKCAT and 
pTKCAT constructs containing mutations in the -108 to -66 bp ACCα fragment are 
described in (9). 
 
Transient transfection 
 Chick embryo hepatocytes were transfected as described in Zhang et al (7).  
Briefly, cells were isolated and incubated on 60 mm petri dishes.  At 6 h of incubation, 
the medium was replaced with one containing 10 μg of lipofectin (Invitrogen), 1.5 μg of 
p[ACC-2054/+274]CAT or an equimolar amount of another reporter plasmid and 
pBluescript KS(+) to bring the total amount of transfected DNA to 1.5 μg per plate.  At 
18 h of incubation, the transfection medium was replaced with fresh medium with or 
without T0-901317 (6 μM).  At 66 h of incubation, chick embryo hepatocytes were 
harvested, and cell extracts were prepared as described in (36).  CAT activity (37) and 
protein (38) were assayed by the indicated methods. 
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Western blot analysis   
Nuclear extracts were prepared from chick embryo hepatocytes as described (9).  
The proteins of the nuclear extract were subjected to electrophoresis in 10% SDS-
polyacrylamide gels and then transferred to polyvinylidene difluoride membranes 
(Millipore) using an electroblotting apparatus (Bio-Rad Laboratories, Hercules, CA).    
Immunoblot analysis was carried using a mouse monoclonal antibody against SREBP-1 
(IgG-2A4) (American Type Culture Collection, Manassas, VA).  Antibody/protein 
complexes on blots were detected using enhanced chemiluminescence (Amersham 
Biosciences).  Chemiluminescence on the blots was visualized using a FluorChem 8000 
imager (Alpha Innotech Corporation) and signals for mature form of SREBP-1 were 
quantified using FluorChem V200 software. 
 
Gel mobility shift analysis 
Nuclear extracts were prepared from hepatocytes incubated with or without T0-
901317 (9).  A double-stranded oligonucleotide containing the ACCα LXRE/T3RE (-108 
to -82 bp relative to the transcription initiation site of ACCα promoter 2) was labeled by 
filling in overhanging 5’-ends using Klenow fragment of E. coli DNA polymerase in the 
presence of [α-32P] dCTP.  Binding reactions were carried out as previously described 
(7).  DNA and DNA-protein complexes were resolved on 6% nondenaturing 
polyacrylamide gels at 4 ºC in 50 mM Tris (pH 8.8) and 50 mM glycine.  Following 
electrophoresis, the gels were dried and subjected to storage phosphor autoradiography. 
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Histone acetylation  
 The extent of histone acetylation on ACCα promoter 2 was measured using a 
chromatin immunoprecipitation (ChIP) assay.  The procedure for this assay was the same 
as that described by Yin et al. (39).  Chromatin immunoprecipitations were carried out 
with antibodies against acetyl-histone H3 (06-599) and acetyl-histone H4 (06-866) 
(Upstate Biotechnology).  Precipitated DNA was analyzed in PCR reactions using Taq 
DNA polymerase (New England Biolabs) and primers specific for the ACCα and malic 
enzyme promoters.  The cycling parameters were: 1 cycle of 95°C for 4 min, 30 cycles of 
95°C for 1 min, 61°C for 1 min, 72°C for 1 min, and 1 cycle of 72°C for 10 min.  The 
forward primer of the ACCα gene was 5’-TCCCCTCCGTCAGCAGCCAATGGG-3’; 
the reverse primer was 5’-ATCCCCGGTCCCGCCCTCGGCTCC-3’.  The forward 
primer of the SCD1 gene was 5’-AGCGAACAGCAGATTGCGGCAG-3’; the reverse 
primer was 5’-TCTCGGCGTGCCAGAAGGGAGGT-3’.  Amplified products were 
subjected to electrophoresis in 2% agarose gels and visualized by ethidium bromide 
staining. 
 
Statistical methods 
 Data were subjected to analysis of variance, and statistical comparisons were 
made with Dunnett’s test or Student’s t-test.  Statistical significance is defined as P < 
0.05. 
 
RESULTS 
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LXR activation increases the expression of ACCα in primary cultures of chick 
embryo hepatocytes 
 Oral administration of T0-901317 to chickens and rats causes a 2- to 3-fold 
increase in hepatic ACCα mRNA levels (23, 24).  To investigate whether this 
phenomenon was due to a direct effect of T0-901317 n the liver, we determined whether 
T0-901317 regulated the expression of ACCα in primary cultures of chick embryo 
hepatocytes.  Incubating hepatocytes with T0-901317 in the absence of other hormones 
for 24 h caused a 2.4-fold increase in the abundance of ACCα mRNA (Fig. 1).  
Treatment with the RXR agonist, 9-cis retinoic acid, had no effect on ACCα mRNA 
abundance in the absence or presence of T0-901317.  Thus, LXR agonists but not RXR 
agonists regulate ACCα expression in hepatocytes in culture. 
 In chick embryo hepatocytes, insulin has no effect by itself but amplifies the 
increase in ACCα transcription caused by T3 (6).  This observation prompted us to 
investigate whether insulin modified the effects of T0-901317 on ACCα expression.  
Incubating hepatocytes with T0-901317 stimulated a greater increase in ACCα mRNA 
abundance in the presence of insulin (3.5-fold) than in the absence of insulin (2.4-fold) 
(Fig. 1).  Thus, as observed for T3 regulation of ACCα, insulin enhances the stimulatory 
effects of T0-901317 on ACCα expression.  
 In previous work, we showed that both TR and LXR bind the ACCα T3RE as 
heterodimers with RXR (7).  This observation raised the possibility that a common cis-
acting regulatory sequence is involved in mediating the effects of T0-901317 and T3 on 
ACCα transcription.  As a first step in investigating this possibility, we determined the 
effects of T0-901317 on the expression of ACCα in the presence of T3.  Incubating 
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hepatocytes with T3 and insulin caused a 4.6-fold increase in the abundance ACCα 
mRNA abundance (Fig. 1).  Addition of T0-901317 in the presence of T3 and insulin 
caused a further increase in ACCα mRNA abundance, however the magnitude of this 
effect (39%) was substantially smaller than the effect of T0-901317 on ACCα expression 
in the presence of insulin alone (350%).  Addition of T0-901317 in the presence of T3, 
insulin, and 9-cis retinoic acid had no effect on ACCα mRNA abundance.  The non-
additive effects of T0-901317 and T3 on ACCα mRNA abundance support the proposal 
that a common cis-acting sequence(s) mediates the actions of T0-901317 and T3 on 
ACCα transcription. 
 We also investigated the effects of T0-901317 on the expression of other 
lipogenic enzymes.  In hepatocytes incubated in the absence and presence of insulin, 
addition of T0-901317 to the culture medium increased the abundance of mRNAs 
encoding FAS, SCD1, and ATP-CL (Fig. 1).  T0-901317-induced expression of FAS, 
SCD1, and ATP-CL was higher in the presence of insulin than in the absence of insulin.  
In hepatocytes incubated with T3 and insulin, addition of T0-901317 had little or no 
effect on the abundance of mRNA encoding FAS, SCD1, and ATP-CL.  Incubating 
hepatocytes with 9-cis retinoic acid in the absence or presence of T0-901317 had no 
effect on FAS, SCD1, and ATP-CL mRNA levels.  Thus, regulation of expression of 
FAS, SCD1, and ATP-CL by agonists of LXR and RXR is similar to that of ACCα.   
 In contrast to ACCα, FAS, SCD1, and ATP-CL, the ability of T0-901317 to 
increase the expression of malic enzyme (ME) was substantially lower than that of T3.  
Treatment with T0-901317 and insulin caused a 2.9-fold increase in ME mRNA 
abundance, whereas treatment with T3 and insulin caused a 35-fold increase in ME 
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mRNA abundance (Fig. 1).  These observations are consistent with previous work 
demonstrating that the major T3RE mediating T3 regulation of malic enzyme 
transcription lacks the ability to bind LXR•RXR heterodimers (7).  
 To determine whether the T0-901317-induced increase in lipogenic enzyme 
expression was associated with an elevation in triacylglycerol production, the 
triacylglycerol concentration in the culture medium was monitored in hepatocytes treated 
with or with or without T0-901317.  The triacylglycerol concentration of the culture 
medium increased progressively during a 48 h incubation period (Fig. 2).  The extent of 
the increase in triacylglycerol concentration was higher in cells treated with T0-901317 
relative to cells not receiving T0-901317.  An elevation in hepatic lipogenic enzyme 
expression and triacylglycerol secretion likely contributes to the hypertriglyceridemia 
observed in animals treated with T0-901317 (21, 22, 24).  
 
Identification of a LXR response unit that mediates the effects of T0-901317 on 
ACCα transcription 
 Previous studies have shown that T3 regulation of ACCα transcription is 
mediated by a 23 bp region (-101 to -71 bp) in promoter 2 of the ACCα gene (7).  This 
region contains a DR-4 element (-101 to -86 bp) that binds heterodimers comprised of 
TR•RXR and LXR•RXR and a SRE (-82 to -71 bp) that binds SREBP-1.  To determine 
the role of these sequences and other sequences in ACCα gene in mediating the 
stimulatory effects of T0-901317 on ACCα transcription, transient transfection 
experiments were performed using reporter constructs containing portions of ACCα 
promoter 2 linked to the chloramphenicol acetyltransferase (CAT) gene.  In chick embryo 
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hepatocytes transfected with a reporter construct containing 2054 bp of 5’-flanking DNA, 
T0-901317 caused a 2.9-fold increase in promoter activity (Fig. 3).  5’-Deletion of ACCα 
sequences to -391, -136, and -108 bp had no effect on T0-901317 responsiveness.  
Deletion of ACCα sequences containing the DR-4 element (-108 to -84 bp) abolished the 
stimulatory effect of T0-901317 on ACCα transcription.  Further deletion to -41 bp had 
no effect on T0-901317 responsiveness.  Mutation of the SRE (-80 to -71 bp) in the 
context of 108 bp of 5’-flanking DNA caused a 49% reduction in T0-901317 
responsiveness.  These results indicate that the DR-4 element (LXRE) is required for T0-
901317 regulation of ACCα transcription and that the SRE enhances the ability of the 
LXRE to activate ACCα transcription in the presence of T0-901317.  
 To determine whether the functional interaction between the ACCα LXRE and 
SRE required the presence of additional cis-acting sequences, hepatocytes were 
transfected with constructs containing fragments of the ACCα gene linked to the minimal 
promoter of the herpes simplex virus thymidine kinase (TK) gene.  The TK promoter 
alone was unresponsive to T0-901317 (Fig. 4).  When a DNA fragment containing both 
the ACCα LXRE and ACCα SRE (-108 to -66 bp) was linked to the TK promoter, 
treatment with T0-901317 caused a 5.5-fold increase in promoter activity.  Mutation of 
the ACCα SRE in the context of the ACCα -108 to -66 bp fragment caused a 49% 
decrease in T0-901317 responsiveness.  When a DNA fragment containing the ACCα 
SRE alone (-84 to -66 bp) was appended to the TK promoter, T0-901317 treatment had 
no effect on promoter activity.  These data demonstrate that the ACCα SRE can function 
alone to enhance T0-901317 regulation conferred by the ACCα LXRE.  Thus, a region of 
the ACCα gene containing a LXRE and a SRE is responsible for mediating the effects of 
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T0-901317 on ACCα promoter 2 activity.  We refer to this region as the ACCα liver X 
receptor response unit (LXRU). 
 
LXR activation increases the abundance of mature SREBP-1 in chick embryo 
hepatocytes 
 In our studies analyzing the regulation of the ACCα gene by T3, we showed that 
T3 treatment increased the abundance of the mature, active form of SREBP-1 in chick 
embryo hepatocytes and that this effect contributed to the activation of ACCα 
transcription by T3 (8).  This observation prompted us to ask whether T0-901317 
regulated SREBP-1 levels in chick embryo hepatocyte cultures.  The time course of the 
effects of T0-901317 on the abundance of mature SREBP-1 protein, SREBP-1 mRNA, 
and ACCα mRNA was determined in hepatocytes cultured in the presence of insulin.  
Treatment with T0-901317 for 6 h caused an 1.5-fold increase in mature SREBP-1 
concentration (Fig. 5).  A larger increase in mature SREBP-1 concentration (2.2-fold) 
was observed after 24 h of treatment with T0-901317.  In contrast to the time course for 
mature SREBP-1, the T0-901317-induced stimulation of ACCα mRNA levels occurred 
at a later time point (between 24 and 48 of treatment).  This observation is consistent with 
the proposal that alterations in SREBP-1 levels play a role in mediating the regulation of 
ACCα transcription by T0-901317.  Treatment with T0-901317 increased in the 
abundance of SREBP-1 mRNA and this effect was maximal (1.9 to 2.1-fold) at or before 
2 h of incubation.  Thus, T0-901317-induced changes in mature SREBP-1 concentration 
appear to be mediated by a pretranslational mechanism. 
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LXR activation modulates the binding of nuclear receptor complexes to the ACCα 
LXRE/T3RE 
 In previous work, we showed that the ACCα LXRE/T3RE (-101 to -86 bp) bound 
four protein complexes in nuclear extracts prepared from chick embryo hepatocytes (7).  
Three of these complexes (designated complexes 1, 2 and 3) contained LXR•RXR 
heterodimers, whereas the fourth complex (designated complex 4) contained TR•RXR 
heterodimers.  In the absence of nuclear receptor agonists, complexes 1 and 2 were the 
predominant complexes that bound to the ACCα LXRE/T3RE.  T3 treatment caused a 
marked reduction in the binding of complexes 1 and 2 and an increase in the binding of 
complexes 3 and 4.  These findings have led us to propose that changes in the binding of 
nuclear receptor complexes to the ACCα T3RE/LXRE play a role in mediating the 
activation of ACCα transcription by T3.  In the present study, we wanted to determine 
whether treatment with LXR agonists also modulated the binding of nuclear receptor 
complexes to the ACCα LXRE/T3RE.  Gel mobility shift assays were performed using 
nuclear extracts from chick embryo hepatocytes treated with or without T0-901317.  As 
reported previously, a DNA probe containing the ACCα LXRE/T3RE bound to 
complex 1, complex 2, and complex 4 in nuclear extracts from hepatocytes incubated in 
the absence of nuclear receptor agonists (Fig. 6).  The binding activity of complex 1 and 
complex 2 was substantially greater than that of complex 4.  Complex 3 binding activity 
was not detected in the absence of T0-901317 treatment.  Incubating hepatocytes with 
T0-901317 had no effect on the binding activity of complexes 1 and 3.  In contrast, 
T0-901317 treatment decreased the binding activity of complex 2 after 6, 12, and 24 h of 
treatment.  Between 24 and 48 h of T0-901317 treatment, the binding activity of complex 
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2 increased to a level that was similar to that of cells not treated with T0-901317.  
Treatment with T0-901317 also regulated the binding activity of complex 4.  Incubating 
hepatocytes with T0-901317 had no effect on complex 4 binding activity after 2, 6, and 
12 h of treatment but increased complex 4 binding activity between 24 and 48h of 
treatment.  These data indicate that T0-901317 has opposing effects on the binding of 
LXR•RXR and TR•RXR complexes to the ACCα LXRE/T3RE. 
 
The effect of LXR activation on histone acetylation of the ACCα gene 
 The T0-901317-induced increase in ACCα transcription may be mediated in 
whole or in part by alterations in histone acetylation.  Previous studies have shown that 
the activation of LXR•RXR heterodimers by LXR ligands/agonists triggers the 
recruitment of coactivator complexes containing histone acetyltransferase (HAT) activity 
(40, 41).  Increased histone acetylation causes a chromatin decondensation that enhances 
the accessibility of the basal transcriptional machinery and other transcription factors to 
the target promoter.  To investigate the role of histone acetylation in mediating the 
activation of ACCα transcription by T0-901317, ChIP experiments were performed in 
chick embryo hepatocytes incubated in the absence or presence of T0-901317.  
Hepatocytes were treated with 1% formaldehyde to cross-link DNA to associated 
proteins.  Protein-DNA complexes were immunoprecipitated with an antibody against 
acetylated histone H3 or an antibody against acetylated histone H4.  Immunoprecipitated 
DNA was analyzed by PCR using primers that flanked the ACCα LXRU.  In hepatocytes 
incubated in the absence of T0-901317, acetylation of histone H3 and histone H4 was 
detected at the ACCα LXRU.  Addition of T0-901317 to the culture medium stimulated a 
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rapid increase (≤ 2 h) in the acetylation of histone H3 and H4 (Fig. 7, Table 1).  Histone 
acetylation remained elevated for 6 h of T0-901317 treatment and then declined between 
6 and 24 h of T0-901317 treatment.  These results support the proposal that an elevation 
in histone acetylation plays a role in mediating the effects of T0-901317 on ACCα 
transcription. 
 We also used ChIP to assess the effects of T0-901317 treatment on histone 
acetylation in a uncharacterized region of the SCD1 promoter using a primer set that 
amplified SCD1 sequences between -369 and -127 bp.  In contrast to the data for the 
ACCα gene, treatment with T0-901317 had no effect on histone acetylation at this region 
of the SCD1 gene (Fig. 7).  This observation indicates that the effects of T0-901317 on 
histone acetylation are sequence specific. 
 
DISCUSSION 
 In previous work analyzing the effects of T3 on ACCα transcription in avian 
hepatocytes, we identified a T3RE that conferred T3 regulation on ACCα promoter 2 (7).  
Interestingly, this T3RE not only bound protein complexes containing TR•RXR 
heterodimers but also bound protein complexes containing LXR•RXR heterodimers.  In 
the present report, we provide functional evidence that LXR•RXR heterodimers regulate 
ACCα transcription.  A specific ligand/agonist of LXR (T0-901317) activates ACCα 
transcription and this effect is mediated by the LXRE/T3RE in ACCα promoter 2.  We 
also demonstrate that SREBP-1 is an accessory factor that enhances the ability of 
LXR•RXR to increase ACCα transcription in the presence of T0-901317 and that LXR 
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activation by T0-901317 increases the concentration of mature, active form of SREBP-1 
in chick embryo hepatocytes.  
 How does SREBP-1 enhance the stimulatory effects of T0-901317 on ACCα 
transcription?  One possibility is that SREBP-1 facilitates the recruitment of coactivators 
to T0-901317-bound LXR•RXR complexes.  LXRα, LXRβ, and SREBP-1 interact with 
several coactivator proteins including CREB-binding protein (CBP) and the 
TRAP/ARC/DRIP complex (40-45).  We postulate that the presence of SREBP-1 on 
ACCα promoter 2 provides additional coactivator interaction sites that stabilize the 
binding of CBP, TRAP/ARC/DRIP, and other coactivators to T0-901317-bound 
LXR•RXR.  In support of this model, SREBP-1 and nuclear hormone receptors interact 
with separate peptide sequences on CBP and separate subunits of the TRAP/ARC/DRIP 
complex (46-49).  
 SREBP-1 also enhances the ability of TR•RXR to activate ACCα transcription in 
the presence of T3 (9).  In analyzing the mechanism mediating this effect, we showed 
that SREBP-1 physically interacted with TR and that binding of T3 to TR enhanced this 
interaction.  We postulated that SREBP-1•SREBP-1 homodimers formed a tetrameric 
complex with TR•RXR heterodimers and that tetrameric complex formation enhanced 
the recruitment of coactivators to ACCα promoter 2.  We also showed in these studies 
that LXR•RXR heterodimers do not physically interact with SREBP-1.  Thus, in contrast 
to the mechanism by which SREBP-1 enhances TR•RXR activity, direct interactions 
between SREBP-1 and LXR•RXR do not play a role in mediating the stimulatory effects 
of SREBP-1 on LXR•RXR activity. 
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  The mechanism by which LXR agonists regulate transcription has been analyzed 
for other lipogenic genes.  In human hepatoma cells, T0-901317 activation of FAS 
transcription is mediated by a single LXRE in the FAS promoter (50).  In primary rat 
hepatocyte cultures, the T0-901317-induced increase in SREBP-1c transcription is 
mediated by two LXREs in the SREBP-1c promoter  (51, 52).  Both the FAS promoter 
and the SREBP-1c promoter contain one or more SREs that are located approximately 
110 to 540 bp downstream of the LXRE(s).  In cells that express physiological levels of 
LXR, these SREs enhance basal transcription but have little or no effect on the regulation 
of transcription by T0-901317.  In contrast to these findings, the SRE in ACCα promoter 
2 enhances T0-901317 regulation of transcription but has no effect on basal transcription 
(Figs. 3 and 4).  These gene-specific differences in SRE activity may be due to variations 
in the proximity of the SRE relative to the LXRE and other cis-acting regulatory 
sequences.  For example, the close association of the SRE with the LXRE/T3RE in 
ACCα promoter 2 may facilitate interactions between LXR•RXR and SREBP-1 and the 
ability of SREBP-1 to enhance T0-901317 responsiveness, whereas the wide separation 
of the SREs and LXREs in the FAS and SREBP-1c promoters may impede interactions 
between LXR•RXR and SREBP-1 and the ability of SREBP-1 to enhance T0-901317 
responsiveness.  Previous studies have shown that the SREs in the FAS and SREBP-1c 
promoters are closely linked to a binding site for nuclear factor-Y (NF-Y) and that 
SREBP-1 activity is dependent on interactions between SREBP-1 and NF-Y (51-54).  
These interactions enhance the ability of SREBP-1 to stimulate basal transcription.  In 
contrast, the SRE in ACCα promoter 2 is not closely associated with binding sites for 
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NF-Y.  The lack of interaction of SREBP-1 with NF-Y on ACCα promoter 2 may 
explain why the ACCα SRE is not effective in modulating basal transcription. 
 Another finding of the present study is that LXR plays a permissive role in 
mediating the actions of insulin on ACCα transcription in chick embryo hepatocytes.  
Insulin stimulates ACCα expression in the presence of T0-901317 but has no effect on 
ACCα expression in the absence of T0-901317 (Fig. 1).  In rat hepatocytes, insulin 
enhances the ability of T0-901317 to increase mature SREBP-1 concentration due to a 
stimulatory effect of insulin on the processing of precursor SREBP-1 to mature SREBP-1 
(55).  We have confirmed this finding in chick embryo hepatocytes (data not shown).  
Because SREBP-1 enhances LXR activation of ACCα transcription in chick embryo 
hepatocytes, we postulate that alterations in mature SREBP-1 abundance mediate the 
stimulatory effects of insulin on ACCα transcription.  In support of this hypothesis, 
insulin does not increase the expression of ABCA1 in the presence of T0-901317 (Fig. 1).  
Previous work has shown that the ABCA1 gene is not a target of SREBP-1 (56).   
 Previous studies performed in rat hepatocytes indicate that insulin induces ACCα 
expression by increasing the activity of LXR.  For example, Tobin et al. (57) have shown 
that insulin stimulates a 10-fold increase in the expression of LXRα mRNA and that 
ablation of the LXRα gene abolishes the stimulatory effect of insulin on ACCα 
expression.  Other laboratories have shown that insulin increases the transcription of 
SREBP-1c and that this effect is mediated by two LXR•RXR binding sites in the 
SREBP-1c promoter (51, 52).  SREBP-1c is a key factor mediating the effects of insulin 
on ACCα transcription in rat hepatocytes (25, 58).  These findings contrast with our data 
indicating that LXR plays a permissive role in mediating the effects of insulin on ACCα 
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transcription in chick embryo hepatocytes.  The reason for the differences between avians 
and rodents in the mechanism by which insulin regulates ACCα transcription is not clear.  
They may reflect subtle class-dependent differences in the role of insulin in the control of 
lipogenesis and/or other metabolic processes in liver. 
 Results from DNA binding studies suggest that T0-901317 treatment causes a 
transient reduction in the binding of a complex containing LXR•RXR (complex 2) 
(Fig. 6).  This change in the ACCα LXRE/T3RE protein binding profile would limit the 
activation of ACCα transcription by T0-901317.  T0-901317 treatment also causes an 
increase in the binding of a complex containing TR•RXR (complex 4).  The latter 
phenomenon would also suppress the stimulatory effects of T0-901317 on ACCα 
transcription because unliganded TR•RXR functions as a repressor of gene transcription 
(59).  Evidence that unliganded TR•RXR is associated with a subset of ACCα promoters 
during LXR activation is provided by the observation that T3 causes an increase in 
ACCα mRNA abundance in the presence of T0-901317 (Fig. 1).  We postulate that T0-
901317-induced changes in the binding of nuclear receptor complexes to the ACCα 
LXRE/T3RE constitutes a mechanism to prevent the over stimulation of 
ACCα transcription by the LXR signaling pathway.  The mechanism by which T0-
901317 alters the binding of nuclear receptor complexes to the ACCα LXRE/T3RE is 
presently unclear but does not involve changes in the expression of LXRα mRNA 
(Fig. 1), TRα mRNA, and TRβ mRNA (data not shown). 
 The ACCα LXRE/T3RE enhances ACCα transcription both in the absence and 
presence T0-901317 and T3 with a greater activation observed in the presence of T0-
901317 and T3 (Figs. 3 and 4) (7).  We previously hypothesized that the enhancer 
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activity of the ACCα LXRE/T3RE in the absence of T0-901317 and T3 was mediated by 
LXR•RXR heterodimers, as the primary protein complexes that bind the ACCα 
LXRE/T3RE in the absence of T0-901317 and T3 contain LXR•RXR heterodimers (7).  
Recent studies have shown that unliganded form of LXR•RXR represses gene 
transcription due to its ability to interact with corepressor proteins and that the addition of 
LXR ligand increases gene transcription by causing the release of corepressors and the 
recruitment of coactivators to LXR•RXR (60).  In view of these observations, we further 
hypothesize that LXR•RXR complexes associated with the ACCα LXRE/T3RE in the 
absence of T0-901317 and T3 are bound by endogenous LXR and/or RXR ligands.  
Several lines of evidence support this proposal.  First, treatment of chick embryo 
hepatocytes with naturally occurring agonists of LXR [22-(R)-hydroxy cholesterol] and 
RXR (9-cis retinoic acid) has little or no effect on ACCα mRNA abundance (Fig. 1 and 
data not shown).  Second, the ACCα LXRE/T3RE is not associated with the corepressor 
protein, nuclear receptor corepressor (NCoR), in the absence of T0-901317 and T3 (39).  
Last, the ACCα LXRE/T3RE is associated with acetylated histone H3 and acetylated 
histone H4 in the absence of T0-901317 and T3 (Fig. 7).  The ability of T0-901317 to 
increase the transcriptional activity and histone acetylation of the ACCα LXRE/T3RE is 
likely due to the fact that this synthetic agonist is more effective than endogenous LXR 
agonists in stimulating the recruitment of HAT-containing coactivators to LXR•RXR 
(40).  
 In summary, we show that T0-901317 activates of ACCα transcription by 
increasing the activity of LXR•RXR and SREBP-1 and the acetylation of histone H3 and 
histone H4 on ACCα promoter 2.  The identification of small molecules that selectively 
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inhibit of one or more of these processes will enhance the utility of T0-901317 in the 
treatment of atherosclerosis. 
Acknowledgments– This work was supported by a National Research Initiative 
Competitive Grant from the USDA Cooperative State Research, Education, and 
Extension Service (2001-35206-11133) and by a Grant-in-Aid Award from the American 
Heart Association (0355193B).  
 
REFERENCES 
1. Barber, M. C., N. T. Price, and M. T. Travers. 2005. Structure and regulation of 
acetyl-CoA carboxylase genes of metazoa. Biochim. Biophys. Acta 1733: 1-28. 
2. Brownsey, R. W., A. N. Boone, J. E. Elliott, J. E. Kulpa, and W. M. Lee. 2006. 
Regulation of acetyl-CoA carboxylase. Biochem. Soc. Trans. 34: 223-227. 
3. Leonard, A. E., S. L. Pereira, H. Sprecher, and Y. S. Huang. 2004. Elongation of 
long-chain fatty acids. Prog. Lipid Res. 43: 36-54. 
4. Abu-Elheiga, L., M. M. Matzuk, P. Kordari, W. Oh, T. Shaikenov, Z. Gu, and S. 
J. Wakil. 2005. Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically 
lethal. Proc. Natl. Acad. Sci. U S A 102: 12011-12016. 
5. Hillgartner, F. B., T. Charron, and K. A. Chesnut. 1996. Alterations in nutritional 
status regulate acetyl-CoA carboxylase expression in avian liver by a 
transcriptional mechanism. Biochem. J. 319 ( Pt 1): 263-268. 
6. Hillgartner, F. B., T. Charron, and K. A. Chesnut. 1997. Triiodothyronine 
stimulates and glucagon inhibits transcription of the acetyl-CoA carboxylase gene 
   75
in chick embryo hepatocytes: Glucose and insulin amplify the effect of 
triiodothyronine. Arch. Biochem. Biophys. 337: 159-168. 
7. Zhang, Y., L. Yin, and F. B. Hillgartner. 2001. Thyroid hormone stimulates 
acetyl-CoA carboxylase-α transcription in hepatocytes by modulating the 
composition of nuclear receptor complexes bound to a thyroid hormone response 
element. J. Biol. Chem. 276: 974-983. 
8. Zhang, Y., L. Yin, and F. B. Hillgartner. 2003. SREBP-1 integrates the actions of 
thyroid hormone, insulin, cAMP, and medium-chain fatty acids on ACCα 
transcription in hepatocytes. J. Lipid Res. 44: 356-368. 
9. Yin, L., Y. Zhang, and F. B. Hillgartner. 2002. Sterol regulatory element-binding 
protein-1 interacts with the nuclear thyroid hormone receptor to enhance acetyl-
CoA carboxylase-α transcription in hepatocytes. J. Biol. Chem. 277: 19554-
19565. 
10. Lehmann, J.. M., S. A. Kliewer, L. B. Moore, T. A. Smith-Oliver, B. B. Oliver, J. 
L. Su, S. S. Sundseth, D. A. Winegar, D. E. Blanchard, T. A. Spencer, and T. M. 
Willson. 1997. Activation of the nuclear receptor LXR by oxysterols defines a 
new hormone response pathway. J. Biol. Chem. 272: 3137-3140. 
11. Janowski, B. A., P. J. Willy, T. R. Devi, J. R. Falck, and D. J. Mangelsdorf. 1996. 
An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature 
383: 728-731. 
12. Teboul, M., E. Enmark, Q. Li, A. C. Wikstrom, M. Pelto-Huikko, and J. A. 
Gustafsson. 1995. Or-1, a member of the nuclear receptor superfamily that 
   76
interacts with the 9-cis-retinoic acid receptor. Proc. Natl. Acad. Sci. U S A 92: 
2096-2100. 
13. Willy, P. J., K. Umesono, E. S. Ong, R. M. Evans, R. A. Heyman, and D. J. 
Mangelsdorf. 1995. LXR, a nuclear receptor that defines a distinct retinoid 
response pathway. Genes Dev. 9: 1033-1045. 
14. Repa, J. J., and D. J. Mangelsdorf. 2002. The liver X receptor gene team: 
Potential new players in atherosclerosis. Nat. Med. 8: 1243-1248. 
15. Edwards, P. A., H. R. Kast, and A. M. Anisfeld. 2002. BAREing it all: The 
adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. 43: 
2-12. 
16. Zelcer, N., and P. Tontonoz. 2006. Liver X receptors as integrators of metabolic 
and inflammatory signaling. J. Clin. Invest 116: 607-614. 
17. Peet, D. J., S. D. Turley, W. Ma, B. A. Janowski, J. M. Lobaccaro, R. E. Hammer, 
and D. J. Mangelsdorf. 1998. Cholesterol and bile acid metabolism are impaired 
in mice lacking the nuclear oxysterol receptor LXRα. Cell 93: 693-704. 
18. Alberti, S., G. Schuster, P. Parini, D. Feltkamp, U. Diczfalusy, M. Rudling, B. 
Angelin, I. Bjorkhem, S. Pettersson, and J. A. Gustafsson. 2001. Hepatic 
cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient 
mice. J. Clin. Invest 107: 565-573. 
19. Joseph, S. B., E. McKilligin, L. Pei, M. A. Watson, A. R. Collins, B. A. Laffitte, 
M. Chen, G. Noh, J. Goodman, G. N. Hagger, J. Tran, T. K. Tippin, X. Wang, A. 
J. Lusis, W. A. Hsueh, R. E. Law, J. L. Collins, T. M. Willson, and P. Tontonoz. 
   77
2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. 
Proc. Natl. Acad. Sci. U S A 99: 7604-7609. 
20. Terasaka, N., A. Hiroshima, T. Koieyama, N. Ubukata, Y. Morikawa, D. Nakai, 
and T. Inaba. 2003. T-0901317, a synthetic liver X receptor ligand, inhibits 
development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536: 
6-11. 
21. Grefhorst, A., B. M. Elzinga, P. J. Voshol, T. Plosch, T. Kok, V. W. Bloks, F. H. 
van der Sluijs, L. M. Havekes, J. A. Romijn, H. J. Verkade, and F. Kuipers. 2002. 
Stimulation of lipogenesis by pharmacological activation of the liver X receptor 
leads to production of large, triglyceride-rich very low density lipoprotein 
particles. J. Biol. Chem. 277: 34182-34190. 
22. Chisholm, J. W., J. Hong, S. A. Mills, and R. M. Lawn. 2003. The LXR ligand 
T0901317 induces severe lipogenesis in the db/db diabetic mouse. J. Lipid Res. 
44: 2039-2048. 
23. Mulligan, J. D., M. T. Flowers, A. Tebon, J. J. Bitgood, C. Wellington, M. R. 
Hayden, and A. D. Attie. 2003. ABCA1 is essential for efficient basolateral 
cholesterol efflux during the absorption of dietary cholesterol in chickens. J. Biol. 
Chem. 278: 13356-13366. 
24. Schultz, J. R., H. Tu, A. Luk, J. J. Repa, J. C. Medina, L. Li, S. Schwendner, S. 
Wang, M. Thoolen, D. J. Mangelsdorf, K. D. Lustig, and B. Shan. 2000. Role of 
LXRs in control of lipogenesis. Genes Dev. 14: 2831-2838. 
25. Liang, G., J. Yang, J. D. Horton, R. E. Hammer, J. L. Goldstein, and M. S. 
Brown. 2002. Diminished hepatic response to fasting/refeeding and liver X 
   78
receptor agonists in mice with selective deficiency of sterol regulatory element-
binding protein-1c. J. Biol. Chem. 277: 9520-9528. 
26. Goodridge, A. G. 1973. Regulation of fatty acid synthesis in isolated hepatocytes 
prepared from the livers of neonatal chicks. J Biol. Chem. 248: 1924-1931. 
27. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by 
acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162: 
156-159. 
28. Feinberg, A. P., and B. Vogelstein. 1983. A technique for radiolabeling DNA 
restriction endonuclease fragments to high specific activity. Anal. Biochem. 132: 
6-13. 
29. Amasino, R. M. 1986. Acceleration of nucleic acid hybridization rate by 
polyethylene glycol. Anal. Biochem. 152: 304-307. 
30. Yuan, Z. Y., W. Liu, and G. G. Hammes. 1988. Molecular cloning and 
sequencing of DNA complementary to chicken liver fatty acid synthase mRNA. 
Proc. Natl. Acad. Sci. U S A 85: 6328-6331. 
31. Lefevre, P., C. Diot, P. Legrand, and M. Douaire. 1999. Hormonal regulation of 
stearoyl coenzyme-A desaturase 1 activity and gene expression in primary 
cultures of chicken hepatocytes. Arch. Biochem. Biophys. 368: 329-337. 
32. Zhang, Y., and F. B. Hillgartner. 2004. Starvation and feeding a high-
carbohydrate, low-fat diet regulate the expression sterol regulatory element-
binding protein-1 in chickens. J. Nutr. 134: 2205-2210. 
   79
33. Daval, S., F. Pitel, C. Le Nigen, M. Douaire, A. Vignal, and S. Lagarrigue. 2000. 
Cloning and mapping of the ACLY gene to a chicken microchromosome. Anim. 
Genet. 31: 412-413. 
34. Handschin, C., M. Podvinec, R. Amherd, R. Looser, J. C. Ourlin, and U. A. 
Meyer. 2002. Cholesterol and bile acids regulate xenosensor signaling in drug-
mediated induction of cytochromes p450. J. Biol. Chem. 277: 29561-29567. 
35. Winberry, L. K., S. M. Morris, Jr., J. E. Fisch, M. J. Glynias, R. A. Jenik, and A. 
G. Goodridge. 1983. Molecular cloning of cDNA sequences for avian malic 
enzyme. Nutritional and hormonal regulation of malic enzyme mRNA levels in 
avian liver cells in vivo and in culture. J. Biol. Chem. 258: 1337-1342. 
36. Baillie, R. A., S. A. Klautky, and A. G. Goodridge. 1993. Transient transfection 
of chick-embryo hepatocytes. J. Nutr. Biochem. 4: 431-439. 
37. Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes 
which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. 
Biol. 2: 1044-1051. 
38. Sedmak, J. J., and S. E. Grossberg. 1977. A rapid, sensitive, and versatile assay 
for protein using coomassie brilliant blue G250. Anal Biochem. 79: 544-552. 
39. Yin, L., Y. Wang, S. Dridi, C. Vinson, and F. B. Hillgartner. 2005. Role of 
CCAAT/enhancer-binding protein, histone acetylation, and coactivator 
recruitment in the regulation of malic enzyme transcription by thyroid hormone. 
Mol. Cell. Endocrinol. 245: 43-52. 
40. Albers, M., B. Blume, T. Schlueter, M. B. Wright, I. Kober, C. Kremoser, U. 
Deuschle, and M. Koegl. 2006. A novel principle for partial agonism of liver X 
   80
receptor ligands. Competitive recruitment of activators and repressors. J. Biol. 
Chem. 281: 4920-4930. 
41. Wiebel, F. F., K. R. Steffensen, E. Treuter, D. Feltkamp, and J. A. Gustafsson. 
1999. Ligand-independent coregulator recruitment by the triply activatable 
or1/retinoid X receptor-α nuclear receptor heterodimer. Mol. Endocrinol. 13: 
1105-1118. 
42. Huuskonen, J., P. E. Fielding, and C. J. Fielding. 2004. Role of p160 coactivator 
complex in the activation of liver X receptor. Arterioscler. Thromb Vasc Biol. 24: 
703-708. 
43. Lee, S. K., S. Y. Jung, Y. S. Kim, S. Y. Na, Y. C. Lee, and J. W. Lee. 2001. Two 
distinct nuclear receptor-interaction domains and CREB-binding protein-
dependent transactivation function of activating signal cointegrator-2. Mol. 
Endocrinol. 15: 241-254. 
44. Naar, A. M., P. A. Beaurang, S. Zhou, S. Abraham, W. Solomon, and R. Tjian. 
1999. Composite co-activator ARC mediates chromatin-directed transcriptional 
activation. Nature 398: 828-832. 
45. Oliner, J. D., J. M. Andresen, S. K. Hansen, S. Zhou, and R. Tjian. 1996. SREBP 
transcriptional activity is mediated through an interaction with the CREB-binding 
protein. Genes Dev. 10: 2903-2911. 
46. Belakavadi, M., and J. D. Fondell. 2006. Role of the mediator complex in nuclear 
hormone receptor signaling. Rev. Physiol. Biochem. Pharmacol. 156: 23-43. 
   81
47. Chakravarti, D., V. J. LaMorte, M. C. Nelson, T. Nakajima, I. G. Schulman, H. 
Juguilon, M. Montminy, and R. M. Evans. 1996. Role of CBP/p300 in nuclear 
receptor signalling. Nature 383: 99-103. 
48. Ericsson, J., and P. A. Edwards. 1998. CBP is required for sterol-regulated and 
sterol regulatory element-binding protein-regulated transcription. J. Biol. Chem. 
273: 17865-17870. 
49. Toth, J. I., S. Datta, J. N. Athanikar, L. P. Freedman, and T. F. Osborne. 2004. 
Selective coactivator interactions in gene activation by SREBP-1a and -1c. Mol. 
Cell. Biol. 24: 8288-8300. 
50. Joseph, S. B., B. A. Laffitte, P. H. Patel, M. A. Watson, K. E. Matsukuma, R. 
Walczak, J. L. Collins, T. F. Osborne, and P. Tontonoz. 2002. Direct and indirect 
mechanisms for regulation of fatty acid synthase gene expression by liver X 
receptors. J. Biol. Chem. 277: 11019-11025. 
51. Cagen, L. M., X. Deng, H. G. Wilcox, E. A. Park, R. Raghow, and M. B. Elam. 
2005. Insulin activates the rat sterol-regulatory-element-binding protein 1c 
(SREBP-1c) promoter through the combinatorial actions of SREBP, LXR, SP-1 
and NF-Y cis-acting elements. Biochem. J. 385: 207-216. 
52. Chen, G., G. Liang, J. Ou, J. L. Goldstein, and M. S. Brown. 2004. Central role 
for liver X receptor in insulin-mediated activation of SREBP-1c transcription and 
stimulation of fatty acid synthesis in liver. Proc. Natl. Acad. Sci U S A 101: 
11245-11250. 
53. Magana, M. M., S. H. Koo, H. C. Towle, and T. F. Osborne. 2000. Different 
sterol regulatory element-binding protein-1 isoforms utilize distinct co-regulatory 
   82
factors to activate the promoter for fatty acid synthase. J. Biol. Chem. 275: 4726-
4733. 
54. Xiong, S., S. S. Chirala, and S. J. Wakil. 2000. Sterol regulation of human fatty 
acid synthase promoter requires nuclear factor-Y and SP-1-binding sites. Proc. 
Natl. Acad. Sci. U S A 97: 3948-3953. 
55. Hegarty, B. D., A. Bobard, I. Hainault, P. Ferre, P. Bossard, and F. Foufelle. 
2005. Distinct roles of insulin and liver X receptor in the induction and cleavage 
of sterol regulatory element-binding protein-1c. Proc. Natl. Acad. Sci U S A 102: 
791-796. 
56. Schmitz, G., and T. Langmann. 2005. Transcriptional regulatory networks in lipid 
metabolism control ABCA1 expression. Biochim. Biophys. Acta 1735: 1-19. 
57. Tobin, K. A., S. M. Ulven, G. U. Schuster, H. H. Steineger, S. M. Andresen, J. A. 
Gustafsson, and H. I. Nebb. 2002. Liver X receptors as insulin-mediating factors 
in fatty acid and cholesterol biosynthesis. J. Biol. Chem. 277: 10691-10697. 
58. Stoeckman, A. K., and H. C. Towle. 2002. The role of SREBP-1c in nutritional 
regulation of lipogenic enzyme gene expression. J. Biol. Chem. 277: 27029-
27035. 
59. Privalsky, M. L. 2004. The role of corepressors in transcriptional regulation by 
nuclear hormone receptors. Annu. Rev. Physiol. 66: 315-360. 
60. Wagner, B. L., A. F. Valledor, G. Shao, C. L. Daige, E. D. Bischoff, M. 
Petrowski, K. Jepsen, S. H. Baek, R. A. Heyman, M. G. Rosenfeld, I. G. 
Schulman, and C. K. Glass. 2003. Promoter-specific roles for liver X 
   83
receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene 
expression. Mol. Cell. Biol. 23: 5780-5789. 
 
FIGURE LEGENDS 
 
Figure 1.  The LXR agonist, T0-901317, increases the expression of ACCα and other 
lipogenic enzymes in primary cultures of chick embryo hepatocytes.  Hepatocytes were 
isolated as described under Material and Methods and incubated in serum-free 
Waymouth’s medium.  At 18 h of incubation, the medium was changed to one of the 
same composition supplemented with or without T0-901317 (10 μM) in the absence or 
presence of insulin (50 nM), insulin and 9-cis retinoic acid (9-cis RA) (100 nM), insulin 
and T3 (1.5 μM), or insulin, T3 and 9-cis-RA.  After 28 h of treatment, total RNA was 
isolated and the abundance of mRNA encoding acetyl-CoA carboxylase α (ACCα), fatty 
acid synthase (FAS), stearoyl-CoA desaturase-1 (SCD1), ATP-citrate lyase (ATP-CL), 
malic enzyme (ME), ATP-binding cassette transporter A1 (ABCA1), and liver X receptor 
α (LXRα) was measured by Northern analysis.  Levels of mRNA in cells treated without 
T0-901317, 9-cis-RA, insulin, and T3 were set at 1, and the other values were adjusted 
proportionately.  Values are the means ± SEM of four experiments.  Hybridization 
signals from a representative experiment are shown for each mRNA.  Ribosomal subunits 
(27S and 18S) stained with ethidium bromide are shown as controls for RNA loading.  
aMean is significantly (P < 0.05) different from that of cells treated without T0-901317, 
9-cis-RA, insulin, and T3.  bMean is significantly (P < 0.05) different from that of cells 
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treated with insulin.  cMean is significantly (P < 0.05) different from that of cells treated 
with insulin and T3. 
 
Figure 2.  Effect of T0-901317 on the accumulation of triacylglycerols in the culture 
medium of chick embryo hepatocytes.  Hepatocytes were plated on 90 mm petri dishes (1 
x 107 cells/dish) in Waymouth’s medium containing insulin.  At 18 h of incubation, the 
medium was changed to one of the same composition supplemented with or without T0-
901317.  After 0, 24, 36, and 48 h of incubation with T0-901317, the concentration of 
triacylglycerol in the culture medium was measured using a spectrophotometric assay.  
Data are the means ± SEM of three experiments.  *Mean is significantly (P < 0.05) 
different from that of cells incubated with insulin for the same time period. 
 
Figure 3.  Effect of mutations of the 5’-flanking region of ACCα promoter 2 on 
transcriptional activity in the absence and presence of T0-901317.  Chick embryo 
hepatocytes were transiently transfected with p[ACC-2054/+274]CAT or equimolar 
amounts of other plasmids as described under Materials and Methods.  After transfection, 
cells were treated with or without T0-901317 for 48 h.  Cells were then harvested, 
extracts prepared, and CAT assays performed.  Left: The constructs used in these 
experiments.  The number at the left of each construct is the 5' end of ACCα DNA in 
nucleotides relative to the transcription initiation site of promoter 2.  The 3' end of each 
construct was +274 bp.  The location of the LXR response element (LXRE) (-101 to -86 
bp) and the sterol regulatory element (SRE) (-80 to -71 bp) is indicated by vertical lines.  
A block mutation of the SRE is indicated by a X through the vertical line.  Right: CAT 
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activity of cells transfected with p[ACC-108/+274] CAT and treated with T0-901317 was 
set at 1, and the other activities were adjusted proportionately.  The fold stimulation by 
T0-901317 was calculated by dividing the CAT activity for hepatocytes treated with T0-
901317 (+T0-901317) by that for hepatocytes not treated with T0-901317 (-T0-901317).  
The fold responses were calculated for individual experiments and then averaged.  The 
results are the means ± SEM of six experiments.  aThe fold stimulation by T0-901317 is 
significantly (P < 0.05) lower than that of p[ACC-108/+274]CAT.  bThe fold stimulation 
by T0-901317 is significantly (P < 0.05) lower than that of p[ACC-108/+274]CAT 
containing a block mutation of the SRE. 
 
Figure 4.  The ACCα SRE alone enhances the transcriptional activity of the ACCα 
LXRE in the presence of T0-901317.  Fragments of the ACCα gene containing the 
LXRE and/or SRE were linked to the minimal TK promoter in TKCAT.  Chick embryo 
hepatocytes were transiently transfected with these constructs and treated with or without 
T0-901317 as described in the legend of Fig. 3 and under Materials and Methods.  Left: 
The constructs used in these experiments.  Numbers indicate the 5’ and 3’ boundaries of 
ACCα DNA relative to the transcription initiation site of promoter 2.  A block mutation 
of the SRE is indicated by a X across the box representing the SRE.  Right: CAT activity 
in hepatocytes transfected with TKCAT and treated without T0-901317 was set at 1, and 
the other activities were adjusted proportionately.  The fold stimulation by T0-901317 
was calculated as described in the legend to Fig. 3.  The results are the means ± SEM of 
five experiments.  aThe fold stimulation by T0-901317 for p[ACC-108/-66]TKCAT is 
significantly (p < 0.05) higher than any other construct. 
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Figure 5.  T0-901317 increases the concentration of mature SREBP-1 in chick embryo 
hepatocyte cultures.  Chick embryo hepatocytes were isolated and incubated in serum-
free Waymouth’s medium containing insulin.  At 18 h of incubation, the medium was 
changed to one of the same composition.  T0-901317 was added at this time.  After 2, 6, 
12, 24, and 48 h of T0-901317 treatment, cellular extracts or total RNA were prepared as 
described under Materials and Methods.  A: The abundance of mature SREBP-1 in 
nuclear extracts was measured by Western analyses.  The abundance of SREBP-1 mRNA 
and ACCα mRNA was measured Northern analysis..  These data are from a 
representative experiment.  B: Signals for mature SREBP-1 protein from Western 
analyses and SREBP-1 mRNA and ACCα mRNA from Northern analyses were 
quantitated.  Levels of mature SREBP-1 protein, SREBP-1 mRNA, and ACCα mRNA in 
hepatocytes treated with T0-901317 for 0 h were set at 1.  Values are the means ± SEM 
of four experiments.  Asterisks indicate that the mean is significantly (P < 0.05) different 
from that of cells incubated with T0-901317 for 0 h or without T0-901317 for 24 or 48 h.   
 
Figure 6.  Effect of T0-901317 treatment on the binding of nuclear receptor complexes to 
the ACCα LXRE/T3RE in chick embryo hepatocytes.  Eighteen hours after being placed 
in culture, chick embryo hepatocytes were incubated in Waymouth’s medium containing 
insulin with or without T0-901317 for the indicated time periods.  Cells were harvested 
and nuclear extracts were prepared as described in Methods and Materials  Nuclear 
extracts were subjected to gel mobility shift analyses using an oligonucleotide probe 
containing the ACCα LXRE/T3RE (-108 to -82 bp).  Specific protein-DNA complexes 
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are indicated by arrows.  Previous studies have shown that complexes 1 and 2 contain 
LXR·RXR heterodimers, whereas complex 4 contains TR·RXR heterodimers (5).  A: 
Data from a representative experiment.  B: Signals for complex 1, complex 2, and 
complex 4 were quantitated.  The binding activities of complex 1, complex 2, and 
complex 4 in hepatocytes treated with T0-901317 for 0 h were set at 1, and the other 
activities were adjusted proportionately.  Values are the means ± SEM of four 
experiments.  Asterisks indicate that the mean is significantly (P < 0.05) different from 
that of cells incubated with T0-901317 for 0 h or without T0-901317 for 24 or 48 h. 
 
Figure 7.  Treatment of chick embryo hepatocyte cultures with T0-901317 causes a 
transient increase in histone acetylation at the ACCα liver X receptor response unit.  
Chick embryo hepatocytes were isolated and incubated in serum-free Waymouth’s 
medium containing insulin.  At 18 h of incubation, the medium was changed to one of the 
same composition.  T0-901317 was added at this time.  After 2, 6, 24, and 48 h of T0-
901317 treatment, the association of acetylated histone H3 and acetylated histone H4 
with ACCα and SCD1 genomic sequences was measured.  ChIP assays were performed 
as described in Materials and Methods.  Immunoprecipitates were analyzed by PCR using 
primers that flanked the liver X receptor response unit (LXRU) of ACCα promoter 2 and 
an uncharacterized region of the SCD1 promoter.  The region of the ACCα gene and 
SCD1 gene that was amplified by PCR is indicated at the top of the figure.  Chromatin 
samples that were processed in parallel without the application of primary antibody 
served as controls.  The input lanes show the results of PCR reactions using chromatin 
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samples taken before the immunoprecipitation step.  Results are representative of three 
independent experiments 
 
 
TABLE 1. 
 
Effect of T0-901317 treatment on the acetylation of histones at the acetyl-CoA 
carboxylase-α LXR response unit 
 
                                                        T0-901317 Treatment (h) 
 
 0 2 6 24 48 
 
 
Ac-H3 1.0 1.4 ± 0.1* 1.8 ± 0.1* 1.1 ± 0.2 1.1 ± 0.1 
 
Ac-H4 1.0 1.7 ± 0.1* 2.2 ± 0.2* 1.0 ± 0.1 1.1 ± 0.1 
 
 
Signals from ChIP assays using the indicated antibodies were quantitated.  The data are 
expressed as the fold difference relative to samples from hepatocytes treated with T0-
901317 for 0 h.  Values are the means ± SEM of three experiments.  Results from a  
representative experiment are shown in Fig. 7.  *Significantly different (P < 0.05) from 
cells treated with T0-901317 for 0 h. 
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INTRODUCTION 
 
The liver X receptors (LXRs) have emerged as important regulators of genes 
involved in lipid and lipoprotein metabolism in higher vertebrates.  LXRs were initially 
identified in 1995 as orphan members of the nuclear receptor superfamily (61, 70).  Two 
isoforms exist with different expression patterns.  LXRα is expressed at high levels in 
liver, adipose tissue and macrophages, whereas LXRβ is expressed ubiquitously (64, 70).  
The majority of the LXR proteins are localized in the nucleus and require 
heterodimerization with the retinoid X receptor (RXR) in order to bind DNA and regulate 
transcription (70).  
The screening of organic tissue extracts using a cell-based reporter assay led to 
the breakthrough discovery that oxysterols were the endogenous ligands that bound and 
activated LXRα and LXRβ (35, 40).  The most potent endogenous LXR ligands are 
24(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, and 24(S) epoxycholesterol.  LXR 
agonists activate a battery of genes involved in cholesterol efflux (ABCA1, ABCG1, 
ABCG5, and ABCG8), cholesterol clearance (cholesterol ester transfer protein and 
apolipoprotein E), and cholesterol catabolism (cholesterol 7α-hydroxylase) (reviewed in 
(18, 57).  Because oxysterols are produced in proportion to cellular cholesterol content, 
LXRs have been proposed to function as sensors in a feed-forward pathway that 
stimulates reverse cholesterol transport and cholesterol excretion in response to high 
cholesterol levels in the diet.  Consistent with this proposal, mice lacking the LXRα 
and/or LXRβ gene exhibit diminished cholesterol excretion and elevated cholesterol 
levels in the blood and liver when fed a high-cholesterol diet (2, 50). 
The effects of LXR agonists on gene transcription are mediated by cis-acting 
sequences that are comprised of hexameric half-sites arranged as direct repeats with a 4 
bp spacer separating the half-sites (70).  These sequences, termed LXR response elements 
(LXREs), bind heterodimers comprised of LXR and RXR.  Ligand-bound nuclear 
receptors activate transcription by recruiting auxiliary transcriptional regulatory proteins 
referred to as coactivators (71).  Examples of coactivators of LXR include steroid 
receptor coactivator-1 (69) and PGC-1α (48).  Coactivators facilitate the ability of LXR 
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to activate transcription by directly interacting with the basal transcriptional machinery, 
by modulating interactions between LXR and the basal transcriptional machinery, and by 
modifying chromatin structure. 
We and other investigators have shown that LXR agonists also activate the 
transcription of genes involved in triglyceride synthesis including ATP-citrate lyase, fatty 
acid synthase, stearoyl-CoA desaturase, and ACCα (36, 60).  In the case of ACCα, we 
have shown that this effect is mediated by both a direct mechanism involving the 
activation of LXR/RXR heterodimers on the ACCα gene and by an indirect mechanism 
involving the increased expression of SREBP-1.  SREBP-1 binds a site adjacent to the 
ACCα LXRE and enhances the ability of LXR/RXR to activate ACCα transcription.  
LXR agonists increase the expression of SREBP-1 by activating a LXRE on the SREBP-
1 gene (56). 
HMG-CoA reductase inhibitors (statins) are currently the first-line agents to treat 
and prevent atherosclerosis in humans.  Unfortunately, statins are not effective in 
reducing circulating cholesterol and LDL levels in a significant fraction of patients with 
dyslipidemia (11). This has triggered a strong interest in the development of new 
pharmacological approaches to achieve atheroprotection.  LXR agonists represent one 
such approach because these compounds stimulate reverse cholesterol transport and 
cholesterol excretion.  Accordingly, several laboratories have identified non-steroidal, 
synthetic compounds that are more effective than endogenous oxysterols in stimulating 
LXR activity (15, 60).  The atheroprotective properties of two of these synthetic LXR 
agonists, designated T0901317 (N-(2,2,2-trifluoro-ethyl)-N-[4-(2,2,2-trifluoro-1-hydroxy-
1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide) and GW3965 (2-(3-{3-[[2-chloro-
3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}-phenyl)acetic acid), have 
been evaluated in murine models of atherosclerosis.  Oral administration of T0901317 or 
GW3965 to mice lacking the LDL receptor or apolipoprotein E stimulates an increase in 
blood HDL levels and reverses the formation of atherosclerotic lesions in the aorta (36, 
46, 65).  These exciting findings are tempered by the observation that treatment with 
T0901317 or GW3965 also causes hypertriglyceridemia and the development of a fatty 
liver (14, 26, 60).  These undesired effects of T0901317 and GW3965 are due to an 
increase in hepatic fatty acid synthesis.  One approach to overcome this problem is to 
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activate another signaling pathway that selectively inhibits the effects of LXR agonists on 
lipogenic gene transcription without altering their ability to stimulate genes involved in 
reverse cholesterol transport. 
In the present study, we show that, in primary hepatocyte cultures, 
chenodeoxycholic acid (CDCA) inhibits the stimulatory effects of T0-901317 on the 
expression of ACCα and other lipogenic enzymes and enhances the stimulatory effects of 
T0-901317 on expression of ABCA1, a key gene controlling reverse cholesterol 
transport.  We also demonstrate that CDCA decreases ACCα transcription by inhibiting 
the activity of LXR and SREBP-1 and that extracellular signal-regulated kinase (ERK) 
and p38 mitogen-activated protein kinase (p38 MAPK) are components of the signaling 
pathway(s) mediating this response. 
 
EXPERIMENTAL PROCEDURES 
Preparation of isolated hepatocytes  
Hepatocytes were isolated from livers of 19-day-old chick embryos as previously 
described (Chapter 2).  Cells were incubated in serum-free Waymouth's medium 
MD752/1 containing penicillin (60 µg/ml) and streptomycin (100 µg/ml) on untreated 
petri dishes at 40°C in a humidified atmosphere of 5% CO2 and 95% air.  Hormone and 
other additions were as described in the figure legends.  The triacylglycerol concentration 
of the culture medium was measured using an enzymatic kit (Sigma). 
 
 Isolation of RNA and quantitation of mRNA levels   
 Medium was removed and RNA was extracted from hepatocytes by the 
guanidinium thiocyanate/phenol/chloroform method as described (Chapter 2).  Total 
RNA (20 µg) was separated by size in 1% agarose, 0.7 M formaldehyde gels, and then 
transferred to a Nytran membrane (Schleicher & Schuell) using a Vacuum blotting 
apparatus (Pharmacia Biotechnology).  The RNA was crosslinked to the membrane by 
UV and baked at 80°C for 15 min.  RNA blots were hybridized with 32P-labeled DNA 
probes labeled by random priming.  Hybridization and washes were as described.  
Membranes were subjected to storage phosphor autoradiography.  Hybridization signals 
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were quantified using ImageQuaNT software (Molecular Dynamics).  cDNAs for chicken 
ACCα, FAS, SCD, SREBP-1, ABCA1  have been described (Chapter 2).  
 
 Plasmids  
 Reporter plasmids are named by designating the 5' and 3' ends of the ACCα DNA 
fragment relative to the transcription start site of promoter 2.  A series of 5' deletions and 
3' deletions of ACCα promoter 2 in the context of p[ACC-2054/+274]CAT have been 
previously described (Chapter 2).  An ACCα promoter construct containing a mutation of 
the SRE-1 between -79 and -72 bp in the context of p[ACC-108/+274]CAT has been 
previously described.  p[ACC-108/-66]TKCAT, p[ACC-84/-66]TKCAT and pTKCAT 
constructs containing mutations in the -108 to -66 bp ACCα fragment are described 
(Chapter 2). 
 
 Transient transfection 
 Chick embryo hepatocytes were transfected as described (Chapter 2).  Briefly, 
cells were isolated and incubated on 60 mm petri dishes.  At 6 h of incubation, the 
medium was replaced with one containing 10 μg of lipofectin (Invitrogen), 1.5 μg of 
p[ACC-2054/+274]CAT or an equimolar amount of another reporter plasmid and 
pBluescript KS(+) to bring the total amount of transfected DNA to 1.5 μg per plate.  At 
18 h of incubation, the transfection medium was replaced with fresh medium with or 
without T0-901317 (6 µM).  At 66 h of incubation, chick embryo hepatocytes were 
harvested, and cell extracts were prepared as described in (4).  CAT activity (20) and 
protein (53) were assayed by the indicated methods. 
 
Western blot analysis   
For detection of mature and precursor SREBP-1, nuclear extracts were prepared 
from chick embryo hepatocytes as described (69).  The proteins of the nuclear extract 
were subjected to electrophoresis in 10% SDS-polyacrylamide gels and then transferred 
to polyvinylidene difluoride membranes (Millipore) using an electroblotting apparatus 
(BIORAD).  Immunoblot analysis was carried using a mouse monoclonal antibody 
against SREBP-1 (IgG-2A4) (American Type Culture Collection, Manassas, VA).  
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Antibody/protein complexes on blots were detected using enhanced chemiluminescence 
and or fluorescence, ECL-Plus (Amersham Biosciences).  Chemiluminescence on the 
blots was visualized using a FluorChem 8000 imager (Alpha Innotech Corporation) and 
signals for mature form of SREBP-1 were quantified using FluorChem V200 software.  
Fluorescence was detected by scanning the membrane on Typhoon 9400 scanner 
(Amersham Biosciences) and the signals quantified using ImageQuaNT software.   
For detection of phospho- and total MAP kinase, western analysis was performed 
as described (56).  Briefly, total cell lysates were prepared in a buffer containing 10 mM 
Tris, pH 7.4, 1% SDS.  Protein concentration was determined using Bradford assay 
(BIORAD).  Proteins were run on 10% polyacrylamide gels and transferred to 
polyvinylidene difluoride membrane (Millipore).  Membranes were blocked in 5% nonfat 
dry milk for 1 h and incubated with primary antibody diluted in 5% bovine serum 
albumin overnight at 4°C.  The primary antibodies against phospho-Akt (Ser473), 
phospho-p38 MAPK (Thr180/Tyr182), phospho-AMPK (Thr172), phospho-LKB1 
(Ser428), phospho-ACC (Ser 79), phospho-PKC (pan, βII Ser660), phospho-S6 kinase 
(Thr389), phospho-MKK 3/6 (Ser189/207), phospho-MEK 1/2 (Ser 221), phospho-JNK 
(Thr183/Tyr185), phospho-Raf and total Akt, total p38 MAPK, total AMPK, total ACC, 
total p38 MAPK, total JNK, total ERK were obtained from Cell Signaling Technology.  
Anti-rabbit IgG conjugated with horseradish peroxidase (Cell Signaling Technology) was 
used as the secondary antibody, and the signals were detected by enhanced 
chemiluminescence, ECL-Plus (Amersham Biosciences).  Images were visualized on 
Typhoon 9400 to detect fluorescence and/or Alpha Innotech to detect chemiluminescence 
and quantified by densitometry using ImageQuaNT software (Amersham Biosciences).  
MEK1/2 inhibitor, U0126 was purchased from Cell Signaling Technology.  p38 MAPK 
inhibitors, SB203580 and SB202190 were purchased from Calbiochem.   
 
Real-time RT-PCR 
Total RNA from cells were isolated as described.  Real-time RT-PCR assays 
using SYBR-green (BIORAD) were carried out in ninety-six well plates.  100 ng of total 
RNA was added per well to a total volume of 20 µl.  Thermo-cycling conditions were as 
follows: 15 min at 50°C for reverse transcription; 10 min at 95°C to activate DNA 
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polymerase and to deactivate reverse transcriptase; 35 cycles of 15 s at 94°C to denature 
and 1 min at 59°C to anneal and extend DNA template.  Reverse transcription and PCR 
amplification were performed by using iCycler thermal cycler from Bio-Rad.  The 
primers used for genes have been described.  Primers of chicken ACCα, SREBP-1 and 
SCD were used as described (51).  Primers for the following genes were designed using 
PrimerQuest from IDT.  The name of the genes and the corresponding Pubmed accession 
numbers are indicated in parentheses.  SHP (AY700583), PGC-1α (AB170013), INSIG-1 
(XM_418547), INSIG-2 (XM_422123), HMG-CoA reductase (AB109635), ABCA1 
(NM_204145), LXRα (AF492498). 
 
 Gel mobility shift analysis 
Nuclear extracts were prepared from hepatocytes incubated with or without 
CDCA in the presence of T0-901317.  A double-stranded oligonucleotide containing the 
ACCα LXRE/T3RE (-108 to -82 bp relative to the transcription initiation site of ACCα 
promoter 2) was labeled by filling in overhanging 5’-ends using Klenow fragment of E. 
coli DNA polymerase in the presence of [α-32P] dCTP.  Binding reactions were carried 
out as previously described (Chapter 2).  DNA and DNA-protein complexes were 
resolved on 6% nondenaturing polyacrylamide gels at 4 ºC in 0.5 X TBE (45 mM Tris, 
pH 8.3, 45 mM boric acid, 1 mM EDTA).  Following electrophoresis, the gels were dried 
and subjected to storage phosphor autoradiography. 
 
 Histone acetylation   
 The extent of histone acetylation on ACCα promoter 2 was measured using a 
chromatin immunoprecipitation (ChIP) assay.  The procedure for this assay was the same 
as that described (68).  Chromatin immunoprecipitations were carried out with antibodies 
against acetyl-histone H3 (06-599) and acetyl-histone H4 (06-866) (Upstate 
Biotechnology).  Precipitated DNA was analyzed in PCR reactions using Taq DNA 
polymerase (New England Biolabs) and primers specific for the ACCα and malic enzyme 
promoters.  The cycling parameters were: 1 cycle of 95°C for 4 min, 30 cycles of 95°C 
for 1 min, 61°C for 1 min, 72°C for 1 min, and 1 cycle of 72°C for 10 min.  The forward 
primer of the ACCα gene was 5’-TCCCCTCCGTCAGCAGCCAATGGG-3’; the reverse 
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primer was 5’-ATCCCCGGTCCCGCCCTCGGCTCC-3’.  The forward primer of the 
SCD1 gene was 5’-AGCGAACAGCAGATTGCGGCAG-3’; the reverse primer was 
5’-AGGAAGGATGCTGAGGAAGAGGA-3’.  Amplified products were subjected to 
electrophoresis in 2% agarose gels and visualized by ethidium bromide staining. 
 
 
RESULTS 
Regulation of LXR signaling by Hexanoate and cAMP 
Previous work from our laboratory has shown that cAMP and hexanoate inhibit 
the activation of ACCα expression caused by insulin and T3.  cAMP and hexanoate 
inhibit ACCα transcription at least in part by repressing the ability of T3 and insulin to 
increase the levels of mature SREBP-1 resulting in a disruption of the positive interaction 
between SREBP-1 and nuclear T3 receptor on the ACCα gene (72).  We have also shown 
in Chapter 2 Figure 1, that T0-901317 increases the mRNA abundance of lipogenic genes 
such as ACCα, FAS and SCD.  We wanted to determine whether cAMP and hexanoate 
inhibited the stimulation of ACCα, FAS, SCD, SREBP-1, LXR and ABCA1 caused by 
T0-901317.  Our experiments showed that cAMP had no effect on T0-901317 induced 
expression of ACCα and other lipogenic genes (data not shown).  In contrast, hexanoate 
inhibited T0-901317-induced mRNA abundance of lipogenic genes such as ACCα, FAS 
and SCD in a dose-dependent manner Figure 3.1.  Hexanoate had no effect on the 
abundance of these genes in the absence of T0-901317.  Hexanoate also inhibited T0-
901317-induced ABCA1 mRNA expression in hepatocytes in a dose dependent manner.  
Thus, hexanoate does not qualify as an agent to selectively inhibit the actions of LXR 
agonist on lipogenic gene expression.  As shown previously in Chapter 2, T0-901317 
increases SREBP-1 and LXRα mRNA.  Hexanoate had little or no effect on SREBP-1 
and LXRα mRNA expression both in the absence and presence of T0-901317.   
 
Chenodeoxycholic acid inhibits T0-901317-induced expression of lipogenic genes in 
primary cultures of chick embryo hepatocytes 
As discussed previously, an increase in bile acids has been shown to be inversely 
correlated with a decrease in triglycerides, and vice versa (5, 10, 28, 158, 207, 185, 168).  
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The above observations prompted us to determine whether bile acids could inhibit the 
stimulation of ACCα and other lipogenic genes caused by T0-901317.  Chick hepatocytes 
were incubated in the presence of insulin and insulin and T0-901317.  Chenodeoxycholic 
acid (CDCA) was added in the absence and presence of T0-901317 in increasing 
concentrations.  Incubation of chicken embryo hepatocytes with CDCA in the absence of 
T0-901317 had no effect on expression of ACCα, FAS and SCD mRNA abundance 
Figure 3.2.  In contrast, CDCA inhibited T0-901317-induced mRNA abundance of 
lipogenic genes such as ACCα, fatty acid synthase (FAS), stearoyl CoA desaturase 
(SCD) in a dose dependent manner.  Interestingly, CDCA further potentiated T0-901317-
induced expression of ABCA1 mRNA, indicating that the effects of bile acids on LXR 
signaling are gene specific.  CDCA has no effect on the mRNA abundance of ABCA1 in 
the absence of T0-901317.   
3-hydroxy-3-methyglutaryl-CoA (HMG-CoA) reductase serves as the rate-
limiting enzyme in cholesterol biosynthesis (45).  Inhibitors of HMG-CoA reductase, 
collectively referred to as statins, are extensively used to lower plasma cholesterol both as 
a preventive measure, and cure for heart disease resulting from increased LDL (21).  One 
of the rare, but major side effects of statins is the occurrence of rhabdomyolysis, that 
limits the use of these drugs in some patients (58).  Therefore, it is important to 
investigate other agents that inhibit HMG-CoA reductase, or agents that inhibit other 
genes of the cholesterol synthesis pathway.  CDCA has no effect on HMG-CoA reductase 
mRNA abundance in presence of insulin and causes a slight reduction at 75 µM.  T0-
901317 increases HMG-CoA reductase mRNA by 3-fold in presence of insulin.  CDCA 
inhibits T0-901317-induced expression of HMG-CoA reductase in a dose dependent 
manner.   
 
 
The decrease in ACCα mRNA by CDCA was correlated with a decrease of the 
ACCα protein by CDCA.  Primary chick hepatocytes were incubated in the presence of 
T0-901317 in the absence and presence of CDCA.  Total protein was harvested at the 
indicated time points and western blot analysis was performed to detect the amount of 
total ACC.  CDCA inhibited total ACC protein as early as 2 h and further inhibited at 6 h, 
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12 h and 24 h, with maximal inhibition obtained at 24 h Figure 3.3A.  To determine 
whether CDCA mediated decrease in ACCα expression was associated with a decrease in 
triacylglycerol production, the triacylglycerol concentration in the culture medium was 
measured in hepatocytes treated with T0-901317 in the absence and presence of CDCA.  
Medium was collected and total triglyceride in the medium was determined as outlined in 
Materials and methods.  CDCA inhibited triacylglycerol accumulation in the medium at 
24 hours Figure 3.3B.  These results support that T0-901317-induced 
hypertriglyceridemia can be inhibited upon administration of CDCA.   
 
 
CDCA inhibits T3-induced expression of lipogenic genes 
Previous work in our laboratory showed that thyroid hormone stimulates ACCα 
expression, and that this effect is mediated at least in part, by the binding of the nuclear 
T3 receptor (TR) to a composite T3RE/LXRE (73).  We next asked if bile acids also 
modulated the activity of the nuclear T3 receptor signaling pathways.  Our results showed 
that bile acids inhibit T3-induced expression of ACCα, FAS, SCD and malic enzyme 
(ME) in a dose dependent manner Figure 3.4.  CDCA had no effect on the mRNA 
abundance of these genes in the absence of T3.  T3 causes a small decrease in ABCA1 
mRNA.  However, as shown in the previous figure, CDCA also increases expression of 
ABCA1 in a dose dependent manner with a two-fold induction at 75 µM, in the presence 
of T3.  We propose that a common mechanism may be involved in mediating the effects 
of bile acids on T0-901317 and T3 signaling. 
 
Identification of a bile acid response unit on the ACCα promoter that mediates the 
effect of CDCA on ACCα transcription 
We have previously shown that T0-901317 regulation of ACCα is mediated by a 
23 bp region in promoter 2 of the ACCα gene.  This region consists of a DR-4 element (-
101 to -86 bp) that binds heterodimers comprised of TR•RXR and LXR•RXR and a SRE 
(-82 to -71 bp) that binds SREBP-1 (Chapter 2).  To determine if these cis-acting 
elements or other sequences in the ACCα gene mediate the effects of CDCA on ACCα 
transcription, transient transfection experiments were performed using reporter constructs 
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containing portions of ACCα promoter 2 linked to chloramphenicol acetyl transferase 
(CAT) gene.  In chick embryo hepatocytes transfected with a reporter construct 
containing -2054 bp of 5’-flanking DNA, CDCA caused a 58% decrease in promoter 
activity Figure 3.5A.  5’-deletion of ACCα sequences to -391, -136, and -108 bp had no 
effect on CDCA responsiveness.  Deletion of ACCα sequences containing the DR-4 
element (-108 to -84 bp) abolished the inhibitory effect of CDCA on ACCα transcription.  
Further deletion to -41 bp had no effect on CDCA responsiveness.  Mutation of the SRE 
(-80 to -71 bp) in the context of 108 bp of 5’-flanking DNA caused a 35% attenuation of 
CDCA responsiveness on the ACCα promoter.  These results indicate that the DR-4 
element (LXRE) is required for CDCA regulation of ACCα transcription and that the 
SRE enhances the ability of the LXRE to inhibit ACCα transcription in the presence of 
CDCA.  
 To determine whether the functional interaction between the ACCα LXRE and 
SRE required the presence of additional cis-acting sequences, hepatocytes were 
transfected with constructs containing fragments of the ACCα gene linked to the minimal 
promoter of the herpes simplex virus thymidine kinase (TK) gene Figure 3.5B.  The TK 
promoter alone was unresponsive to CDCA.  When a DNA fragment containing both the 
ACCα LXRE and ACCα SRE (-108 to -66 bp) was linked to the TK promoter, treatment 
with CDCA caused a 60% decrease in promoter activity.  Mutation of the ACCα SRE in 
the context of the ACCα -108 to -66 bp fragment caused a 23% decrease in CDCA 
responsiveness.  When a DNA fragment containing the ACCα SRE alone (-84 to -66 bp) 
was appended to the TK promoter, CDCA treatment almost completely abolished ACCα 
promoter activity.  These data demonstrate that the ACCα SRE can function alone to 
enhance CDCA regulation conferred by the ACCα LXRE. 
 
CDCA inhibits ACCα gene transcription by inhibiting the abundance of mature 
SREBP-1 via a post-translational mechanism in chick embryo hepatocytes 
 In our previous studies analyzing the regulation of the ACCα gene by T0-901317, 
we showed that T0-901317 treatment increased the abundance of mature, active form of 
SREBP-1 in chick embryo hepatocytes and this effect contributed to the activation of 
ACCα transcription by T0-901317 Chapter 2, Figure 5.  Further, our studies in Figure 
   107
3.5 suggest the involvement of the ACCα-SRE in CDCA regulation of the ACCα gene.  
We wanted to determine the mechanism by which CDCA inhibits ACCα gene 
transcription, and whether SREBP-1, at least in part, mediates the inhibition.  We 
performed time course experiments to determine the effects of CDCA on the abundance 
of mature SREBP-1 protein, ACCα mRNA, SREBP-1 precursor and SREBP-1 mRNA in 
hepatocytes cultured in the presence of T0-901317.  Nuclear and membrane extracts and 
total RNA was isolated at the indicated time points and Northern and Western blot 
analysis was performed to detect levels of RNA and protein respectively.  CDCA 
inhibited the abundance of the mature, active form of SREBP-1 as early as 2 h with 
maximal inhibition of about 40% at 12 h Figure 3.6A.  The decrease in mature SREBP-1 
by CDCA is correlated with the fact that treatment with CDCA caused a 20% decrease in 
the abundance of ACCα mRNA as early as 2 h, with maximal inhibition of about 50% 
obtained at 6 h Figure 3.6B.  This observation is consistent with the proposal that 
alterations in SREBP-1 levels play a role in mediating the regulation of ACCα 
transcription by CDCA.  Interestingly, CDCA increased the abundance of the inactive 
precursor form of SREBP-1 in the membrane, significantly at 12 h and 24 h by 3- and 5-
fold respectively Figure 3.6C.  CDCA had no effect on SREBP-1 mRNA abundance 
Figure 3.6D.  An increase in precursor SREBP-1 suggests a mechanism by which CDCA 
increases retention of SREBP-1 in the membrane and implicates a posttranslational 
mechanism that is involved in regulation of ACCα.   
Several factors are associated with retention of inactive precursor SREBP-1 in the 
membrane.  For example, Insig-1 and Insig-2 are two proteins that have been shown to 
play a role in transporting SREBP-1 from the ER to the Golgi (16, 24, 65-67).  We 
measured the mRNA abundance of these two genes upon addition of CDCA in presence 
of T0-901317.  CDCA caused a transient increase in mRNA abundance of Insig-1 about 
200% at 2 h, but inhibited the abundance of the mRNA at 12 h and 24 h Figure 3.6E.  
CDCA inhibited mRNA abundance of INSIG-2 mRNA transiently at 2 h Figure 3.6F.  
CDCA had no effect on INSIG-2 mRNA at later time points.  It is unclear whether the 
transient increase of INSIG-1 mRNA at 2 h by CDCA, is sufficient to cause retention of 
the precursor (inactive) form of SREBP-1 in the membrane.  At the same time, CDCA 
significantly inhibits INSIG-2 mRNA which would cause a decrease of the precursor 
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accumulation in the membrane.  Thus, the opposing effects of CDCA on INSIG-1 and -2 
mRNA at 2 hours should have no effect on SREBP-1 processing.  Therefore, our data 
would suggest that other factors independent of the INSIG proteins may be mediating the 
post-translational modification of SREBP-1 by CDCA.   
 
CDCA modulates the binding of nuclear receptor complexes to the ACCα LXRE/T3RE 
 In previous work, we showed that the ACCα LXRE/T3RE (-101 to -86 bp) bound 
four protein complexes in nuclear extracts prepared from chick embryo hepatocytes.  
Three of these complexes (designated complexes 1, 2 and 3) contained LXR•RXR 
heterodimers, whereas the fourth complex (designated complex 4) contained TR•RXR 
heterodimers (73).  In the absence of nuclear receptor agonists, complexes 1 and 2 were 
the predominant complexes that bound to the ACCα LXRE/T3RE.  Further, we have 
shown that T0-901317 has opposing effects on the binding of LXR•RXR and TR•RXR 
complexes to the ACCα-LXRE/T3RE Chapter 2, Figure 6.  These findings have led us 
to hypothesize that changes in the binding of nuclear receptor complexes to the ACCα-
T3RE/LXRE may play a role in mediating the inhibition of ACCα transcription by 
CDCA.  Gel mobility shift assays were performed using nuclear extracts from chick 
embryo hepatocytes treated with or without CDCA in the presence of T0-901317.  As 
reported previously, a DNA probe containing the ACCα-LXRE/T3RE bound to complex 
1, complex 2, and complex 4 in nuclear extracts from hepatocytes incubated in the 
presence of nuclear receptor agonists.   
 CDCA had no effect on the binding of Complex 1 to the ACCα-LXRE upto 12 h, 
but caused a slight decrease in Complex 1 binding at 24 h Figure 3.7.  CDCA inhibited 
the binding of Complex 2 to ACCα-LXRE at 6 h and further inhibited the binding at 12 
and 24 h.  As discussed previously, Complex 4 is composed of TR•RXR heterodimers, 
that bind to ACCα-LXRE in the presence of thyroid hormone.  We have previously 
shown that T0-901317 increased the binding of Complex 4 to the promoter, in the 
absence of T3 and presence of T0-901317 Chapter 2, Figure 6.  CDCA inhibits the 
binding of Complex 4 to the ACCα-LXRE significantly at 2 hours, and further inhibits 
the binding over time.  The inhibition of Complex 4 by CDCA is more dramatic than 
CDCA inhibition of Complex 2.  The inhibition of TR•RXR heterodimer binding to the 
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ACCα-LXRE could be due to the fact that CDCA inhibits TRα mRNA abundance over 
time Figure 3.8D.    
 The latter phenomenon would suppress the inhibitory effects of T0-901317 on 
ACCα transcription because unliganded TR•RXR functions as a repressor of gene 
transcription (73).  It is possible that CDCA-mediated changes in the binding of nuclear 
receptor complexes to the ACCα LXRE/T3RE constitutes a mechanism to prevent further 
inhibition of ACCα transcription by the LXR signaling pathway.  The mechanism by 
which CDCA alters the binding of nuclear receptor complexes to the ACCα LXRE/T3RE 
is presently unclear but does not involve changes in the expression of LXRα mRNA 
Figure 3.8E. 
 
CDCA modulates expression of several genes that may mediate inhibition of CDCA on 
ACCα mRNA expression 
Short heterodimeric partner (SHP) is an unusual nuclear hormone receptor that 
lacks a DNA binding domain.  SHP functions by dimerizing with other nuclear hormone 
receptors, such as TR and LXR, and represses their ability to activate transcription.  In 
rodents, bile acids stimulate SHP expression via activation of the LXR signaling 
pathway.  Bile acid induction of SHP expression has been shown to play a role in 
mediating the inhibitory effects of bile acids on cholesterol 7α hydroxylase transcription, 
the rate limiting gene for synthesis of bile from cholesterol (19, 40).  Human SHP 
promoter has been shown to be activated by SREBP-1.  Overexpression of SREBP-1 
activated the human but not mouse SHP promoter (31).  Thus SREBP-1 may mediate the 
species-specific regulation of cholesterol and bile acid homeostasis via modulating SHP 
gene expression. 
To assess the role of SHP in mediating the inhibitory effects of bile acids on T0-
901317 induced lipogenic gene expression, we performed time course experiments with 
CDCA treatment to determine whether CDCA stimulated SHP expression in chick 
hepatocytes in presence of T0-901317.  Surprisingly, CDCA inhibits the SHP mRNA 
abundance in the presence of T0-901317 as early as 2 h and further inhibited over time 
Figure 3.8A.  This result suggests that SHP does not play a role in mediating the 
inhibitory effects of bile acids on lipogenic gene expression in chick hepatocytes.   
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PGC-1α has been shown to be a coactivator for LXRα.  In transient transfection 
studies, PGC-1α potentiates the LXR-mediated autoregulation and transactivation of the 
LXRα promoter via the LXRE on the cholesteryl ester transfer-protein (CETP) gene 
promoter in a ligand-dependent manner.  Further, mutational analyses showed that the 
LXXLL motif of PGC-1α is essential for coactivation of LXR-mediated transcription 
(46).  We wanted to determine if CDCA inhibits LXR activity by inhibiting PGC-1α 
mRNA.  CDCA inhibits PGC-1α mRNA abundance maximally at 2 h by 50% Figure 
3.8B.   
Recently, PGC-1β has been shown to be a coactivator of SREBP-1 and LXR.  
This increase in SREBP-1 and LXR activity increases de novo lipogenesis and 
lipoprotein secretion.  PGC-1β coactivation of SREBP and LXR by high fat leads to 
hypertriglyceridemia and hypercholesterolemia (39).  We wanted to determine if CDCA 
inhibition of ACCα mRNA is mediated by a decrease in PGC-1β levels.  Our data shows 
that there is a transient decrease in PGC-1β mRNA at 2 h by 25% Figure 3.8C.  
However, CDCA has no effect on PGC-1β mRNA at later time points.  It is unclear 
whether this decrease of PGC-1β at 2 hours results in ACCα inhibition.   
We have shown that CDCA inhibits the binding of unliganded TR•RXR on the 
ACCα-LXRE.  We wanted to determine whether this decrease in the binding of the 
complex is due to changes in TR mRNA levels.  Our results showed that CDCA inhibits 
TR mRNA maximally at 2 h Figure 3.8D.  This may explain the decreased binding of the 
TR•RXR on the ACCα-LXRE.  We have also shown that CDCA inhibits the binding of 
LXR•RXR heterodimers on the ACCα-LXRE.  This decrease in binding could be either 
due to the inhibition of LXR mRNA abundance or the inhibition of LXR•RXR binding to 
the ACCα-LXRE.  Our results showed that CDCA had little or no effect on the 
abundance of LXRα RNA in presence of T0-901317 Figure 3.8E. 
Recent work has shown that bile acids stimulate fibroblast growth factor-19 
(FGF-19) expression in human hepatocytes via a FXR-mediated mechanism.  FGF-19 is 
a member of the fibroblast growth factor (FGF) family of secreted signaling molecules.  
FGF-19’s action is initiated by binding to the membrane-bound, tyrosine kinase receptor, 
FGFR4.  Studies with transgenic mice have shown that overexpression of FGF-19 
enhances basal energy metabolism and reduces adipose stores.  Expression of malic 
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enzyme (ME) and stearoyl CoA desaturase (SCD) are reduced in FGF-19 transgenic 
mice.  (22, 23, 59, 64, 71).   
Based on this information, we hypothesized that bile acids stimulate FGF-19 
expression and that increased FGF-19 levels inhibit lipogenic gene expression.  
Consistent with results reported for human hepatocytes, CDCA caused a transient 
increase of FGF-19 mRNA abundance in chick hepatocytes in presence of T0-901317 by 
750% at 2 h Figure 3.8F.  CDCA increased expression of FGF-19 mRNA by 450% at 6h 
and 12 h.  FGF-19 mRNA levels were further increased to 600% by CDCA at 24 h.   
 
CDCA increases the phosphorylation and activation of the mitogen activated protein 
kinase (MAP Kinase) pathways 
 Bile acids have been shown to increase phosphorylation and activation of MAP 
kinase pathways in several cell types (44).  Recently, two reports showed an involvement 
of ERK and p38 MAP kinase pathways as inhibitors of lipogenic gene expression (7, 56).  
We hypothesized that CDCA inhibits ACCα mRNA by activating MAP kinase pathways.  
Primary chick hepatocytes were treated with T0-901317 in the absence and presence of 
CDCA, for the time points indicated in the figure.  Total protein was isolated and western 
blot analysis was performed to determine the levels of phosphorylated, active ERK, JNK 
and p38 MAPK Figure 3.9.  CDCA increased the phosphorylation of ERK, JNK and p38 
MAP kinases at 5 min and this increase in phosphorylation was sustained upto 24 h.  
CDCA also increased the phosphorylation and activation of MEK1/2, a MAPK kinase 
(MAPKK), responsible for phosphorylation and activation of ERK.  This increase in 
phosphorylation and activation of MEK1/2 is correlated with the activity of ERK.  CDCA 
also increases phosphorylation and activation of MKK3/6, another MAPKK, that is 
responsible for phosphorylation and activation of p38 MAPK.  Again, this activation of 
MKK3/6 is correlated with the activity of p38 MAPK.  We also measured the 
phosphorylation of Raf and found that CDCA has no effect on phosphorylation of the 
protein.  This shows that the effects of CDCA on phosphorylation of MAP kinases are 
selective.   
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ERK and p38 MAPK mediate the inhibitory effects of CDCA on ACCα mRNA 
abundance 
 In Figure 3.9 we have shown that CDCA increases the phosphorylation and 
activation of ERK, JNK and p38 MAPK.  To determine whether one or all of these 
MAPKs mediate CDCA inhibition of ACCα mRNA, we used inhibitors of MAPK 
activity, such as U0126 for ERK, SP600125 for JNK and SB203580 for p38 MAPK.  
Primary chick hepatocytes were treated with T0-901317 in the absence and presence of 
CDCA.  Medium was changed after 12 hours with the addition of insulin and T0-901317 
in all plates and CDCA in the indicated plates.  12 hours later, cells were treated with 
either the inhibitors or DMSO as control.  6 hours after addition of inhibitors and DMSO, 
total RNA was isolated and ACCα mRNA was measured using real time RT-PCR.  In 
vehicle treated cells, CDCA inhibited the ACCα mRNA expression by about 60% Figure 
3.10.  However, in presence of the ERK inhibitor, U0126, the inhibition of ACCα mRNA 
by CDCA was significantly decreased to about 27% Figure 3.10A.  As U0126 inhibits 
MEK1/2 activity, it inhibits phosphorylation and activation of ERK.  Western blot 
analyses with proteins isolated from identically treated plates showed that U0126 
completely inhibits the phosphorylation and activation of ERK Figure 3.10C.   
 In presence of the p38 MAPK inhibitor SB203580, CDCA inhibition of ACCα 
mRNA was almost completely abolished Figure 3.10B.  We also observed similar effects 
with another p38 MAPK inhibitor, SB202190 (data not shown).  Our studies with the 
JNK inhibitor SP600125 remain inconclusive.  At the least, our data would suggest that 
JNK mediates the activation of ACCα mRNA abundance by T0-901317.  In presence of 
T0-901317, SP600125 completely abolishes the increase in ACCα mRNA abundance by 
T0-901317.  More about the role of JNK in ACCα expression will be discussed in 
Chapter 4, Figure 4.10. 
 
CDCA increases FGF-19 mRNA abundance via both ERK and p38 MAPK and inhibits 
PGC-1α mRNA via p38 MAPK, but not ERK 
 Our data upto this point shows that CDCA increases FGF-19 mRNA abundance 
and increases the phosphorylation and activation of ERK and p38 MAPK.  To determine 
whether the increase in FGF-19 is mediated by the MAP kinases, we measured mRNA 
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abundance of FGF-19 in the absence and presence of CDCA in presence of vehicle, 
U0126 and SB203580.  In vehicle treated cells, CDCA increases FGF-19 by about 640% 
Figure 3.11.  This data is consistent with our previous results showing that CDCA 
increases FGF-19 over time.  In presence of the ERK inhibitor U0126, the increase of 
FGF-19 mRNA by CDCA was completely abolished Figure 3.11A.  Similarly, in 
presence of p38 MAPK inhibitor SB203580, the increase in FGF-19 mRNA by CDCA 
was completely abolished Figure 3.12B.  These results show that CDCA increases FGF-
19 mRNA via ERK and p38 MAPK.   
 Next, we wanted to determine whether the inhibition of PGC-1α mRNA by 
CDCA is mediated by ERK and/or p38 MAPK.  Chick hepatocytes were plated in the 
absence and presence of CDCA in the presence of vehicle, U0126 and SB203580.  Total 
RNA was isolated and real time RT-PCR was performed to measure relative mRNA 
abundance.  In vehicle treated cells, CDCA inhibited PGC-1α mRNA by 60%, in 
agreement with our previous data Figure 3.12.  U0126 had no effect on CDCA inhibition 
of PGC-1α mRNA Figure 3.12A.  However, SB203580 completely abolished CDCA 
inhibition of PGC-1α expression Figure 3.12B.  These results show that CDCA 
inhibition of PGC-1α is mediated by p38 MAPK, but not ERK.   
 
Hepatocytes infected with adenovirus vectors expressing PGC-1α does not reverse 
CDCA inhibition of ACCα mRNA 
 As discussed previously, PGC-1α is a coactivator of LXR.  Our data show that 
CDCA inhibits PGC-1α mRNA in chick hepatocytes, and that p38 MAPK but not ERK 
mediates this effect.  To establish a role of PGC-1α in mediating inhibition of ACCα 
mRNA by CDCA we infected hepatocytes with adenovirus containing PGC-1α in frame 
with GFP.  Cells were also infected with adenovirus containing GFP and no DNA (null), 
and no virus as controls.  Hepatocytes were treated with equal amounts (2.2 x 1012) of 
null, GFP and PGC-1α virus particles.  The fluorescence of cells treated with GFP and 
PGC-1α was determined to ensure infectivity.  After 24 hours, 90-100% of cells treated 
with both GFP and PGC-1α expressed green fluorescence (data not shown).  CDCA 
inhibits ACCα mRNA in uninfected cells and cells infected with adenovirus containing 
null, GFP and PGC-1α Figure 3.13.  Cells treated with adenovirus containing PGC-1α 
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had a 10-fold increase in PGC-1α protein levels over control cells (data not shown).  One 
interpretation of these findings maybe that PGC-1α does not mediate CDCA inhibition of 
ACCα mRNA in chick hepatocytes.  However, as we cannot measure endogenous PGC-
1α protein for lack of a suitable antibody, our results are inconclusive.  Adenovirus was 
prepared by Callee M. Walsh in Dr. Salati’s lab. 
 
Inhibition of p38 MAPK activity, but not ERK activity attenuates the effects of CDCA 
on mature SREBP-1 
Previous reports have shown that phosphorylation of Thr426 and Ser430 of 
SREBP-1a by Gsk3β facilitates binding of the ubiquitin ligase, SCFFbw7, which targets 
SREBP for 26S proteasomal degradation.  Inhibition of Gsk3β activity by LiCl or insulin 
increases the accumulation of SREBP (55), (32).  Another report showed that n-3 
polyunsaturated fatty acids (PUFAs) decrease the mature, active form of SREBP-1 in 
primary rat hepatocytes through 26S proteasome and Erk-dependent pathways.  Specific 
inhibitors of these pathways attenuate the inhibitory effect of PUFA on mature SREBP-1 
levels (7).  The mechanisms by which Erk phosphorylation, and 26S proteasomal mediate 
degradation of mature SREBP-1 are yet to be identified. 
Based on these reports, we wanted to determine whether CDCA inhibition of 
mature SREBP is mediated by ERK and/or p38 MAPK.  We plated hepatocytes in the 
absence and presence of CDCA in presence of either vehicle, U0126 or SB203580.  As 
shown previously, CDCA inhibits mature SREBP by 60% in vehicle treated cells Figure 
3.14.  In presence of U0126, CDCA inhibition of mature SREBP was not affected as 
compared to vehicle treated controls.  However, inhibition of p38 MAPK activity by 
SB203580 significantly attenuated CDCA inhibition of mature SREBP-1 by about 35%.  
We propose that CDCA mediates inhibition of ACCα mRNA by increasing p38 MAPK 
pathway, which in turn, phosphorylates SREBP-1 and targets it for degradation.   
 
Effects of CDCA on ACCα mRNA abundance, ERK and p38 MAPK activity are 
selective 
  CDCA increases low density lipoprotein receptor (LDLr) gene expression via 
ERK activation-mediated stabilization of LDLr mRNA via activating SHP (44).  These 
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authors reported that ursodeoxycholic acid (UDCA) had no effect on LDLr and SHP 
mRNA.  These results suggested that the structural difference between CDCA and 
UDCA, specifically the 7β-hydroxy epimer of CDCA, is critical for the activation of 
ERK and binding to FXR (41, 48).  The lack of inhibitory effect of UDCA on LDLr can 
be accounted for the fact that UDCA does not activate ERK (8).  Octyl β-D-
glucopyranoside, a detergent also had no effect on ERK activity (43).  These results 
suggest that bile acids activate MAP kinases in a specific manner, not by their detergent 
effects, but by specific side chain residues and three-dimensional structure.   
 We wanted to determine whether other bile acids besides CDCA, demonstrated 
similar effects on ACCα mRNA, ERK and p38 MAPK.  We tested cholic acid (CA), 
deoxycholic acid (DCA), ursodeoxycholic acid (UDCA), taurocholic acid (TCA), 
hyodeoxycholic acid (HDCA), and taurodeoxycholic acid (TDCA) for their ability to 
modulate ACCα mRNA abundance, ERK and p38 MAPK activity.  Chick hepatocytes 
were plated in presence of T0-901317 in absence and presence of the indicated bile acids.  
6 hours after incubation with bile acids, total RNA and protein was isolated.  Real time 
RT-PCR analysis showed that CDCA inhibits ACCα mRNA about 50%, and all other 
bile acids tested had no effect Figure 15.  Western blot analysis showed that only CDCA 
robustly activates ERK and p38 MAPK.  There may be a slight effect of CA and DCA on 
p38 MAPK activity.  These results showed that the effects of CDCA are highly selective.   
 
CDCA is the most potent modulator of gene expression 
 As discussed in Chapter 1, relative hydrophobicity is a major determinant of bile 
acid action.  CDCA is one of the most hydrophobic bile acids.  We wanted to determine 
whether effects of CDCA on gene expression are specific and also wanted to determine 
the effects of other bile acids on gene expression.  We performed Northern blot and real 
time RT-PCR analysis to determine mRNA abundance of FAS, SCD, FGF-19, ABCA1, 
PGC-1α and PGC-1β Figure 3.16.  We have shown that CDCA inhibits FAS, SCD and 
PGC-1α, increases FGF-19 and ABCA1, and has no effect on PGC-1β mRNA.  Both CA 
and DCA inhibit FAS and SCD mRNA abundance by about 50%.  CDCA inhibits both 
these genes by about 80%.  Other bile acids had no effect on FAS and SCD mRNA 
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abundance.  CDCA causes an 8-fold increase in FGF-19 mRNA.  CA and DCA cause a 
two-fold increase in FGF-19 mRNA. Other bile acids had no effect on FGF-19 mRNA.   
 CDCA causes a two-fold increase in ABCA1 mRNA.  TDCA causes a significant 
(1.5-fold) increase in ABCA1 mRNA, although the extent of increase is not as great as by 
CDCA.  All other bile acids had no effect on ABCA1 mRNA.  CDCA causes a 60% 
decrease in PGC-1α mRNA, but other bile acids had no effect on PGC-1α mRNA.  
CDCA had no effect on PGC-1β mRNA.  Both DCA and UDCA significantly inhibited 
PGC-1β by 30% and 25% respectively.  Other bile acids have no effect on PGC-1β 
mRNA.  The effect of CDCA on all these genes is consistent with results shown in this 
Chapter.   
 
CDCA inhibits the recruitment of acetylated histones H3 and H4 on the ACCα 
promoter 
 The decrease in ACCα transcription by CDCA may be mediated in whole or in 
part by alterations in histone acetylation on the ACCα promoter.  Previous studies have 
shown that the activation of LXR•RXR heterodimers by LXR ligands/agonists recruits  
coactivator complexes containing histone acetyltransferase (HAT) activity (1, 61).  We 
have shown that T0-901317 causes a transient increase in histone acetylation on the 
ACCα promoter Chapter2, Figure 7.  Increased histone acetylation causes a chromatin 
decondensation that enhances the accessibility of the basal transcriptional machinery and 
other transcription factors to the target promoter.  On the other hand, decreased histone 
acetylation causes chromatin condensation that inhibits the recruitment of basal 
transcription machinery and cofactors on the promoter.   
To investigate the role of histone acetylation in mediating the inhibition of ACCα 
transcription by CDCA, chromatin immunoprecipitation (ChIP) were performed in chick 
embryo hepatocytes incubated in the absence or presence of CDCA.  Hepatocytes were 
treated with 1% formaldehyde to cross-link DNA to associated proteins.  Protein-DNA 
complexes were immunoprecipitated with an antibody against acetylated histone H3 or 
acetylated histone H4.  Immunoprecipitated DNA was analyzed by PCR using primers 
that flanked the ACCα LXRE/T3RE.  In hepatocytes incubated in the absence of CDCA, 
acetylation of histone H3 and histone H4 was detected at the ACCα LXRE Figure 3.17.  
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Addition of CDCA to the culture medium caused a significant decrease in the acetylation 
of histone H3 and H4.  We also performed ChIP analysis in an uncharacterized region of 
the SCD1 promoter using a primer set that amplified SCD sequences between -369 and -
193 bp.  In contrast to the data for ACCα, CDCA had no effect on histone acetylation on 
SCD.  
 
 
DISCUSSION 
Data so far demonstrated that the previously identified ACCα-LXRE confers 
CDCA regulation on ACCα promoter 2.  We also demonstrated that SREBP-1 is an 
accessory factor that enhances the ability of LXRE to inhibit ACCα transcription by 
CDCA Figure 3.5.  Our results showed that CDCA decreases the concentration of 
mature, active form of SREBP-1 in chick embryo hepatocytes.  As shown previously, 
CDCA inhibits mature SREBP-1 by inhibiting post-translational modification of SREBP-
1 Figure 3.6.   
 We have shown that p38 MAPK but not ERK mediates inhibitory effects of 
CDCA on ACCα expression by modulating mature SREBP-1 levels.  It is possible that 
activation of p38 MAPK by CDCA results in phosphorylation of SREBP-1 at Thr426 
and/or Ser430 as these residues are conserved in chicken.  Dr. Johan Ericsson has kindly 
provided us with a phospho-Thr426 antibody.  Data from western blot experiments 
performed with this antibody are inconclusive.  We speculate that p38 MAPK 
phosphorylates SREBP-1 at Thr426 and/or Ser430 and targets the protein for 
degradation.   
 Although we have provided evidence that shows LXRE mediates ACCα 
inhibition by CDCA, data from in vitro binding assay showed that CDCA does not 
directly modulate binding activity of LXR•RXR heterodimers on the ACCα-LXRE 
Figure 3.7.  We have shown that CDCA enhances the recruitment of unliganded 
TR•RXR on the LXRE.  This would result in an increase in ACCα expression as previous 
reports have shown that unliganded TR•RXR is an inhibitor of ACCα expression.  
Therefore it is possible that the increase in binding activity of TR•RXR acts to prevent 
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inhibition of ACCα mRNA below basal levels to allow the cells to have a steady supply 
of fatty acids that are an integral part of membranes.    
 Our data shows that CDCA mediates its inhibitory effects on ACCα mRNA 
expression by activation of p38 MAPK.  Using SB203580, a p38 MAPK inhibitor, the 
inhibition of ACCα mRNA by CDCA was completely abolished.  It is interesting to note 
that SB203580 alone causes a 60% increase in ACCα mRNA in the absence of CDCA 
Figure 3.10.  In the absence of CDCA, P-p38 MAPK levels are readily detected, as 
shown in Figure 3.9.  Taken together, these results would suggest that basal levels of P-
p38 MAPK have an inhibitory effect on ACCα mRNA expression.  Upon CDCA 
addition, p38 MAPK is further activated, and this results in ACCα mRNA inhibition as 
shown in Figure 3.10B.  The role of basal P-p38 MAPK as an inhibitor of ACCα mRNA 
is also consistent with the fact that SB203580 alone increases mature SREBP-1 levels 
Figure 3.14, Lane 5.  We have previously shown that an increase in mature SREBP-1 is 
correlated with an activation of ACCα mRNA expression Chapter 2, Figure 5.  As 
discussed in Chapter 1, oxysterols (oxidized derivatives of cholesterol) are endogenous 
ligands/agonists of LXR.  An increase in oxysterols would lead to an increase in 
lipogenic enzyme expression that would lead to the formation of triglycerides.  Thus, p38 
MAPK prevents the over-activation of the lipogenic pathway, thereby preventing the 
accumulation of plasma triglycerides.  
 One interesting finding in our work is the sustained activity of the MAPKs Figure 
3.9.  The sustained activation of ERK and p38 MAPK may be required for the sustained 
inhibition of ACCα mRNA.  Early activation of ERK and p38 MAPK trigger cellular 
processes that inhibit ACCα initially.  Once ACCα mRNA levels are inhibited, other 
processes may be involved to ensure that ACCα mRNA levels are still reduced.  Our 
studies on CDCA inhibition show the involvement of multiple pathways that mediate 
CDCA inhibition of ACCα such as SREBP-1, histone acetylation and possibly FGF-19.  
Activated MAPKs at later time points act to ensure low abundance of ACCα mRNA in 
presence of T0-901317.   
 The mechanisms responsible for the sustained activity of MAPKs are unclear.  
One possibility is that CDCA inhibits the activity of the specific phosphatases that 
inactivate MAPKs.  For example, it has been reported that MAPK phosphatase-3 (MKP-
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3), which is a highly selective phosphatase that inactivates ERK, inhibits insulin-
mediated repression of the PEPCK promoter (11).  However, this study also showed that 
the effect of MKP-3 is not due to dephosphorylation and inactivation of ERK.  It is 
possible that in hepatocytes the activity of other MKPs is inhibited by CDCA.   
 We have also determined that CDCA increases the phosphorylation and activation 
of JNK.  Our data with ERK and p38 MAPK inhibitors showed that both these MAPKs 
mediate inhibitory effects of CDCA on ACCα mRNA.  In contrast, studies with the JNK 
inhibitor SP600125 showed that JNK mediates activation of ACCα mRNA by T0-901317 
(Chapter 4).  The mechanism for such selective activity by the MAPKs is unclear.   
 The role of bile acids in recent times have emerged from that of lipid solubilizers 
to signaling molecules that modulate several important cellular processes.  Recently the 
identification of a cell surface receptor TGR5, a member of the G-protein coupled 
receptor (GPCR) family has further established an endocrine role for bile acids.  In fact 
reports have shown that bile acid treatment increases cAMP levels, that is a classic 
measure of GPCR activity (30).  Another report has shown that bile acids promote energy 
expenditure by increasing cAMP.  GPCRs have been shown to activate MAPKs (42).  It 
is therefore tempting to speculate that bile acids bind to a cell surface receptor on 
hepatocytes that belong to the GPCR family.  The activated GPCR increases cAMP 
levels that would in turn activate MAPKs, which in turn would lead to an inhibition of 
lipogenic genes.  This theory although attractive, is probably not the mechanism for 
ACCα inhibition by CDCA in chick hepatocytes.  First, cAMP does not inhibit T0-
901317-induced ACCα mRNA expression in chick hepatocytes (Data not shown).  
Second, cAMP does not activate any MAPK pathways in chick hepatocytes (Data not 
shown).  Taken together, these reports suggest that in hepatocytes, bile acids inhibit 
lipogenic enzyme expression by a mechanism not involving cAMP.   
 Finally, this report shows that CDCA inhibits T0-901317-induced expression of 
lipogenic genes by increasing MAPKs such as p38 MAPK.  CDCA mediates inhibition of 
ACCα by modulating mature SREBP-1.  Identification of the signaling pathways 
mediating CDCA inhibition of lipogenic genes may lead to identification of compounds 
that would combat atherosclerosis.   
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FIGURE LEGENDS 
 
Figure 3.1:  Hexanoate inhibits the stimulatory effect of T0-901317 on acetyl CoA 
carboxylase α (ACCα), fatty acid synthase (FAS), stearoyl CoA desaturase (SCD) and 
ATP-binding cassette protein A1 (ABCA1) mRNA, but not sterol regulatory element 
binding protein-1 (SREBP-1) and liver X receptor α (LXRα) mRNA expression, in a dose 
dependent manner.  Chicken embryo hepatocytes were plated in the absence of hormones 
overnight.  Medium was changed and the cells were treated with indicated amounts of 
hexanoate, T0-901317 (6 µM), and insulin (50 nM) for 24 hours.  Total RNA was 
isolated and Northern blot analysis was performed to determine the mRNA levels of the 
genes.  Data shown are representative of two experiments for SREBP-1 and LXRα, and 
three experiments for ACCα and ABCA1.   
 
 
Figure 3.2:  Chenodeoxycholic acid (CDCA) inhibits the T0-901317 induced expression 
of ACCα, FAS, SCD and HMG-CoA reductase mRNA, but increases the T0-901317 
induced expression of ABCA1 mRNA in a dose dependent manner.  Chicken embryo 
hepatocytes were plated in the absence of hormones overnight.  Medium was changed 
and the cells were treated with the indicated amounts of CDCA, insulin (50 nM) and T0-
901317 (6 µM) for 24 hours.  Total RNA was isolated and Northern blot analysis was 
performed to determine mRNA levels. HMG-CoA reductase mRNA was detected using 
real time RT-PCR as described in Methods.  Data represents mean ± SE of at least four 
experiments.  The values for mRNA abundance for the treatments have been calculated 
with respect to the insulin treatment (Lane 1), the value of which was set to 1.  
 
 
Figure 3.3:  CDCA inhibits total ACC protein and triglyceride secretion in medium.  A) 
Chick hepatocytes were plated in the absence of hormones overnight.  Medium was 
changed and insulin and T0-901317 were added to all plates.  24 hours later, medium was 
changed again with the addition of insulin and T0-901317 to all plates and CDCA (75 
µM) was added in the indicated plates.  Total protein was isolated from plates at the 
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indicated time points and western blot analysis was performed to determine total ACC.  
B) For triglyceride measurements, cells were plated in the absence of hormones 
overnight.  Medium was changed with the addition of insulin (50 nM) and T0-901317 (6 
µM) to all plates in the absence and presence of CDCA (75 µM).  Medium from the 
plates were collected 24 hours later, and triglyceride assay was performed according to 
manufacturer’s protocol (Sigma).  Data shown are mean ± SE of three experiments.   
 
 
Figure 3.4:  Chenodeoxycholic acid (CDCA) inhibits the T3-induced expression of 
ACCα, FAS, SCD and ME mRNA, but increases the expression of ABCA1 mRNA in a 
dose dependent manner.  Chicken embryo hepatocytes were plated in the absence of 
hormones overnight.  Medium was changed and the cells were treated with the indicated 
amounts of CDCA, insulin (50 nM) and T3 (1.5 µM) for 24 hours.  Total RNA was 
isolated and Northern blot analysis was performed to determine mRNA levels. Data 
represents mean ± standard deviation of two experiments.  The values for mRNA 
abundance for the treatments have been calculated with respect to the insulin treatment 
(Lane 1), the value of which was set to 1.  
 
 
Figure 3.5:  A) Effects of deletions of the 5'-flanking region of ACCα promoter 2 on 
transcriptional activity in the absence and presence of CDCA.  CEHs were transiently 
transfected with p[ACC-2054/+274] chloramphenicol acetyltransferase (CAT) or 
equimolar amounts of other plasmids as described under Experimental Procedures.  After 
transfection, cells were treated with T0-901317 and insulin in the absence or presence of 
CDCA for 48 h.  Protein extracts prepared as described in Materials and methods, and 
CAT assays performed.  Left: The constructs used in these experiments. The number at 
the left of each construct is the 5'-end of ACCα DNA in nucleotides relative to the 
transcription initiation site of promoter 2.  The 3'-end of each construct was +274 bp.  
The location of the LXR response element (LXRE) is between -101 to -86 bp and SRE-1 
is between -80 to -71 bp is indicated by the vertical lines.  Right: CAT activity of cells 
transfected with p[ACC-108/+274]SRE(mut2)CAT and treated with T0-901317 and 
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insulin was set at 1, and the other activities were adjusted proportionately. The percent 
inhibition by CDCA is the CAT activity of cells treated with T0-901317, insulin, and 
CDCA expressed as a percentage of that in cells treated with T0-901317 and insulin and 
subtracted from 100.  The results are the means ± SEM of at least four experiments.  
Significant differences between means within the column (P < 0.05) are as follows: a 
indicates that p[ACC-108/+274]SRE(mut 2)CAT is different from all other constructs.  b 
indicates that p[ACC-82/+274]CAT is significantly different from all other constructs.   
 
B) Fragments of the ACCα gene containing the LXRE and/or SRE-1 were linked to the 
minimal thymidine kinase (TK) promoter in TKCAT.  CEHs were transiently transfected 
with these constructs and treated with T0-901317 and insulin in the absence or presence 
of CDCA as described in Part A (above) and under Experimental Procedures.  Left: 
Constructs used in these experiments.  Numbers indicate the 5' and 3' boundaries of 
ACCα DNA relative to the transcription initiation site of promoter 2.  Right: CAT 
activity in CEH transfected with p[ACC-TKCAT and treated with T0-901317 and insulin 
was set at 1, and the other activities were adjusted proportionately.  The percent 
inhibition by CDCA on ACCα promoter activity was calculated as described in the 
legend to Part A.  The results are the means ± SEM of at least five experiments.  
Significant differences between means within the column (p < 0.05) are as follows: a, 
versus any other construct. 
 
 
Figure 3.6:  CDCA inhibits ACCα mRNA by inhibiting mature SREBP-1 via a post-
translational mechanism.  CEHs were plated in the absence of hormones overnight.  
Medium was changed with the addition of insulin (50 nM) and T0-901317 (6µM) in all 
plates.  24 hours later, medium was changed again, with the addition of CDCA (75 uM) 
in the indicated plates.  Total RNA, nuclear and membrane protein extracts were prepared 
at the indicated time points.  ACCα, SREBP-1, INSIG-1 and INSIG-2 mRNA abundance 
was measured using Northern blot analysis.  Mature and precursor SREBP-1 was 
determined using Western blot analysis.  The signals from blots were quantified using 
ImageQuaNT software.  The value of insulin and T0-901317 treated sample at time 0, 
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was set at 1.  Data represents mean ± SE for at least three experiments.  * indicates 
significant values at p<0.05. 
 
 
Figure 3.7:  Effect of CDCA on the binding of hepatic nuclear proteins to the ACCα 
LXRE.  A) Eighteen hours after being placed in culture, CEHs were incubated in 
Waymouth's medium containing insulin (50 nM), and T0-901317 (6 µM), with or without 
CDCA 75 µM for the indicated times.  Cells were harvested and nuclear extracts were 
prepared as described in Experimental Procedures.  Nuclear extracts were subjected to 
gel mobility shift analyses using an oligonucleotide probe containing the ACCα LXRE (-
108 to -82 bp).  Specific protein-DNA complexes are indicated by arrows.  Previous 
studies have shown that complexes 1 and 2 contain liver X receptor (LXR)•retinoid X 
receptor (RXR) heterodimers, whereas complex 4 contains nuclear T3 receptor 
(TR)•RXR heterodimers.  These data are representative of five experiments employing 
independent preparations of nuclear extract.  B)  Signal from the complexes was 
quantified using ImageQuaNT software.  The value for the samples treated with insulin 
and T0-901317 at 0 h was set to 1.  Data represents mean ± SE of four experiments.   
 
 
Figure 3.8:  CDCA modulates the mRNA abundance of short heterodimeric partner 
(SHP), PPAR-gamma coactivator -1α (PGC-1α), PPAR-gamma coactivator -1β (PGC-
1β), thyroid receptor (TR), liver X receptor (LXR) and fibroblast growth factor-19 (FGF-
19).  CEHs were plated in the absence of hormones overnight.  Medium was changed 
with the addition of insulin and T0-901317 in all plates.  24 hours later, medium was 
changed again, with the addition of insulin (50 nM), T0-901317 (6 µM) and CDCA (75 
µM) as indicated.  Total RNA was harvested from the plates at the indicated time points 
and relative mRNA abundance was measured using realtime RT-PCR.  The value for 
insulin and T0-901317 treated sample at time 0 was set at 1.  Data represents mean ± SE 
of at least three experiments.   
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Figure 3.9:  CDCA phosphorylates and activates mitogen-activated protein kinase 
(MAPK) pathways.  CEHs were plated in the absence of hormones overnight.  Medium 
was changed with the addition of insulin (50 nM) and T0-901317 (6 µM) in all plates.  24 
hours later, medium as changed again, with the addition of insulin and T0-901317 in all 
plates and CDCA (75 µM) in the indicated plates.  Total protein was harvested from the 
plates at the indicated time points.  Western blot analysis was performed to determine 
MAPK levels using antibodies as described in Methods.  Phosphorylation of Raf at all the 
corresponding time points serves as a negative control.  Data are representative of at least 
three experiments.   
 
 
Figure 3.10:  CDCA mediates inhibitory effects on ACCα mRNA abundance via ERK 
and p38 MAPK pathways.  CEHs were plated in the absence of hormones overnight.  
Medium was changed with the addition of insulin and T0-901317 in all plates.  12 hours 
later, medium was changed again with the addition of insulin and T0-901317.  12 hours 
later, ERK inhibitor U0126 (20 µM) A), and p38 MAPK inhibitor SB203580 (20 µM) 
B), was added to the indicated plates.  Control cells were treated with equal volume of 
DMSO.  DMSO by itself has no effect on ACCα mRNA levels (data not shown).  1 hour 
after the addition of inhibitors, CDCA was added to the indicated plates.  Total RNA was 
isolated 6 hours after the addition of CDCA and relative mRNA was determined using 
real time RT-PCR.  The column indicates percent inhibition by CDCA for vehicle 
treated, U0126 treated A), and SB203580 treated B), plates.  The percent inhibition by 
CDCA relative mRNA abundance of cells treated with T0-901317, insulin, and CDCA 
expressed as a percentage of that in cells treated with T0-901317 and insulin and 
subtracted from 100.  * represents that the data is significant at p<0.05.  Data represents 
mean ± SE of five experiments.   
 
 
Figure 3.11:  CDCA mediates stimulatory effects on ACCα mRNA abundance via ERK 
and p38 MAPK pathways.  CEHs were plated in the absence of hormones overnight.  
Medium was changed with the addition of insulin (50 nM) and T0-901317 (6 µM) in all 
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plates.  12 hours later, medium was changed again with the addition of insulin and T0-
901317.  12 hours later, ERK inhibitor U0126 (20 µM) A), and p38 MAPK inhibitor 
SB203580 (20 µM) B), was added to the indicated plates.  Control cells were treated with 
equal volume of DMSO.  DMSO by itself has no effect on FGF-19 mRNA levels (data 
not shown).  1 hour after the addition of inhibitors, CDCA was added to the indicated 
plates.  Total RNA was isolated 6 hours after the addition of CDCA and relative mRNA 
was determined using real time RT-PCR.  The column indicates percent activation by 
CDCA for vehicle treated, U0126 treated A), and SB203580 treated B), plates.  The 
percent activation by CDCA relative mRNA abundance of cells treated with T0-901317, 
insulin, and CDCA expressed as a percentage of that in cells treated with T0-901317 and 
insulin.  * represents that the data is significant at p<0.05.  Data represents mean ± SE of 
four experiments.   
 
 
Figure 3.12:  CDCA mediates inhibitory effects on PGC-1α mRNA abundance via p38 
MAPK, but not ERK pathway.  CEHs were plated in the absence of hormones overnight.  
Medium was changed with the addition of insulin and T0-901317 in all plates.  12 hours 
later, medium was changed again with the addition of insulin and T0-901317.  12 hours 
later, ERK inhibitor U0126 (20 µM) A), and p38 MAPK inhibitor SB203580 (20 µM) 
B), was added to the indicated plates.  Control cells were treated with equal volume of 
DMSO.  DMSO by itself has no effect on PGC-1α mRNA levels (data not shown).  1 
hour after the addition of inhibitors, CDCA was added to the indicated plates.  Total 
RNA was isolated 6 hours after the addition of CDCA and relative mRNA was 
determined using real time RT-PCR.  The column indicates percent inhibition by CDCA 
for vehicle treated, U0126 treated A), and SB203580 treated B), plates.  The percent 
inhibition by CDCA relative mRNA abundance of cells treated with T0-901317, insulin, 
and CDCA expressed as a percentage of that in cells treated with T0-901317 and insulin 
and subtracted from 100.  * represents data is significant at p<0.05.  Data represents mean 
± SE of five experiments.   
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Figure 3.13:  Chick hepatocytes infected with adenovirus overexpressing PGC-1α does 
not reverse the inhibitory effects of CDCA on ACCα mRNA expression.  CEH were 
plated in the absence of hormones.  Four hours later, medium was changed with the 
addition of insulin (50 nM) and T0-901317 (6 µM) and infected with adenovirus 
containing the indicated proteins.  Cells were treated with approximately 2.2 x 1012 virus 
particles of null, GFP and PGC-1α per plate.  Hepatocytes that were uninfected by virus 
and treated in parallel served as controls.  24 hours after addition of the adenovirus, 
medium was changed again with addition of insulin and T0-901317 in all plates and 
CDCA in the indicated plates.  24 hours later, total RNA was harvested from the cells and 
real time RT-PCR was performed to determine relative ACCα mRNA levels.  Data is 
representative of three experiments.   
 
 
Figure 3.14:  CDCA inhibits mature SREBP-1 via p38 MAPK, but not ERK.  CEHs 
were plated in the absence of hormones overnight.  Medium was changed with the 
addition of insulin and T0-901317 in all plates.  12 hours later, medium was changed 
again with the addition of insulin and T0-901317 in all plates.  12 hours later, DMSO 
(vehicle), U0126 and SB203580 were added in the indicated plates.  One hour after the 
addition of inhibitors, CDCA was added to the indicated plates.  6 hours later, nuclear 
extracts were prepared and western blot analysis was performed to determine mature 
SREBP-1 levels.  The signals for SREBP-1 were quantified by ImageQuaNT.  The values 
for CDCA, insulin and T0-901317 treated cells were expressed as a percent of cells 
treated with T0-901317 and insulin.  * represents significance at p<0.05.  Data represents 
mean ± SE of five experiments.    
 
 
Figure 3.15:  CEHs were plated in the absence of hormones.  Eighteen hours later, 
medium was changed with the addition of insulin and T0-901317 to all plates.  12 hours 
later, medium was changed again, with the addition of insulin and T0-901317 in all 
plates.  12 hours later, cells were treated with CDCA, cholic acid (CA), deoxycholic acid 
(DCA), ursodeoxycholic acid (UDCA), taurocholic acid (TCA), hyodeoxycholic acid 
   134
(HDCA) and taurodeoxycholic acid (TDCA).  The concentration of all bile acids in the 
medium was 75 µM.  6 hours after addition of bile acids, total RNA and total protein was 
harvested from cells.  ACCα mRNA abundance was determined using real time RT-PCR 
analysis.  ERK and p38 MAPK were determined by western blot analysis using 
antibodies as described.  Data are representative of three experiments.   
 
 
Figure 3.16:  CEHs were plated in the absence of hormones.  Eighteen hours later, 
medium was changed with the addition of insulin and T0-901317 to all plates.  12 hours 
later, medium was changed again, with the addition of insulin and T0-901317 in all 
plates.  12 hours later, cells were treated with CDCA, cholic acid (CA), deoxycholic acid 
(DCA), ursodeoxycholic acid (UDCA), taurocholic acid (TCA), hyodeoxycholic acid 
(HDCA) and taurodeoxycholic acid (TDCA).  The concentration of all bile acids in the 
medium was 75 µM.  6 hours after addition of bile acids, total RNA and total protein was 
harvested from cells.  FAS, SCD, FGF-19 and ABCA1 mRNA was determined by 
Northern blot analysis, and PGC-1α and -1β mRNA was determined by real time RT-
PCR analysis.  The value of the sample treated with insulin and T0-901317 was set to 1.  
Data represents mean ± STDEV for FAS, SCD, FGF-19 and ABCA1 mRNA and mean ± 
SE of three experiments for PGC-1α and -1β. 
 
 
Figure 3.17:  CDCA inhibits recruitment of acetylated histones on the ACCα promoter.  
Chick hepatocytes were plated in presence of insulin (50 nM) and T0-901317 (6 µM) n 
the absence and presence of CDCA (75 µM).  The association of acetylated histones H3 
and H4 with ACCα and SCD gene was measured by chromatin immunoprecipitation 
assay as described in Methods.  Immunoprecipitates were analyzed by PCR using primers 
described in Methods and indicated in the figure.  Chromatin samples that were processed 
identically in the absence of primary antibody served as controls.  Data are representative 
of three independent experiments.   
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Chapter 4 
Appendix 
RESULTS 
CDCA activates PKC, but synthetic activators of PKC do not mimic the effects of 
CDCA in chick embryo hepatocytes 
  Previous reports have shown that bile acids induce the expression of 
inflammatory cytokines such as tumor necrosis factor-α (TNFα) and interleukin (IL-1β).  
These cytokines are recognized by high affinity receptors on hepatic parenchymal cells, 
that activate protein kinase-C (PKC) (13).  Activation of PKC has been shown to increase 
Mg2+ accumulation in hepatocytes via ERK and p38 MAPK (18).  We wanted to 
determine whether bile acids activate PKC in chick hepatocytes, and whether activation 
of PKC results in ACCα mRNA inhibition via ERK and/or p38 MAPK.  Chick 
hepatocytes were plated and treated with CDCA and inhibitors as described in Chapter 3.  
6 hours after addition of CDCA, total protein was harvested from cells.  Western blot 
analysis showed that CDCA increases phoshorylation and activation of phospho-PKC at 
6 h Figure 4.1.  ERK inhibitor U0126, and p38 MAPK inhibitor SB203580 did not 
reverse the effects of CDCA on PKC activation.  These results suggest that PKC 
activation by CDCA is not mediated by ERK and p38 MAPK and that both these MAPKs 
are probably downstream of PKC.   
 Next, we wanted to determine whether phorbol esters that are very well 
documented activators of PKC (11, 12, 20) were able to mimic the inhibitory effects of 
CDCA on ACCα mRNA expression and activation of ERK and/or p38 MAPK.  Chick 
hepatocytes were treated as described above.  12-O-tetradecanoyl-phorbol-13-acetate 
(TPA) was added to plates as indicated and total RNA and protein was isolated at the 
indicated time points.  ACCα mRNA was detected using real time RT-PCR.  TPA had no 
effect on ACCα mRNA both at 6 h and 12 h.  Moreover, addition of the p38 MAPK 
inhibitor SB203580, also had no effect on ACCα mRNA in the presence of TPA.  To 
determine whether TPA activated PKC and ERK and/or p38 MAPK, we performed 
western blot analysis to determine the levels of phospho-PKC, phospho-ERK and 
phospho-p38 MAPK.  Our results showed that TPA had no effect on the phosphorylation 
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of PKC, ERK and p38 MAPK (Data not shown).  One explanation for this observation is 
that TPA is not active in chick hepatocytes.   
 To further determine the role of PKC in mediating CDCA inhibition of ACCα, we 
incubated chick hepatocytes in presence of insulin and T0-901317, insulin and T0-
901317 and CDCA, and insulin and T0-901317 and CDCA plus the PKC inhibitor GF-
109203X.  The PKC inhibitor did not attenuate or abolish the effects of CDCA on ACCα 
mRNA (Data not shown).  It is possible that GF-109203X is not active in chick 
hepatocytes or that PKC does not mediate CDCA inhibition of ACCα.  At present our 
results are inconclusive.   
 
CDCA increases phosphorylation of AMP-activated protein kinase in presence of 
insulin and T0-901317 
 We have shown in Chapter 3 that CDCA inhibits ACCα mRNA levels by 
inhibiting mature SREBP-1.  We wanted to determine whether CDCA activates other 
agents that inhibit SREBP-1 expression.  Reports in the literature has shown that 
phosphorylated active AMP-activated protein kinase (P-AMPK) inhibits SREBP-1 (22).  
Further, studies have also shown that activators of AMPK such as 5-aminoimidazole-4-
carboxamide 1-beta-ribofuranoside (AICAR), and the alkaloid drug berberine, inhibits 
triglyceride and cholesterol synthesis (1, 6, 16).  LKB1 is upstream kinase of AMPK (8, 
15, 19).  CDCA increased phosphorylation of AMPK at Thr172 at 6 h, 12 h and 24 h 
Figure 4.2.  The activation of AMPK at 6 h was preceded by an increase in 
phosphorylation and activation of the AMPK upstream kinase, LKB1.  CDCA activates 
LKB1 at 2 h and the activation is sustained through 24 h.  CDCA also activated 
phosphorylation of ACC at Ser79.  Phosphorylation of ACC at Ser 79 is a direct measure 
of AMPK activity (1, 3, 6).  As we showed previously in Chapter 3, CDCA inhibited total 
ACC levels.  Phospho ACC/total ACC ratio was greater than 1.5 from 6 h.  CDCA had 
no effect on total AMPK levels.   
 
AICAR has no effect on ACCα mRNA abundance in presence of insulin and T0-
901317 
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Since CDCA increases AMPK activity, we wanted to determine whether known 
activators of AMPK such as AICAR, can mimic inhibitory effects of CDCA on ACCα 
mRNA.  We incubated chick hepatocytes in the presence of insulin, insulin and T0-
901317 for 40 hours.  AICAR was added to the plates after 40 hours.  6 hours after 
addition of AICAR, total RNA was isolated and real time RT-PCR was performed to 
determine ACCα mRNA.  Surprisingly, AICAR had no effect on ACCα mRNA 
abundance in presence of insulin and T0-901317 and insulin Figure 4.3.   
Next, we wanted to determine whether AICAR phosphorylated AMPK, ACC 
protein and p38 MAPK.  Cells were plated and treated with AICAR as described above.  
Total protein was harvested from the cells 6 hours after addition of AICAR.  Western blot 
analysis showed that AICAR had no effect on phosphorylation of AMPK, ACC and p38 
MAPK.  The lack of effect of AICAR on AMPK is surprising as AICAR is a very well 
documented activator of AMPK.  These results suggest that increase in AMPK activity 
by CDCA does not mediate inhibition of ACCα mRNA.   
 
AICAR inhibits T3-induced ACCα mRNA expression by activating AMPK, p38 MAPK 
and inhibiting mature SREBP-1 
Our results showed that CDCA inhibits both T0-901317 and T3 induced 
expression of lipogenic genes in chick hepatocytes.  We also showed that CDCA 
activated P-AMPK in presence of T0-901317.  However, AICAR that is an activator of 
AMPK, had no effect on ACCα expression or AMPK activation in presence of insulin 
and insulin and T0-901317.  We therefore wanted to determine whether AICAR inhibits 
ACCα mRNA in presence of T3 by activating AMPK.  Chick hepatocytes were plated 
and treated as described.  40 hours after stimulation with T3, AICAR was added in the 
indicated concentrations. 6 hours after AICAR addition, total protein and RNA was 
isolated.  Western blot analysis was performed to determine P-AMPK, P-ACC and P-p38 
MAPK, and real time RT-PCR was performed to analyze ACCα mRNA levels.   
Consistent with our earlier findings, AICAR had no effect on P-AMPK, P-ACC, 
P-p38 MAPK and ACCα mRNA in presence of insulin Figure 4.4.  Surprisingly, AICAR 
phosphorylated and activated AMPK and p38 MAPK, and phosphorylated ACC.  AICAR 
also inhibited mature, active SREBP-1 protein.  The increase in p38 MAPK activity and 
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decrease of mature SREBP-1 by AICAR is correlated with an inhibition of ACCα mRNA 
inhibition by AICAR in presence of T3 in a dose dependent manner.  These data provide 
evidence that AMPK mediates the inhibitory effect of CDCA on T3-induced ACCα 
mRNA expression, but not T0-901317-induced ACCα mRNA expression.  The 
implications of AMPK activation and specificity of effects are unclear.   
It has already been established that feeding a high carbohydrate diet causes an 
increase in insulin and T3 that mediate an increase in lipogenic gene transcription in liver 
(4, 5, 10).  Increase in T3 concentration in liver activates the transcription of the genes for 
ACCα (9), fatty acid synthase (17) and malic enzyme (14).  Feeding carbohydrate also 
increases the levels of nuclear T3 receptors (TRs) in liver that may result in the 
stimulation of lipogenic gene transcription by dietary carbohydrate (2).  Thus inhibition 
of lipogenic gene expression in presence of insulin and T3 by bile acids may act to inhibit 
lipogenic gene transcription in a feedback mechanism.  
 
CDCA inhibits T3-induced ACCα mRNA via a cis acting element on the promoter 
We have previously shown that T0-901317 and CDCA regulation on ACCα is 
mediated by a 23 bp region (-101 to -71 bp) in promoter 2 of the ACCα gene.  This 
region consists of a DR-4 element (-101 to -86 bp) that binds heterodimers comprised of 
TR•RXR and LXR•RXR and a SRE (-82 to -71 bp) that binds SREBP-1.  To determine 
whether the functional interaction between the ACCα T3RE and SRE required the 
presence of additional cis-acting sequences, hepatocytes were transfected with constructs 
containing fragments of the ACCα gene linked to the minimal promoter of the herpes 
simplex virus thymidine kinase (TK) gene.  The TK promoter alone was unresponsive to 
CDCA Figure 4.5.  When a DNA fragment containing both the ACCα T3RE and ACCα 
SRE (-108 to -66 bp) was linked to the TK promoter, treatment with CDCA caused a 
50% decrease in promoter activity.  Mutation of the ACCα SRE in the context of the 
ACCα -108 to -66 bp fragment had no change in CDCA responsiveness.  Similarly, when 
the ACCα T3RE was linked to the TK promoter, there was no change in promoter 
activity by CDCA.  When a DNA fragment containing the ACCα SRE alone (-84 to -66 
bp) was appended to the TK promoter, CDCA treatment almost completely abolished 
ACCα promoter activity.   
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CDCA modulates the binding of nuclear receptor complexes to the ACCα LXRE/T3RE 
in presence of insulin and T3 
 In previous work, we showed that the ACCα LXRE/T3RE (-101 to -86 bp) bound 
four protein complexes in nuclear extracts prepared from chick embryo hepatocytes ().  
Three of these complexes (designated complexes 1, 2 and 3) contained LXR•RXR 
heterodimers, whereas the fourth complex (designated complex 4) contained TR•RXR 
heterodimers.  In the absence of nuclear receptor agonists, complexes 1 and 2 were the 
predominant complexes that bound to the ACCα LXRE/T3RE.  T3 treatment caused an 
increase in the binding of complexes 3 and 4.  These findings have led us to propose that 
changes in the binding of nuclear receptor complexes to the ACCα-LXRE/T3RE play a 
role in mediating the activation of ACCα transcription by T3.  In this experiment, we 
wanted to determine whether treatment with AICAR inhibited the binding of nuclear 
receptor heterodimers on the ACCα-LXRE/T3RE.  Gel mobility shift assays were 
performed using nuclear extracts from chick embryo hepatocytes treated insulin alone, 
insulin and T0-901317 and insulin and T3, in the absence and presence of AICAR.  As 
reported previously, a DNA probe containing the ACCα LXRE/T3RE bound to complex 
1, complex 2, and complex 4 in nuclear extracts from hepatocytes incubated in the 
absence of nuclear receptor agonists.   
 There was no change in binding activity of complex 1 in presence of insulin, and 
insulin and T0-901317, in the absence and presence of AICAR Figure 4.6.  T3 causes a 
small increase in complex 1 binding activity in presence of T3 and AICAR caused a 
small reduction in binding of complex 1.  However, the decrease in complex 1 binding 
activity by AICAR in presence of T3 is not significant.  There was no change in binding 
activity of complex 2 in presence of insulin and insulin and T0-901317 in the absence 
and presence of AICAR.  Treatment of T3 did not change binding activity of complex 2 
in the absence of AICAR.  However, AICAR caused a slight reduction in complex 2 
binding activity in presence of insulin and T3.   
 T0-901317 caused an increase in binding activity of complex 4.  This result is 
consistent with that shown in Chapter 2.  AICAR had no effect on complex 4 binding 
activity in presence of insulin and insulin and T0-901317.  T3 caused a 4-fold increase in 
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complex 4 binding activity.  This result is consistent previous findings from our lab that 
showed complex 4 mediates the increase in enhancer activity of ACCα-LXRE/T3RE in 
presence of T3 complex 4 mediate the increase in enhancer activity of ACCα-
LXRE/T3RE caused by the addition of T3 (21).  AICAR caused a 75% inhibition of 
complex 4 binding activity.  This result shows that AICAR inhibits ACCα mRNA 
abundance by inhibiting TR•RXR heterodimers recruitment to the ACCα-LXRE/T3RE in 
presence of insulin and T3.   
 
CDCA increases FGF-19 mRNA in presence of insulin and T3 
Our data shows that bile acids inhibit T0-901317-induced ACCα mRNA and that 
FGF-19 mRNA may mediate this process.  We have also shown that bile acids inhibit T3-
induced ACCα mRNA expression.  We therefore wanted to determine whether FGF-19 
may mediate this effect in presence of T3.  Consistent with results reported for human 
hepatocytes, and in chick hepatocytes in presence of insulin and T0-901317, CDCA 
increased FGF-19 mRNA abundance in chick hepatocytes in a dose dependent manner in 
absence and presence of T3 Figure 4.7.  This result would further suggest that CDCA 
inhibits T0-901317- and T3-induced ACCα mRNA expression by increasing FGF-19.   
 
Recombinant human FGF-19 has no effect on gene expression in chick hepatocytes 
We investigated whether recombinant human FGF-19 modulated lipogenic gene 
expression in chick hepatocytes.  Addition of FGF-19 at concentrations that were within 
or exceeded the physiological range had no effect on mRNA abundance of ACCα, ME, 
FAS, SCD, ATP-CL, SREBP-1 and ABCA1 in the absence or presence of T0-901317 or 
T3 Figure 4.8.  One interpretation of this finding is that FGF-19 is not a mechanism 
mediating the effects of bile acids on lipogenic gene expression in chick hepatocytes.  
However, it is possible that human recombinant FGF-19 (61% sequence homology with 
chicken FGF-19) is not active in the chicken system or that recombinant FGF-19 derived 
from bacteria has low biological activity due to improper folding.  This experiment was 
performed in collaboration with Sushant Bhatnagar in our lab.   
It has been reported that FGF-19 has a unique loop that binds heparin.  This loop 
accounts for the affinity of FGF-19 for the receptor FGFR4.  Studies have shown that 
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heparin also facilitates functioning of FGF-19 (7).  We treated chick hepatocytes with 
insulin and T0-901317 and heparin in the absence and presence of recombinant human 
FGF-19.  FGF-19 had no effect on ACCα mRNA abundance even in the presence of 
heparin.   
 
 
Hepatocytes infected with adenovirus vectors expressing chicken FGF-19 inhibits 
ACCα mRNA expression 
 As discussed previously, recombinant human FGF-19 had no effect on ACCα 
mRNA abundance.  To establish a role of FGF-19 in mediating inhibition of ACCα 
mRNA by CDCA we infected hepatocytes with adenovirus containing chicken FGF-19.  
Cells were also infected with adenovirus containing no DNA (null) and no virus as 
controls.  CDCA inhibits ACCα mRNA in uninfected cells and cells infected with 
adenovirus containing null virus Figure 4.9.  Cells infected with chicken FGF-19 virus 
inhibited ACCα mRNA in a dose dependent manner.  Cells treated with adenovirus 
containing FGF-19 had a 10-25-fold increase in FGF-19 mRNA levels over control cells.  
Western blot analysis using an antibody against chicken FGF-19 (provided by Dr. 
Ladher) to detect overexpression of FGF-19 protein was inconclusive.  Adenovirus was 
prepared by Callee M. Walsh in Dr. Salati’s lab. 
 
Effect of the specific JNK inhibitor SP600125 on CDCA mediated inhibition of 
lipogenic genes 
Previous work has established that bile acids activate JNK and that this pathway 
is involved in the bile acid-mediated inhibition of cholesterol 7α hydroxylase 
transcription in human hepatocytes.  We have confirmed this finding in chick 
hepatocytes.  To investigate the role of JNK in mediating the reduction of lipogenic gene 
expression caused by bile acids, we used a specific inhibitor of JNK, SP600125 to 
measure lipogenic gene expression. 
Consistent with our previous experiments, CDCA inhibits both T3 and T0-
901317-induced ACCα, FAS and SCD expression, and increases FGF-19 expression 
(Lanes 3 and 7)  Figure 4.10.  SP600125 inhibits expression of ACCα and FAS in 
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presence of both T3 and T0-901317 compared to T3 and T0-901317 alone (Lanes 2 & 6 
vs. Lanes 1 & 5).  In presence of T3, SP600125 has no effect on expression of SCD, but 
in presence of T0-901317, SP600125 inhibits expression of SCD (Lanes 2 & 6).  In 
presence T0-901317, SP600125 increases expression of FGF-19 (Lane 6), but SP600125 
does not increase expression of FGFG-19 in presence of T3. 
In presence of CDCA, SP600125 has an additional inhibitory effect on expression 
of ACCα, FAS and SCD than CDCA alone, and an additional inductive effect on 
expression of FGF-19 than CDCA alone, both in the presence of T3 or T0-901317 (Lanes 
5 & 11).  SP600125 decreases expression of lipogenic genes by almost half and increases 
FGF-19 expression two fold, with respect to CDCA alone, in presence of T0-901317.  
Results from this experiment are inconsistent with bile inhibiting lipogenic gene 
expression via activation of JNK.  Results from this experiment suggest that JNK 
mediates activation of lipogenic genes by T0-901317 and T3.  These results would also 
suggest that JNK inhibits activation of FGF-19, at least in presence of T0-901317.  
However, this experiment provides further data of an inverse correlation between 
lipogenic gene expression and FGF-19 expression in chicken embryo hepatocytes.   
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FIGURE LEGENDS 
 
Figure 4.1:  CDCA activates PKC and phorbol esters have no effect on ACCα mRNA 
abundance.  Chick hepatocytes were plated in presence of insulin (50 nM) and T0-
901317 (6 µM).  12 hours later medium was changed with the addition of insulin and T0-
901317.  24 hours later, medium was changed again, with the indicated treatments.  Total 
protein and RNA was harvested and western blot and real time RT-PCR was performed.   
 
 
Figure 4.2:  CDCA activates AMPK signaling pathway.  CEH were plated in absence of 
hormones overnight.  Medium was changed with addition of insulin (50 nM) and T0-
901317 (6 µM) in all plates.  24 hours later medium was changed again with addition of 
insulin and T0-901317 in all plates and CDCA in the indicated plates.  Total protein was 
isolated from cells at the indicated time points and western blot was performed using 
antibodies as described in Chapter 3. 
 
 
Figure 4.3:  AICAR has no effect on ACCα mRNA abundance, AMPK and p38 MAPK 
in presence of insulin and T0-901317.  Cells were plated in absence of hormones.  16 
hours later medium was changed with addition of insulin (50 nM) and T0-901317 (6 µM) 
in all plates.  24 hours later, medium was changed again with addition of insulin and T0-
901317.  18 hours later, AICAR was added in the indicated concentration.  6 hours after 
AICAR addition, total RNA and protein was harvested and A) real time RT-PCR analysis 
was performed to determine ACCα mRNA abundance and B) western blot analysis was 
performed to determine P-AMPK, P-ACC and P-p38.   
 
 
Figure 4.4:  AICAR activates AMPK signaling pathway, inhibits mature SREBP-1 and 
inhibits ACCα mRNA abundance in presence of insulin and T3.  CEH were plated and in 
absence of hormones overnight.  Medium was changed with addition of insulin (50 nM) 
and T3 (1.5 µM) in all plates.  24 hours later, medium was changed again with the same 
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treatments.  18 hours later, AICAR was added to the indicated plates and concentration as 
indicated. 6 hours later, total RNA, total protein and nuclear protein was harvested.  Data 
represents mean + SE of three experiments.  * represents significance at p<0.05. 
 
 
Figure 4.5:  Fragments of the ACCα gene containing the T3RE and/or SRE-1 were 
linked to the minimal thymidine kinase (TK) promoter in TKCAT.  CEHs were 
transiently transfected with these constructs and treated with T3 (1.5 µM) and insulin (50 
nM) in the absence or presence of CDCA as described in Part A (above) and under 
Experimental Procedures.  Left: Constructs used in these experiments.  Numbers indicate 
the 5' and 3' boundaries of ACCα DNA relative to the transcription initiation site of 
promoter 2.  Right: CAT activity in CEH transfected with p[ACC-TKCAT and treated 
with T3 and insulin was set at 1, and the other activities were adjusted proportionately.  
The results are the means ± SEM of three experiments.   
 
 
Figure 4.6:  Effect of CDCA on the binding of hepatic nuclear proteins to the ACCα 
T3RE in presence of insulin and T3.  A) Eighteen hours after being placed in culture, 
CEHs were incubated in Waymouth's medium containing insulin (50 nM), and T3 ( 1.5 
µM), with or without CDCA 75 µM for the indicated times.  Cells were harvested and 
nuclear extracts were prepared as described in Experimental Procedures.  Nuclear 
extracts were subjected to gel mobility shift analyses using an oligonucleotide probe 
containing the ACCα T3RE (-108 to -82 bp).  Specific protein-DNA complexes are 
indicated by arrows.  Previous studies have shown that complexes 1 and 2 contain liver X 
receptor (LXR)•retinoid X receptor (RXR) heterodimers, whereas complex 4 contains 
nuclear T3 receptor (TR)•RXR heterodimers.  These data are representative of three 
experiments employing independent preparations of nuclear extract.  B)  Signal from the 
complexes was quantified using ImageQuaNT software.  The value for the samples 
treated with insulin and T3 at 0 h was set to 1.  Data represents mean ± SE of three 
experiments.   
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Figure 4.7:  CDCA increases expression of fibroblast growth factor 19 (FGF-19) in the 
absence and presence of T3 in a dose dependent manner.  Northern Blot analysis was 
performed to determine mRNA levels. Chicken embryo hepatocytes were treated with the 
indicated amounts of CDCA, insulin (50 nM) and T3 (1.5 μM).  Data shows mean ± 
standard deviation of two experiments.  The values for mRNA abundance for the 
treatments have been calculated with respect to insulin treatment, the value of which was 
set to 1. 
 
 
Figure 4.8:  Recombinant human FGF-19 has no effect on gene expression.  CEH were 
plated in absence of hormones.  16 hours later, medium was changed with addition of 
insulin (50 nM), T0-901317 (6 µM) and T3 (1.5 µM).  FGF-19 was added to the 
indicated plates at indicated concentrations.  24 hours later total RNA was isolated.  A) 
Northern blot analysis was performed to measure relative mRNA abundance of the genes.  
This part of the experiment was performed in collaboration with Sushant Bhatnagar.  B) 
Real time RT-PCR was performed to measure relative mRNA levels of ACCα. 
 
 
Figure 4.9:  Hepatocytes infected with adenovirus expressing chicken FGF-19 inhibit 
ACCα mRNA expression.  CEH were plated in the absence of hormones.  Four hours 
later, medium was changed with the addition of insulin (50 nM) and T0-901317 (6 µM) 
in all plates and infected with adenovirus containing the indicated proteins.  The amount 
of adenovirus is used in plaque forming units (pfu).  Hepatocytes that were uninfected by 
virus and treated in parallel served as controls.  24 hours after addition of the adenovirus, 
medium was changed again with addition of insulin and T0-901317 in all plates and 
CDCA (75 µM) in the indicated plates.  24 hours later, total RNA was harvested from the 
cells and real time RT-PCR was performed to determine relative ACCα and FGF-19 
mRNA levels.  Data is representative of three experiments.  * Significant at p < 0.05. 
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Figure 4.10:  Effects of the JNK inhibitor SP600125 on gene expression.  CEH were 
plated in the absence of hormones overnight.  Medium was changed with addition of 
insulin (50 nM) in all plates and T3 (1.5 µM) and T0-901317 (6 µM) in the indicated 
plates.  SP600125 and CDCA were added to the plates indicated.  24 hours later total 
RNA was isolated and Northern Blot analysis was performed to determine relative 
mRNA levels.   
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